Rheumatic fever and rheumatic heart disease : prevalence among Yemeni school children and studies of the immunopathogenesis of the disease by Ba-Saddik, Iman Ali Mahmoud
Rheumatic Fever and Rheumatic Heart Disease: 
Prevalence among Yemeni School Children
and
Studies of the Immunopathogenesis of the Disease
By
Iman Ali Mahmoud Ba-Saddik
Thesis submitted in accordance with the requirement of 
theUniversity of Liverpool for the degree of Doctor in
Philosophy
Liverpool School of Tropical Medicine
January 2012
Dedication
This thesis is dedicated to:
My father, Ali, who taught me the best knowledge to have, is that which is learned for 
its own sake.
My mother, Thuriya who taught me that even the largest task can be accomplished if it 
is done step by step.
My husband, Ahmed who has been a great source of inspiration, unwavering 
encouragement, motivational support, unending help and dynamic generous spirit that 
continues to enrich my life.
My daughters, Daliah, Fatima and Dalai for their unconditional love, support and a 
treasure beyond compare throughout the course of this thesis.
It is dedicated to all our journeys in learning to thrive
i
Acknowledgement
First and foremost, I offer my deepest and sincerest gratitude to my supervisor Dr. John 
Brian Stewart Coulter who has supported me with immense knowledge and valuable 
supervision throughout my PhD study. A very special thanks to Prof Bernard Brabin for 
his continuous inspiration and great efforts during my PhD thesis who became more of 
a mentor and friend, than a professor. I doubt that that I will ever be able to convey my 
appreciation fully, but I owe him my eternal gratitude. I would like to express sincere 
gratitude to my supervisor, Dr.Luis Cuevas for his wide knowledge and valuable 
comments. I am deeply grateful to my supervisor, Dr. Christopher Parry for his 
constructive comments and continous vital encouragement. I owe my most sincere 
gratitude and warm thanks to late Professor Tony Hart who gave me untiring support 
and valuable advice during the project analysis. I am heartily thankful to Dr.Abdul 
Nasser Munibair for his sound advice and careful guidance from the initial to the final 
level. I would like to thank Dr .Michael Chance for his insightful encouragement. I am 
greatly thankful to Dr Brian Flanagan for reviewing the chapter on cytokines.
Special gratitude to Caroline Broughton, Farook Murshed, John Corkhill, Greg Harper 
and Lorna Wilson who offered invaluable help and guidance in my laboratory analysis. 
My warmest thanks to Dr.Amir Hassan, Dr.Saeed Ismail, Dr.Gamal Mohammed,
Dr.Abdulla Hattab, Dr.Mohammed AlNaqeeb, Dr.Anisa Abood, Mr.Fuad Nooman, 
Amina Ba-Saddik, Gamal Alhasany, Abdulla Omer, Inas Aldan, Alawia AlHibshi. I 
owe loving thanks to my husband Ahmed Taha Makki, for his moral support and 
continuous guidance with valuable suggestions to complete my work. I owe loving 
thanks to my daughters, Daliah, Fatima and Dalai who have lost a lot due to my 
research abroad and without their encouragement it was not possible to finish this work. 
My love and gratitude to my beloved parents, brother and sisters for their endless love. 
My loving thanks are due to Drs John and Muriel Berkeley, Wafa, Intisar and Byan who 
let me own a happy family in the U.K. Special thanks to my PhD collegues, Amin, 
A.Wahab, Asma, Gibby, Zainab, Fayza, Samira, Nabil, Mohamed, Rukhsana, Getrude, 
Yaser, Hazel, Daniel, John, Pamela, and Alex. The financial support of the WHO in the 
school survey is gratefully acknowledged. Lastly, I offer my regards and blessings to all 
of those who supported me in any respect during the completion of the project.
n
Thesis Structure
Chapter one includes a general overview of the problem of Acute Rheumatic Fever 
(ARF) and Rheumatic Heart Diseae (RHD) following acute pharyngotonsillits with 
Group A p haemolyitc Streptococcal (GAS) infection. Chapter two describes the type of 
patients and the methodology including study design, sample size, paraclinical 
investigations and the statistical analysis used in the different phases of the research.
The prevalence of RHD among a representative sample of 6000 Yemeni schoolchildren 
in Aden City is dealt with in Chapter three. Chapter four describes the prevalence of 
GAS infections among 730 patients with acute pharyngotonsillitis attending public and 
private primary health centres and school children. Chapter five gives the prevalence of 
Non Group A p haemolytic Streptococcal (SNA) pharyngotonsillits among patients and 
school children. The emm genotyping and the virulence factors including superantigen 
prophage exotoxin and sof genes of 21 GAS and 13 SNA throat isolates from patients 
with history of ARF and RHD is discussed in chapter six. Chapter seven includes the 
antimicrobial sensitivity and resistance patterns in 24 GAS and SNA pharyngotosnillitis 
throat isolates. The immunopathogenesis and genetic aspects of ARF and RHD 
including the study of 14 cytokines and chemokines in 49 patients with ARF and RRF is 
reviewed in chapter eight. The general discussion, conclusions and recommendations 
with study limitations are outlined in chapter nine. The final chapter ten includes all the 
references reviewed in this thesis.
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Abstract
Background: The epidemiological, genetic and host immunogenetic association 
between Group A p haemolytic Streptococcal (GAS) pharyngotonsillitis and the 
subsequent development of Acute Rheumatic Fever (ARF) and Rheumatic Heart 
Disease (RHD) is an area of major interest. RHD still remains an important contributor 
to cardiovascular disease in children and adults in Yemen.
Aims: The purpose of this study was to determine: (i) the prevalence of RHD among 
primary school children in Aden City, Yemen, (ii) the prevalence of GAS and Non 
Group A P haemolytic Streptococcal (SNA) pharyngotonsillitis among patients 
attending primary health care centres, (iii) the distribution of emm genotypes and 
selected superantigen prophage exotoxin and sof genes among GAS and SNA, (iv) the 
antimicrobial susceptibility pattern of GAS and SNA in patients with a history of ARF 
and RHD, (v) comparision of a profile of selected cytokines and chemoldnes between 
ARF and recurrent rheumatic fever (RRF) patients.
Methods: A cross-sectional case-finding survey of RHD was conducted in 6000 school 
children aged 5-16 years in Aden City to determine the prevalence of RHD. A cross- 
sectional descriptive survey was undertaken in 730 children aged 1-16 years with acute 
pharyngotonsillitis to deteimine the prevalence of GAS and SNA infections. Thirty four 
throat culture isolates from patients with GAS and SNA pharyngotonsillitis with history 
of ART and echo-proven cases of RHD were analyzed by a multiplex PCR method to 
determine the emm genotypes, presence of superantigen prophage-associated virulence 
genes and sof genes. Antibiotic sensitivity tests were conducted on 24 GAS and SNA 
throat culture isolates using the BSAC disc diffusison method. Fourteen serum cytokine 
and chemokine concentrations including interleukin-1(3 (IL-1(3), interleukin-6 (IL-6), 
interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-10 (IL-10), 
interleukin-12p70 (IL-12p70), tumor necrosis factor (TNF-a), interferon gamma (IFN- 
y), chemokines monocyte chemotactic protein-l(MCP-l), macrophage inflammatory 
protein-la (MIP-la), macrophage inflammatory protein-Ip (MIP-lp), human interferon 
inducable protein-10 (IP-10) and regulated upon activation, normal T-cell expressed and 
secreted (RANTES) protein levels from children with ARF and RRF were analyzed by 
the BD FACS Array Bioanalyzer using FCAP Array Sq/tware.
Results: The prevalence of RHD was 36.5/1000 school children which is one of the 
highest reported among school echocardiography surveys in the world. RHD had a high 
preponderance in 10-16 years old students. 49.8% had mitral regurgitation (MR) 
lesions, 26.6% hadMR with mitral valve prolapse (MVP) and 17.8% with combined 
MR and aortic regurgitation (AR) lesions. RHD was diagnosed in more than one family 
member in 53 (24.2%) of the children. A high prevalence of GAS pharyngotonsillitis 
(41.5%) was noticed in children of 11 - 15 years of age. A red erythematous uvula and 
petechie on the soft palate were observed significantly more commoinlyin GAS 
pharyngotonsillitis. Group B (GBS), Group C (GCS) and Group G p haemolytic 
streptococci (GGS) were isolated from pharyngotonsillitis in 4.3% patients with history 
of ARF/RHD.
v
The most frequent GAS isolates among ART and RHD patients with pharyngotonsillitis 
were emmll, emm2$ and emm5. This is the first report of emm%l and emm2&
genotypes to be potentially rheumatogenic. The 11 emmSl GAS isolates shared a 
common PFGE pattern and profile of five exotoxin prophage genes spec, spdl, sdn, silC 
and silD with the sof%l sequence. emml2 and emm2% GAS strains were positive for 
gene sof, spec and spdl. This is the first report to describe the pattern of exotoxin 
prophage genes of spec, spdl, sdn, silC and silD among emml2, emm2$ and
emm5 GAS and SNA (GBS, GCS and GGS) isolates with history of ARF and RHD.
The genotypic characteristics of GBS, GCS and GGS isolates confirmed seven new 
emm sequence types first detected among children with acute pharyngotonsillitis. GAS 
and SNA isolates were susceptible to the p-lactam antimicrobials, penicillin and 
amoxicillin. Erythromycin resistance was detected in sof positive emml2 and emm2% in 
50% and 33% of isolates respectively.
Chemokine MCP-1 was significantly correlated with cytokines, IL-lp, IL-6, IL-10, IL~ 
12p70, TNF-a, IFN-y and RANTES in patients with RRF. This suggests that MCP-1 
could serve as a potential inflammatory biomarker for patients with RRF having 
underlying RHD. MIP-1[3 had significant correlations with IL-8, IL-10, IL-12p70, IP- 
10, TNF-a and IFN-y in patients with ARF. MIP-lp may serve as a potential 
inflammatory biomarker in patients with ARF without RHD.
Conclusions: The high prevalence of RHD is an alarming public health problem in 
Yemen. Urgent screening surveys and a preventive RHD prophylactic program with 
appropriate management of GAS pharyngotonsillitis are required. Future studies are 
needed to confirm the rheumatogenic GAS and SNA strains with their exotoxin prohage 
genes and the role of the chemokines and cytokines as biomarkers for ARF within the 
complex network of autoimmune reactions in RF/RHD. This study hopes to provide a 
further small step in elucidating the pathogenesis of this complex immunological 
disease.
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Chapter 1
1 Introduction
1.1 General overview on GAS
Infection with Streptococcus pyogenes known as group A p haemolytic 
Streptococcus(GAS), an important Grampositive extra cellular bacterial pathogen, has 
remained among the most universal human bacterial pathogens with great diversity for 
centuries (Bisno, et al 2003, Dagnelie, etal 1998, Tart, etal 2007)
, GAS is responsible for a wide spectrum of human diseases, ranging from the relatively 
benign pharyngitis to potentially life threatening invasive disease and post-infectious 
sequelae such as acute rheumatic fever (ARF)(Carapetis 2008a, Cunningham 2000, 
Lazar’ R. 2004).
Humans are the only natural reservoir for GAS which has a world-wide 
distributionAlmred, et al 2003, Pichichero 1998). Millions of children each year 
develop GAS pharyngotonsillitis(Bessen, etal 2000, Sierig, et al 2003). The prevalence 
of GAS in throat accounts for approximately 20 to 30% of sore throats with an 
estimated seven sore throat episodes occurring per child per year (Armengol, et al 2004, 
Darrow and Buescher 2002). Occurrence of GAS tonsillopharyngitis is known to be 
highest in 5 - 18 years old school-aged children, the target population, irrespective of 
gender (Brook and Dohar 2006, Tart, et al 2007). It varies geographically and in 
temperate climates GAS tonsillopharyngitis is more common during the winter and 
early spring months (Bisno, et al 2003, Shulman, et al 2006).
Modern molecular biology techniques has taught us much about the GAS virulence and 
some types of its genomes (Bisno, et al 2003).The basic phenotypic typing methods of 
serotyping, biotyping and antibiotic resistance patterns have been supplemented with 
molecular’ methods such as random amplified polymorphic DNA analysis, 16S rRNA 
gene sequencing, restriction fragment length polymorphism, pulsed-freld gel 
electrophoresis (PFGE) and PCR serotyping (Chiou, et al 2004, Desai, et al 1999, 
Seppala, et al 1994a, Stanley, et al 1995). Sequence-based typing methods such as
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multilocus sequence typing and emm sequence typing have also been introduced 
(Bessen, et al 2008, Carrico, et al 2006, Maiden, et al 1998). These techniques have a 
wide application as they provide unambiguous data, fonn databases that are easily 
accessible through the internet and allow comparison with reports from different 
countries.
Multilocus sequence typing (MLST) provides a practical approach to study the 
molecular epidemiology and population structures of bacterial species such as GAS 
(Enright and Spratt 1999, Maiden, et al 1998). MLST can be used to identify clusters of 
isolates that have similar or closely related genotypes (Maiden, et al 1998, Urwin and 
Maiden 2003). The method is based on the nucleotide sequence variation in seven stable 
housekeeping genes (Brian G 1999, McGregor and Spratt 2005). A disadvantage of 
MLST for routine use is that the set-up procedures are slow and they are expensive as 
seven DNA sequences are needed for each isolate (Cooper and Fell 2004, McGregor, et 
al 2004b, Richardson, et al 2011).
The emm gene sequencing method has been shown to be an accurate and reliable 
substitute for M typing (Beall, et al 1996, Neal, et al 2007). Anti-M serum is produced 
in a limited number of central laboratories, is quite expensive and does not type all 
strains. The gene coding for GAS M protein, the most important virulence determinant 
of the organism, has a hypervariable 59 region with many single nucleotide 
polymorphisms. Detection of the variation in this region is the basis for GAS emm 
typing isolates (Bahnan, et al 2011, Beall, et al 1997, Pruksalcorn, et al 2000). Despite 
the limitations of basing a typing system on a highly recombinant region subject to a 
high degree of selective pressure, emm gene sequencing is currently considered the 
molecular gold standard for typing GAS (Neal, et al 2007, Steer, et al 2009d).
Analysis of the clonal relationships between clinical throat isolates of GAS from 
patients by various typing methods is a practical approach to clarify the epidemiology of 
ARF. Some GAS strains which cause acute pharyngotonsillitis are clearly also 
associated with the non-suppurative sequelae of ARF and these strains have been found 
to have particular M types (Cunningham 2000, Kaplan 1991, Seckeler and Hoke 2011). 
The M protein is a cell-surface protein that is the major virulence and immunological 
factor of GAS responsible for rheumatogenicity (Bisno, et al 2003, Meisal, et al 2010,
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Metzgar and Zampolli 2011). The M type is now determined by DNA sequencing of the 
emm gene and the method has detected several previously unknown GAS types 
(Bahnan, et al 2011, MA, et al 2009, Sakota, et al 2006). Recovery of GAS isolates 
from the infected throat of patients in areas where ART is common, combined with emm 
sequence genotyping, could clarify the epidemiological associations of M types with 
sequelae in these countries (Bisno, et al 2003, Steer, et al 2009d, Teixeira, et al 2001).
Although previous epidemiological studies have shown specific GAS types responsible 
for rhemnatogenecity, it remains necessary to study new strains in low resource settings 
in order to further clarify strain associations (Cunningham 2000, MA, et al 2009,
Sakota, et al 2006, Seckeler and Hoke 2011). A better understanding of the disease 
epidemiology will help in the practical application of public health measures for 
improved protection against ART (Seckeler and Hoke 2011, Smeesters, et al 2009) and 
will also guide the future development of an effective and safe vaccine with a 
combination of M protein serotypes and genotypes from different rheumatogenic strains 
in different areas of the world (Metzgar- and Zampolli 2011, Shuhnan, et al 2009, Steer, 
et al 2009d).
To date, a number of phenotyping and genotyping schemes have been described for 
GAS but these have not yet been conducted in Yemen. This study will be the first to 
undertake research on GAS in Yemen (Chapter 4).
The epidemiological association between GAS infections and the subsequent 
development of acute rheumatic fever (ART) has been well established (Fae, et. al 2005, 
Gibofsky, et al 1998, Hahn, et al 2005). This delayed autoimmune systemic response 
with variable multiorgan involvement in an individual with GAS pharyngotonsillitis is 
determined by host genetic susceptibility,vinrlence of GAS and a favourable 
environment (Taranta and Markowitz 1989, WHO 2004).
Humans are exposed to GAS infections through the environment. Environmental factors 
and poor socioeconomic status facilitate the transmission and increase the frequency of 
GAS sore throats (Griffiths and Gersony 1990, Jaine, et al 2011). Poverty is an 
important risk factor and overcrowding promote GAS transmission and disease 
development (Carapetis, et al 2005a, Zaman, et al 1997).
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GAS virulence is enhanced in favourable conditions such as overcrowding and close 
interpersonal contacts . This favours person-to-person transmission and contribute to the 
rapid spread and persistence of virulent GAS strains (Cunningham 2000, Steer, et al 
2002, Thakui; et al 1996). Poor housing conditions are a further risk factor for ARF and 
RHD (Bryant, et al 2009, Gerber, et al 2009). Other factors such as decreased access to 
medical care, shortage of resources for providing quality health care, inadequate 
expertise of health-care providers, and a low level of awareness of the disease in the 
community can all affect the expression of ARF in a population (Carapetis, et al 2000, 
Seckeler and Hoke 2011)
Variations in the rheumatogenicity of prevalent GAS probably account for the marked 
temporal and geographic fluctuations in the incidence of ARF (Sakota, et al 2006, 
Shulman, et al 2006). The incidence of ARF varies by season, in time and by location.
In many areas ARF has a high incidence in early autumn, late winter and early spring, 
and this coincides with variations in the frequency of GAS throat infections (Johnson 
1992, Oriin, et al 2012).
Several authors have found that GAS throat infections caused by particular emm strains 
are associated with high rates of ARF (Erdem, et al 2007, Smeesters, et al 2009, Steer, 
et al 2009d). GAS pharyngitis outbreaks caused by emm types 1, 3, 5, 6, 14,18, 19, 24, 
27and 29 were associated with ARF, but other common emm types 2, 4, 12, 22, and 28 
were not associated with ARF even in highly susceptible individuals (Kaplan, et al 
2001, Shulman, et al 2004, Steer, et al 2009d). Bisno et al reported multiple epidemics 
of ARF caused by emm 3, 5, 14 and 18 strains while emm 6,19,27 and 29 were 
correlated with a single epidemic (Bisno, et al 2003).
Different GAS strains are more likely than others to be rheumatogenic (Martin and 
Barbadora 2006). GAS isolates with high M protein content, a mucoid colonial 
morphology, encapsulation and lack of opacity factor are associated with increased 
virulence causing ARF (Bisno, et al 2003, Johnson, et al 2006), During the ARF 
resurgence in the intennountain area of the US, the high ARF incidence was associated 
with the occurrence of an increasing number of GAS mucoid strains in the community 
(Kaplan 1991). The marked decrease in the prevalence of ARF in some countries has 
been attributed to the decline of the proportion of children with rheumatogenic GAS
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types, particularly the mucoid strains in throat infections (Abdul-Mohsen and Lardhi 
2011, Veasy, et al 2004). An increase in extractable M protein has been reported from 
some GAS strains associated with outbreaks of pharyngitis and ARF, compared with 
GAS strains of the same serotypes isolated in communities where pharyngitis was 
common but ARF was rare (Maxted, et al 1973).
The distribution of GAS pharyngeal emm types and their degree of diversity exhibit 
geographical differences (Shulman, et al 2004, Teixeira, et al 2001). emm GAS 
distributions were documented to be similar' in some countries, but unusual inter-site 
variation within season and intra-site variation from season to season has been reported 
(Shulman, et al 2009, Tewodros and Kronvall 2005). The increased levels of immunity 
to certain predominant types have also been associated with a decline in prevalence of 
some rheumatogenic GAS types in recent years and a decline in ARF (Carapetis, et al 
2000, Cunningham 2000).
Changes in the circulating strains of GAS can explain some of the observed temporal 
and geographic fluctuations in ARF incidence (Erdem, et al 2007, Shulman, et al 2006). 
Other factors may also be important. For example, differences in the population 
prevalence in the same geographical area have been attributed to low socioeconomic 
groups and differences in the genetic predisposition to ARF (WHO 2001).
The global burden of disease caused by ARF currently falls disproportionately on 
children living in developing countries (Abella-Reloza 1998, Carapetis 2007). The 
overall annual incidence of the disease worldwide is between 100 and 200/100,000 
school age children, whereas in industrialized countries it is only 0.5 to 2/100,000 
(Olivier 2000, Omurzalcova, et al 2009, Tibazarwa, et al 2008).
1.2 Acute Rheumatic fever
ARF is prevalent in the age of 5 - 14 years in different developed and developing 
countries (WFIO 2001, Zaman, et al 1998a). ARF may cause death due to acute carditis 
or complications of RFID resulting from previous episodes of ARF (Carapetis, et al 
2005b, Vazquez, et al 1991). But RHD is the major source of morbidity and mortality in 
ARF (Carapetis and Currie 1999, Seckeler, et al 2010).
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The first episode of ARF usually occurs between 5-14 year's (Jaine, et allOW, Steer, 
et at 2002). It has rarely been reported in children less than age of 5 years and is very 
rare or almost unheard below 3 year's (Carapetis, et al 2005a, Lennon and Craig 2009, 
Rosenthal, et al 1968). The few reported cases of ARF vary from 1 to 32 cases in 
children less than 5 years of age (Abdin and Eissa 1965, Tani, et al 2003) . The reported 
prevalence of ARF in children less than 5 years of age varies from lower values of 1 % - 
2% to higher values of 4.5% to 6.8% in different countries (Abdin and Eissa 1965,
Jaine, et al 2008, Vazquez, et al\99\, Zaman, et al 1998a). There is lack of data on the 
clinical pattern of ARF in young children. It may due to the fact that some cases may be 
undiagnosed or there may be an underestimation of the disease in children younger than 
5 year's of age (Richmond and Harris 1998, Seckeler and Hoke 2011). There is also 
insufficient data on the age and cause specific mortality under 5 years of age for ARF 
and RHD (Bitar', et al 2000) . Mortality rates for RHD are reported to vary from 0 - 
30% during childhood or early adulthood (Carapetis and Currie 1999, Seckeler and 
Hoke 2011). Around 92% of cases occur under the age of 18 year’s (Carapetis, et al 
2005a, Stollemran 2001a).
The main clinical manifestations of ARF are car'ditis and arthritis, less commonly there 
is chorea and rarely subcutaneous nodules and erythema marginatum (revised Duckett 
Jones criteria update 1992) (Ferrieri 2002). Most manifestations of the disease are 
transient and leave no residua except rheumatic carditis, the most severe complication 
of ARF, can lead to valvular scarring with permanent sequelae in 35 to 79% of cases 
(Padmavati 2001, Ravisha, et al 2003, Saxena 2002).
Certain reports in developed countries documented that protein energy malnutrition 
(PEM) was likely to be associated with ARF(Wahab 1986, Zaman, et al 1998b). 
Although PEM and ARF still remain high in low resource settings, there is insufficient 
data on this association. Children with PEM in early life are among the high risk group 
who develop ARF (Tahemia, et al 1971, Wilcox and Galloway 1954). This may be 
explained by the fact that PEM may modify the immunologic system and the immune 
response to GAS infection(Zaman, et al 1998b). This possibly leads to a state of 
immune hypersensitiveness to a specific GAS cell-wall antigen (Zabriskie 1985). 
Children with PEM exposed to rheumatogenic strains of GAS particularly with a
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genetic susceptibility could have a greater likelihood to develop an attack of ARF 
(Seckeler and Hoke 2011).
Protein and iron deficiencies during childhood are common and cause PEM in several 
underdeveloped and developing countries which is also documented in ARE (Steer, et al 
2009d, Zaman, et al 1997). A few studies have reported that poor nutrition and low egg 
consumption and soybean oil may be related to ARF risk (Zaman, et al 1998b). It is 
suggested that it is not the protein content but the alcohol-soluble material, choline, 
found in abundance in the egg yolk functions in the synthesis of serum phospholipid, 
which is an active component of the natural serum inhibitor of GAS haemolysin, 
streptolysin (Cobum 1950). Both egg yolk and soybean oil contain an anti­
inflammatory compound, A/-(2-hydroxyethyl) pahnitamide that is assumed to suppress 
the hyper-responsiveness of susceptible subjects and maturation of the rheumatic 
process (Swift 1931).
A study was conducted on the effect of low thiamine, riboflavin, ascorbic acid and 
vitamins A and D with ARF which reported that low vitamin A consumption was 
associated with ARF. Another study did not support the association of alpha-tocopherol 
and beta-carotene with ARF (Zaman and Yoshiike 2000). Patients with ARF were 
reported to have low albumin stores compared to healthy subjects. Iron deficiency may 
predispose to repeated GAS infections which may favour ARF (Zaman, et al 1998c).In 
ARF, the lesion in affected organs contain T cells, and PEM favours T cell infiltration 
of damaged tissues mediating imbalance in the immunologic functions (Guilherme and 
Kalil 2010). Furthermore PEM leads to lymphopenia, thymic atrophy and altered cell- 
mediated and antibody responses that may predispose to ARF (Zaman and Yoshiike 
2000). These findings are inconclusive and require further quantitative and qualitative 
specific dietary assessment studies.
Recently, the balance of cytokine production has been implicated as being a key 
coordinator in the development and progression of inflammatory disease activity in 
patients with ARF. In this study, the role of individual cytokines will be reviewed as an 
initial analytic step to evaluate the mechanisms that favour the development of 
autoimmune disease among rheumatic patients (Chapter?).
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1.3 Rheumatic heart disease
Rheumatic heart disease (RHD) is the most serious complication of ARP which 
develops 4-8 weeks (or later) after GAS infection in 30-45% of individuals (Chen, el al 
2003, Oli and Asmera 2004). There is increasing evidence to indicate that patients with 
ARP may be genetically programmed to respond abnormally to GAS infections (Ralph, 
et al 2006, Roodpeyma, et al 2005, Smoot, et al 2002a).
ARP represents an autoimmune response that occurs in individuals who have untreated 
infection with rheumatogenic strains of GAS pharyngitis and who are genetically and 
environmentally predisposed (Guilherme and Kalil 2010, Kaplan 1985). Patients with 
ARP have an abnormal immunological response at both humoral and cellular level to 
GAS antigens which are cross reactive with human tissues (Guilherme and Kalil 2010, 
Kaplan 1980). It is this abnormal immune response on the part of the host that is 
genetically programmed (Bryant, et al 2009, Kurahara et al 2002, Zabriskie 1985). 
Antigenic mimicry between GAS antigens, mainly M protein epitopes and heart 
proteins such as myosin and laminin, is proposed to be the triggering factor causing 
autoimmunity in patients with a genetic predisposition to ARP (Guilherme, et al 2006). 
It is also likely that the genetic background directs the immune response towards either 
a predominantly Thl or Th2 pattern.
The aggregation of cases in families, similar' disease patterns between siblings, identical 
twins and HLA correlation studies provide evidence for a genetic influence on ARP 
susceptibility (Chang 2011, Wilson and Schweitzer 1954, Zabriskie and Tabaqchali 
1983). Twin studies, for example, demonstrate estimated heritability across studies of 
60% (Engel, Stander et al. 201 l).An association with different HLA class II antigen 
related loci (HLA-DR, DQ) as markers for risk of ARP and RHD but with different 
alleles has been demonstrated in several populations(Haydardedeo □ lu, et al 2006). It is 
likely that the HLA-DR antigen may be responsible to mediation of this abnormal 
immunological response in ARP. Other new genes related to immune regulation are 
currently being investigated for understanding how they act in the complex network of 
autoimmune reactions that occur in ARF/RHD(Guilherme, et al 2011, Orim, et al 2012). 
Although there is controversy regarding an inheritance mode, several reports have
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provided evidence that ARP occurs in genetically predisposed individuals (Engel, et al 
2011, Lee, et al 2009)
Molecular antigenic mimicry between GAS antigens, mainly M protein epitopes and 
heart components has been proposed as the triggering factor leading to autoimmunity in 
susceptible individuals (Stanevicha, et al 2003). Known contributing factors include 
substandard living conditions with poverty, overcrowding, malnutrition, and low 
government health financial support. These effects are long-lasting producing a growing 
population of patients with chronic RHD, whose lifestyle and employment are severely 
affected (Chockalingam, et al 2003, Schaffer, et al 2003).
RHD is a major public health problem and is the leading cause of acquired 
cardiovascular morbidity and mortality in children and young adults in developing 
countries (Chen and Zhang 1981, Chockalingam, et al 2004, Supino, et al 2002). In low 
and low-middle income countries the prevalence of RHD ranges from 1.0 to 10 per 
1000. The World Health Organisation estimates that approximately 12 million people 
are affected by RHD/RF globally per year, resulting in about 40 000 deaths annually 
(WHO 2004). ARE with RHD is the major cause of cardiac admissions, 40% to the 
medical centres, and the primary cardiac surgical indication in underdeveloped 
countries, in its acute, recurrent or chronic form. It still remains a real threat to the 
disadvantaged population as it did decades ago (Cilliers 2006).
Besides the enormous burden of medical and surgical costs, recurrent ARP and RHD 
cause severe hardship to patients and their families, with repeated hospitalisations, 
disability, and premature death (Clur 2006, Folomeeva, et al 2003, Steer, et al 2002).In 
Yemen RHD is a significant cause of acquired heart disease in children with a reported 
prevalence of 3.6/1000 school children in Sana’a (Al-Munibari, et al 2001). 
Symptomatic RHD patients are usually detected through the paediatric clinics and 
hospitals in different districts of the country. This will be the first study to assess the 
prevalence of RHD in primary school children in Aden city using echocardiography 
(Chapter 3).
Although some progress has been made in the understanding of the autoimmune 
pathogenesis in ARP and RHD, there is still much to be elucidated about the disease
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process (Dinlda, et al 2003, Zhimin, et al 2006). Disease susceptibility factors, the 
major histocompatibility antigens (HLA) are under investigation as potential risk 
determinants for the disease. The genes of the HLA complex are attractive candidates 
likely to play a role in the genetic susceptibility to RHD and appeal’ to be related to 
racial and ethnic origin (Stanevicha, et al 2003, Weisz, et al 2004).
The determination of a genetic pattern of susceptibility to ARF and RHD has been 
sought for more than a century and has often been debated (Wilson and Morton 1937).
A familial incidence and a single recessive gene suggested that genetic factors play a 
role in ARF susceptibility (Wilson, et al 1943). Some have assumed an autosomal 
recessive model and a Mendelian inheritance (Davis 1970, Winter 1972). Recent studies 
have uncovered specific markers such as B-cell alloantigen D8/17 (Kaur, et al 1998, 
Rodriguez, et al 1990), Subsequent studies of HLA class II antigens have disclosed an 
association with different HLA-DR alleles according to the population analyzed 
(Ayoub, et al 1986). A molecular study of TNF-a documented its association with a 
gene having inflammatory function located in the MHC class II regions (Ramasawmy, 
et al 2007). A key role for TNF- a in immunopathogenesis of ARF/RHD has been 
proposed (Guilherme, et al 2007).
The association of FILA with ARF and RHD was to be explored in Yemeni children 
but it was not conducted due to the passing away of one my principal supervisors during 
the clinical laboratory analysis of this research and the limitations of funding.The 
association of toxins of GAS strains with pharyngotonsillitis and ARF as well as the 
genetic susceptibility in the causation of RHD is an area of worldwide research (Steer, 
et al 2009b). The purpose of this study is to determine tire distribution of genes coding 
for toxins, relate their frequency to the M antigen protein genotypes inGAS and 
characterize an association between ARF/RHD and cytokines. The pathogenesis of ARF 
and RHD includes a network of events with a complex immunological, pathological and 
clinical process. It is ironic that an innocuous “sore throat” should extract such a high 
price from the host and their family (WHO 2004). This study hopes to provide a further 
small step in elucidating the pathogenesis of this complex immunological disease.
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Objectives
Objective: 1
To determine the prevalence of rheumatic heart disease among primary 
school children in Aden
Objective: 2
To determine the prevalence of Group A p haemolytic Streptococcal 
infectionamong children with acute pharyngotonsillitis
Objective: 3
To determine the prevalence of Non-Group A p haemolytic Streptococcal 
infection among children with acute pharyngotonsillitis
Objective: 4
To determine the prevalence of emm serotypes, exotoxin gene and serum 
opacity factor gene among patients diagnosed with Group A p haemolytic 
Streptococcal and Non-Group A p haemolytic Streptococcal GAS and SNA 
pharyngotonsillitis
Objective: 5
To analyse the antimicrobial susceptibility pattern and genetic diversity 
among patients with Group A p haemolytic Streptococcal and Non-Group A p 
haemolytic Streptococcal pharyngotonsillitis
Objective: 6
To compare the concentrations of selected cytokines and chemokines in 
Yemeni children with acute rheumatic fever and recurrent rheumatic fever.
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Chapter 2
2 Methodology
2.1 Introduction
This research was conducted in Aden City, Republic of Yemen, implemented in four 
phases. The methodology undertaken for each objective will be discussed separately 
within the respective section on patients and methods.
2.1.1 Study location
Yemen is located in the south western comer of the Arabian Peninsula occupying an 
area of over half a million square kilometres. It is bordered by the Kingdom of Saudi 
Arabia to the north, the Arabian Sea and Gulf of Aden to the south, the Sultanate of 
Oman in the east, and the Red Sea to the west. The Bab A1 Mandab strait lies off the 
south-western tip of the Republic, and Mayoim, a Yemeni island in the middle of the 
strait, controls the passage into and out of tire Red Sea. There are over 112 Yemeni 
Islands in the Red Sea and the Arabian Sea. Yemen can be divided geographically into 
five major areas: Mountainous area. Coastal area. Plateau area, Desert (Al-Ruba Al- 
Khali) area, and Yemeni islands.
Yemen has a population of 21,069,869 as of the year 2005 in more than 122,000 
settlements and villages. Administratively, the country is divided into 22 governorates 
which are further divided into 333 districts, each of around 45,000 inhabitants. Yemeni 
society is labelled as traditional, with tire agricultural sector absorbing about half of the 
total work force (MOPIC 2005).
The health care system in Yemen consists of a large public sector along with a sizable 
private sector. Public health care is organized in three levels: primary health care (PHC) 
supported by secondary and tertiary referral care. PHC focuses on preventive and 
preventive health programs (immunization, MCH and family planning, health 
education, etc) and provides first aid and curative care. It starts at the village level 
where PHC units are run by paramedical staff. The units are backed up by PHC centres, 
often managed by a physician and have laboratory and X-ray facilities.
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The recommended course of the national Expanded Programme on Immunization [EPI] 
is described below.
Table 2. 1 Schedule for Childhood Routine Immunizations, Yemen
Antigen
(or nutritional
supplement)
Description Schedule
BCG Bacille Calmette-Guerin vaccine Birth
DT Tetanus and diphtheria toxoid childrens' dose 6, 10, 14 weeks
DTwPHibHep Diphtheria and tetanus toxoid with whole cell pertussis, Hib and HepB vaccine 6, 10, 14 weeks
HepB Hepatitis B vaccine 6, 10, 14 weeks
Measles Measles vaccine 9, 18 months
OPV Oral polio vaccine birth; 6, 10, 14 weeks
Pneumo_conj Pneumococcal conjugate vaccine 6, 10, 14 weeks
TT Tetanus toxoid 1st contact; +1, +6 months; +1, +1 year
Vitamin A Vitamin A supplementation 9, 18 months
Source: Ministry of Public Health and Population of Yemen. Health Partners Reform
plus WHO/Yemen, WHO Vaccine-preventable diseases: monitoring system 2011
Patients who cannot be properly cared for at tire PHC level are referred to district or
govemorate hospitals (secondary care) for further diagnostic and curative treatment. 
Some of these hospitals also support national or regional immunization and disease 
control programs. Finally, tertiary hospitals provide specialized care and serve as 
teaching hospitals for the medical faculties of the country’s universities.
The average number of persons per family is 7.1 and the average number of persons per 
dwelling is 6.9 persons, while the average number of persons per sleeping room is 
4.0.The under-15 age group represents 46.3% of the population with a rapid amiual 
growth of 3.5%. The total fertility rate is 6.2% birth/woman. Around 28 percent of 
children reaching their first birthday are fully immunized. The percent of low-weight 
births (less than 2,500 grams) is 19 percent. The crude birth rate is 40 per 1,000 
populations and the crude death rate is 12.6 per 1,000 populations. The under five 
mortality rate is 105 per 1,000 live births. Mortality rate among infants less than a year 
is (74.8) infant per 1000 births. Infant mortality rates account to 37.3deaths/1,000 live 
births. The average life expectancy at birth is 62.9 years (MOPIC2006).
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Yemen's health sector has been described as being in an early stage of epidemiological 
and demographic transition, with morbidity and mortality rates from communicable 
diseases dominating those from non-communicable diseases. Diarrhoeal diseases, 
malnutrition, acute respiratory infections, tuberculosis, malaria and pregnancy related 
complications are among the most prevalent health problems. Chronic diseases such as 
diabetes and hypertension have started to become more prevalent in Yemen.
About half of children under five suffer from malnutrition, 50 percent are stunted and 
13 percent show signs of wasting. Among children, diarrhoeal diseases and acute 
respiratory infections are the major causes of morbidity and mortality. Furthermore, 
one-third of all deaths among the under-fives occur because of vaccine preventable 
diseases. An estimated 12% of children suffer from disabilities, and there are few 
specialized facilities for disabled children.
This study was based in Aden, the economical capital and second largest city of a 
United Yemen. Aden was a British territory from 1839; it became part of independent 
South Yemen in 1967 and was the capital of South Yemen until 1990. Mid-way 
between Europe and the Far East, Aden lies on amajor world trading route through the 
Suez Canal, located at the south west tip of Yemen and the Arab peninsula; situated 346 
lan south of the capital city Sana'a, and 160 km east of Strait of Bab Al-Mandab.
Geographically Aden is situated at latitude 12.47° north and at longitude 44.57° east. 
Aden has no defined climatic season except for two named weathers, a cool winter and 
a hot humid summer. The area of Aden Governorate is 8,321 square kilometres and the 
population is 590,000 inhabitants (MOPIC 2005). It is one of the largest natural 
harbours in the world with an area of about 70 lan2 of sheltered water surrounded by 
Shamsan Mountain, Khormakser, and the shore which extends to the hills of Little 
Aden. The port of Aden consists of the Inner Harbour, the Oil Harbour serving Aden 
Refinery and the anchorage and approach channels of the outer harbour.
In the health field, Aden has 8 districts provided with 5 central hospitals with a capacity 
of more than 1337 beds, 12 health complexes and 25 health facilities in which 799 
doctors, 1127 nurses, 57 assistant doctors, 83 pharmacists and 138 dentists work. The 
private sector has proved to be efficient in providing the public with health services
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through 414 health institutions, 27 opticians, 8 dental workshops, 8 X-ray centres, 78 
laboratories, 88 general doctor offices, 180 specialized doctor offices, 9 medical centres, 
13 clinics and 3 hospitals, with a capacity of 402 beds. The total capacity reached, 
therefore, 1739 beds. In Yemen, there is 1 physician for 4,650, 1 nurse for 2,913 and 
only 1 trained midwife for 14,465 populations. Together Aden and Sana’a lay claim to 
50% of all physicians.
2.2 Objectives: 1 Prevalence of rheumatic heart disease
To determine the prevalence of rheumatic heart disease among primary school children 
in Aden city
2.2.1 Study site and design
Aden governorate has eight districts with 59 primary public schools from first to ninth 
primary class of whom 47 683 were males and 40 952 females. This was a descriptive 
cross-sectional case-finding survey of school children with RHD.
The target population were school children in established governmental primary schools 
of Aden city segregated by gender and selected by clusters through multistage sampling 
with probability proportionate to size (PPS). The schools were selected proportionately 
by stratified random sampling by school size and sex to include 6 schools from each of 
the centre and slum areas that give a total of 12 schools with an estimate number of 
6000 students.
The inclusion criteria were age group 5-16 years, both sexes, Yemeni nationality.
Each student in the selected school population had an equal independent chance of 
being recruited and selected in the study.
2.2.2 Sample size
Based on a study done by Al-Mimibari et al(Al-Munibari el al 2001)the prevalence of 
RHD in Yemeni school children was 3.6/1000, talcing the Cl of 95%, power 80%, and a 
precision of +10% then the number of students was calculated. Epi-Info 2002 (Statcalc) 
was used to estimate the required sample size of 6000 students with a maximum 
sampling error of +1.3%.
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Table 2. 2The Prevalence of RHD among school children was reviewed in different 
neighbouring countries
Country Study Year Prevalence
RHD/1000 Sample size
Kanpur. India 2000 4.54 3963
Sanaur. Indi 1998 3.6 5000
Egypt 1998 9.8 4700
Nepal, India 1997 1.2 4736
Kinshasa, Zaire 1996 14.03 4848
Kenya 1996 2.7 1115
Saudi Arabia 1990 2.4 9418
Ethiopia 1990 4.6 3235
Sudan 1986 3.0 13322
Nigeria 1978 0.08 12755
Source: (WHO 2004)
2.2.3 Informed consent and confidentiality
Permission to conduct the study was obtained from the Ethics Review Committee of 
Aden. The importance and objectives of the screening program was discussed with the 
General Education Department, Aden govemorate and the Primary School Health 
Director Officer. The District Education Officers (DEO) for government schools, and 
head teachers of each school were subsequently informed. It was then discussed with 
the health and social workers in the selected schools who discussed the study with the 
parent schools committees and relevant parents. Informed consent was obtained in 
writing from parents willing to allow their children to undergo the clinical screening, 
blood investigations and echocardiography if found to have an abnormal heart.Teachers 
or school administrators had no role in the selection of children.
2.2.4 Method of examination
The investigator performed the cardiac examination on all recruited students and those 
with organic murmur's were documented and given an appointment with a paediatric 
cardiologist in the central paediatric hospital for echocardiography. If an organic heart 
disorder was detected e.g. congenital heart disease or RHD they were followed up by 
the paediatric cardiology service. The features of an organic murmur are in Table.2.2.
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The children were investigated with a complete blood cell count with antistreptolysin 
titres (ASO) and C-reactive protein (CRP) followed by the echocardiography
Table 2. 3Differentiating non-organic from organic/pathological heart murmurs
Characteristics Non-organic murmur Organic/pathological murmur
Histoiy and physical Asymptomatic Symptoms and signs 
of cardiac disease
Timing Systolic ejection murmur, 
(except venous hum)
All diastolic, pansystolic or 
continuous
Grade <3/6 >3/6 (palpable thrill)
Splitting Physiologic S2 Fixed splitting or single S2
Extra sounds/clicks None Present
Change of position Murmur varies Unchanged
Modified from P12 - Pediatrics MCCQE 2002 Review Notes
2.2.5 Data collection
The students with echo proven RHD were interviewed through an open questionnaire 
by the investigator including information on demographic data, socio-economic factors, 
family history of ARF or RHD and previous history of ARF fulfilling the Duckett Jones 
criteria (TableS.l).
2.3 Objective 2: Prevalence of GAS infections in 
pharyngotonsillitis
Determine the prevalence of GAS infection among symptomatic Yemeni children with 
pharyngotonsillitis.
2.3.1 Study site, design and strategy
This cross-sectional descriptive survey was initially intended to be undertaken among 
children with acute pharyngotonsillitis in primary public health care polyclinics in Aden 
City. However, it became apparent that it was difficult to recruit the required number of
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patients because a high proportion of patients attending the polyclinics were already 
receiving antibiotic treatment, which was an exclusion criterion.
It was thus decided that children could also be selected from schools if they had acute 
pharyngotonsillitis and before receiving antibiotic treatment at the polyclinics or 
pharmacies.
2.3.2 Participants
All Yemeni children with acute pharyngotonsillitis attending public polyclinics and 
primary elementary schools during the study period that fulfilled the inclusion criteria 
of age 1- 16years, both sexes, symptoms of sore throat with evidence of fever, tonsillar 
swelling and exudates and tender anterior cervical adenitis had an equal independent 
chance of being selected after obtaining a verbal consent from the parents through the 
health social worker at school.
Patients with coryza, cough, conjunctivitis and use of antibiotics in the two-week period 
prior to onset of current illness were excluded from the study.
2.3.3 Sampling
A sample size of 730 children was based on published prevalence of GAS from the 
neighbouring countries of 24.3% with similar climatic conditions (Table 2.4). Sample 
size was calculated through Epi-Info 2002 (statcalc) with a Cl of 95%, power 80%, and 
a precision degree of + 10% and a maximum sampling error of +3,6%.
Table 2. 4 Presence of GAS in children with symptomatic pharyngotonsillitis
Year City/country Patients with pharyngotonsill itis GAS positive (%)a
1997 Netherlands 558 33.0 and 75.0b
1995 Northern India 910 13.5
1995 Souise Tunisia 474 17.7
1993 Cairo, Egypt 451 24.0
1992 Zagreb, Croatia 629 44.7
1992 Creteil, France 307 36.8
1987 Havana, Cuba 480 25.0 and 34.5b
1980s Rhode Island USA 8668 24.3
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a GAS positive = patients positive for GASb Patients with clinical features of GAS 
(fever, tonsillar exudates, anterior cervical lymhpadenopathy) Source: (WHO 2000)
2.3.4 Specific Methods
2.3.4.1 Collection of throat swab
Two sterile throat swabs were collected by rubbing sterile cotton tipped swabs over the 
tonsillar area on the eligible child without touching the tongue or lips.
2.3.4.2 First swab
The first swab was tested by Rapid Antigen Detection Test (RADT)using a Reveal 
Color Strept A Latex agglutination test (Murex Company), which detected GAS antigen 
in pharyngeal swabs. The swab was used for evaluation with Group A Strept Test kit 
performed according to the manufacturer instructions. The results of the test was 
obtained in 10 — 15 minutes and read as positive, negative or non-specific.
2.3.4.3 Second swab
The second swab was rolled on a Blood Agar plate containing 5% sheep blood. The 
blood plates were prepared from Trypticase Soy Agar with 5% sheep blood agar 
(Bellon et al 1991) that contained tryptone 15g, phytone/soytone 5g, sodium chloride 
5g, agar 15g and distilled water 1 litre. These ingredients were exposed to heat to 
dissolve agar, then autoclaved for 15 min at 121°C and then cooled to 50°C. Then 50 
ml of sheep blood was added to the melted agar, after which it was mixed and poured 
into sterile 15 x 100 mm petri dishes with a final pH base of 7.3 ± 0.2 (BAM Media 
M20: Blood Agar*, January 2001). When the throat swab reached the laboratory, it was 
inoculated on the prepared sheep blood agar plate.
The inoculum was further distributed by streaking it with a loop to obtain isolated 
colonies. The plates were then incubated at 35°C under anaerobic conditions for 24 to 
48 hours and checked for GAS. Potential GAS was checked by Gram stain, catalase 
(negative) and subcultures on to sheep blood agar for a bacitracin test. A bacitracin disc 
was added to a subculture of the initial isolate and cultures that gave a large zone 
around bacitracin disk >15 mm inhibition in diameter were considered Lancefield
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group A streptococci (GAS). The patients were treated with penicillin if positive for 
GAS infection with either RADTs or culture.
A glycerol nutrient broth was prepared to preserve GAS isolates in the cryobeads. 
Glycerol broth was prepared from a formula preparations of nutrient broth 84ml and 
glycerol 16ml that was mixed well and dispensed in 5ml amounts inscrew cap tubes 
(Cheesebrough M 1989). Those confirmed as having isolates of GAS by RADT} gram 
stain and culture had colonies stored in glycerol nutrient broth and cryobeads in freezers 
at -70°C and then later transported to Department of Microbiology at University of 
Liverpool. Pulsed field gel electrophoresis (PFGE) and Polymerase Chain Reaction 
(PCR) techniques were later undertaken which involved DNA isolation and PCR 
amplification of the toxin genes.
2.3.5 Statistical analysis
Data were entered into computer database SPSS Version 17 for windows (2008 SPSS 
Inc. Chicago, USA). Statistical analysis included quantitative descriptive analysis and 
summary statistics (mean, percentages, and standard deviations) for describing the 
prevalence of GAS. Quantitative analysis of the studied variables included 95% Cl, Chi 
squares and rates stratified by gender, age and other variables. Univariate analysis based 
on “odds ratio” (prevalence ratio was denominated OR) and 95% Cl and p values <0.05, 
Analyses was further based on chi-square tests, exact Fisher tests followed by logistic 
regression analysis for categorical variables and evaluation of the relationship between 
different symptoms and signs of GAS infections in the study population. Sensitivity and 
specificity was calculated for each cut off point and ROC drawn to find the optimal cut 
off point for highest sensitivity and specificity.
2.4 Objective: 3 Prevalence of SNA pharyngotonsillitis
Determine the prevalence of SNA among children with acute pharyngotonsillitis
2.4.1 Study site, design and strategy
This cross-sectional descriptive survey was undertaken among children with acute 
pharyngotonsillitis in Aden city similar' to that described in objective 2.
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2.4.2 Study subjects
The participants were the same patients described in objective 2.
2.4.3 Sampling
The numbers of patients included in this objective were recruited from the participants 
of objective 2
2.4.4 Collection of throat swab
The methodological process for the two throat swab collections followed the same 
procedures as described in objective 2. The positive culture sheep blood agar plates 
were subcultured on another plate with the addition of bacitracin. Bacitracin sensitive p- 
haemolytic streptococci that were isolated from patients with a negative RADT were 
subsequently tested for the Lancefield group by the latex agglutination test, the Oxoid 
streptococcal grouping kit, used for the identification of the streptococcal group 
(Diagnostic Reagents Streptococcal Grouping Kit Code: DR0585).
2.4.5 Diagnostic Reagents Streptococcal Grouping Kit Code: 
DR0585
The Oxoid Streptococcal Grouping Kit, (Oxoid Basinpotche, UK) a latex agglutination 
test was used for the identification of the streptococcal group and reagents were 
provided for groups A, B, C, D, F and G.Each latex reagent and the positive control 
reagent contained 0.1% sodium azide. After reconstitution the extraction enzyme 
solution contained 0.01% thiomersal.
Table 2. 5 Components of the Oxoid Streptococcal Grouping Kit
Kit Group
DR0586 Latex Group Reagent A
DR0587 Latex Group Reagent B
DR0588 Latex Group Reagent C
DR0589 Latex Group Reagent D
DR0590 Latex Group Reagent F
DR0591 Latex Group Reagent G
DR0592 Polyvalent Positive Control
DR0593 Extraction Enzyme
DR0500 Disposable reaction cards
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2.4.6 Preparations of cultures samples for identification
The streptococci were recultured from the cryobeads and grown on a blood agar plate 
overnight at 37°C under anerobic condition. The haemolytic reaction of suspect colonies 
was noted. The bottle of Oxoid Streptococcus Extraction Enzyme (DR.0593) was 
reconstituted with sterile distilled water to the amount shown on the label. The 
eppendorf tubes were labelled appropriately and 0.4 ml of enzyme was dispensed into 
each tube. Then 2-5 test colonies equivalent to 2-3 mm of growth were selected with a 
bacteriological loop and emulsified in the enzyme preparation.
2.4.7 Diagnostic reagent streptococcal kit test method
The latex reagents were brought to room temperature by wanning the bottles by hand. 
The latex suspensions were mixed by vigorous shaking. Any latex horn the dropper 
pipette was expelled for complete mixing. Then 1 drop from each latex reagent was 
dispensed into the circular rings on tire reaction card (DR0500). Using a Pastern pipette,
1 drop of extract was added to each of the 6 rings. With the mixing sticks provided, the 
mixture was spread over the entire area of the ring using a separate stick for each ring. 
Each card was gently rocked. The rings were examined for any agglutination reaction 
that would normally take place within 30 seconds. The positive control was used to 
check performance of latex reagents. Then the reaction card was safely disposed into a 
suitable disinfectant.
2.4.8 Interpretation of Results
The test was considered positive when agglutination occurred with one grouping 
reagent or when one grouping reagent gave a substantially stronger reaction than the 
other five. The test was considered negative when no agglutination occurred.
2.4.9 Statistical analysis
Data were entered into computer database SPSS Version 17 for windows (2008 SPSS 
Inc. Chicago, USA). Statistical analysis included quantitative descriptive analysis and 
summary statistics (mean, percentages, and standard deviations) for describing the 
prevalence of SNA. Univariate analysis based on “odds ratio” and p values <0.05. 
Analyses was further based on chi-square tests, exact Fisher tests followed by logistic
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regression analysis for categorical variables and evaluation of the relationship between 
different symptoms and signs of SNA infections in the study population.
2.5 Objective 4: Prevalence of emm genotypes, exotoxin 
superantigen superantigen and sof genes
Determine the prevalence of emm genotypes, exotoxin genes and serum opacity factor 
genes among patients diagnosed with GAS and SNA pharyngotonsillitis in Aden, 
Yemen.
2.5.1 Sample size and sampling strategy
The required numbers of patients were recruited from objective 2 and objective 
3. Objectives 2 and 3 aimed to establish prevalence of these pathogens in symptomatic 
children. In retrospect it would have been useful to include a group of asymptomatic 
children to document the carriage in apparently healthy children. (Nandi et ol, 2002, 
Dunnaz et al, 2003). This would allow estimation of prevalence in the general 
population and broaden interpretation of the findings. This is thus a limitation of the 
study. Selection of GAS and SNA isolates for genotyping was restricted by logistic 
constraints. The investigator only had resources to sequence 34 isolates. All SNA 
isolates were considered to be of special interest and were included. Available funding 
for genotyping the GAS samples, after inclusion of SNA isolates, allowed the selection 
of 21 samples at random.
2.5.2 Methods for Pulsed Field Gel Electrophoresis (PFGE) of 
GAS
Day 1 The organisms were plated onto blood agar and incubated at 37°C overnight.
Day 2 A single, well isolated colony was picked and suspended in 1 lOpl cold, cell 
suspension buffer .The cell suspension buffer comprises: lOmM tris, 20mM sodium 
chloride, 50mM EDTA (pH 7.2) in a 1.5ml eppendorf tube, to a McFarland Standard of 
“1”. We used the small gel frame for the PFGE tank when running fewer than 10 
samples. This needed lOOmls of gel and a 10 slot comb. On this gel we would usually 
run the marker, a control strain if we had one, and 8 samples( 9 samples for 100ml /10 
comb gel). The large gel frame needed 150mls of gel and takes a 15 slot comb on which
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we could run 13 samples. The marker we used for both was from Sigma: D2416 Pulsed 
Marker 50-1000kb.
Samples were then centrifuged at 13k for 1 minute. The supernatant was aspirated using 
a fine tipped pipette and discarded. The resulting pellet was re-suspended in a further 
HOpl of cold, cell suspension buffer. The tube was maintained at 60°C in a water bath 
for the next stage. 4pl lysozyme solution was added on the side wall of each tube. 1 Omls 
of 2% pulsed field grade agarose in single distilled water was prepared in a microwave 
and when melted, the agarose was placed in water bath to keep it molten. Keeping the 
samples at 60°C, lysozyme droplet was shaken down into buffer of first tube, 1 lOul of 
molten agarose was added, and contents mixed thoroughly and quickly pipetted into 2 
labeled plug moulds. Once all plugs were filled they were left at 4°C for 15 minutes to 
set. The two plugs for each sample were placed into individual plastic universal bottles 
with 1ml Lysozyme buffer plus 40ul Lysozyme and incubated for 1 hour at 37°C in a 
water bath. Lysozyme solution was aspirated and the plugs rinsed with 1.5ml of lx 
washing buffer for 10 mins. The wash buffer was removed and replaced with 1ml of 
Proteinase K buffer containing 40ul of Proteinase K (25mg/ml). The samples were left 
to deproteinate at 50°C in a water bath overnight.
Day 3 Next day Proteinase K solution was carefully aspirated and samples washed with 
gentle agitation, in 1.5ml of lx washing buffer for 30-60 minutes at RT. The wash 
buffer was discarded and replaced with 1.0ml of lx wash buffer containing 20ul of 
1.7% PMSF. Samples were gently agitated for 30 minutes at RT. After carefully 
discarding PMSF solution, plugs were washed 3 times, for 30 min each, in 1ml of lx 
wash buffer. After the last wash, one of the plugs was removed Rom lx wash buffer, 
placed in 500j.il of O.lx wash buffer in eppendorf tube and agitated at RT for 30-60 
minutes to eliminate EDTA salts (the other was stored at 4°C). The wash buffer was 
removed and replaced with 500pl lx sma\ reaction buffer (“React2” lOx buffer diluted 
1:10 in sdw). The samples were agitated for a further 30-60 minutes at RT before buffer 
was removed and replaced with 300jil of fresh lx smal reaction buffer containing 4 jil 
ofsma\ enzyme. The tubes were incubated at 37°C overnight in a water bath (the tubes 
may be stored at 4°C after digestion - for a maximum of 4 days).
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Day 4 A 1% w/v pulse field grade agarose gel was prepared (Ig of agarose to 100ml of 
0.5x TBE buffer for 100 ml gel (10 well)). After cooling slightly the agarose was 
poured into a combed PFGE tray. The gel was left to solidify for 30 minutes at RT 
before removing the comb. Each plug was processed individually by tipping into a Petri 
dish and cut in half lengthways with a scalpel. One half plug was placed into each well; 
final well had a sliver of pulse field marker (50-1000kB). The wells were sealed with 
1% agarose and allowed to set for 10 min. The remaining half plugs were stored at 4°C, 
in digestion solution, until results were obtained.The genomic DNA in the plugs was 
incubated with 24 U of Smal (Promega Corporation, Madison, Wis.) for 24 h at 25°C in 
a water bath.
2.5.2.1 PFGE interpretation
PFGE of the agarose plug inserts was then performed on a CHEF-DR III system (Bio- 
Rad Laboratories, Hercules, CA, USA) on horizontal 1% agarose gel for 20h at 6v 
/120° angle, with a switch time of (initial & final) 3 to 30 s at 14 °C. The gel was 
stained with ethidium bromide (0.5 pg ml * in water) for 45 — 60 mins and photographed 
on a UV transilluminator. Isolates differing in PFGE fragment patterns, by one or two 
bands, were regarded as closely related; minor mutational changes would result in such 
patterns according to Tenover criteria (Tenover, et al 1995) (Table 6.1).
Isolates are considered genetically indistinguishable if their restriction patterns have the 
same numbers of bands and the corresponding bands are of the same apparent size.
These isolates are considered to represent the same strain as the common outbreak 
strain. If the PFGE pattern of the isolate differs from the outbreak pattern by changes 
consistent with a single genetic event, i.e., a point mutation or an insertion or deletion of 
DNA; with changes resulting in two to three band differences, then these are considered 
to be closely related to the outbreak strain. If the PGEF patterns differ from the outbreak 
pattern by changes consistent with two independent genetic events i.e., four to six band 
differences, they are considered possibly related. If an isolate differs from the outbreak 
pattern with three or more independent genetic events (generally seven or more band 
differences), then it is considered an unrelated strain.
The control strain was processed along with the unknown isolates tested to confirm that 
the process of cell lysis, washing, and endonuclease digestion steps was working, the
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gel electrophoretic conditions was correct and the results reproducible from run to run 
within the laboratory were similar to those reported by others for the same strain. A 
molecular size standard must be run in at least one lane of the gel to provide size 
orientations of the fragments. Standards are needed to evaluate minor profile differences 
that may result from single genetic events such as deletions, insertions, or mutations. 
Preparations consisting of phage lambda concatamers, as a 4 ‘lambda ladder,’ ’ were used 
as molecular size standards with an enhanced 48-kb band, helpful for size orientation in 
the gel. Thus the presence of one of these strains in each group of isolates to be tested 
provides both a procedure control and a molecular' size standard.
Selected strains were typed by PFGE of chromosomal digests using Smal, Isolates 
differing by only 1±6 bands from a common reference strain for each group were 
assigned a common type. More than six bands of difference from subtype 1 of each type 
were considered unrelated isolates and assigned a different PFGE type (Haukness, et al 
2002, Tenover, et al 1995).
2.5.3 Isolation of chromosomal DNA
GAS chromosomal DNA was isolated using the PureGene DNA purification kit (Gentra 
Systems, Minneapolis, MN). The protocol supplied by the manufacturer was used with 
the following modifications: with addition of mutanolysin lysozyme (Sigma-Aldi'ich,
St. Louis, MO),
2.5.3.1 Analysis of the emm gene
In the late twentieth century with advances in DNA-sequencing technology, a method 
was developed to determine the M GAS type from the sequence of the gene encoding M 
protein, the emm gene (Beall, et al 1997). The emm gene of GAS is the gene that 
encodes the M protein, which forms the basis of a serological typing scheme. A method 
has been developed to determine the M GAS type from the sequence of tire gene 
encoding M protein, the emm gene (Beall, et al 1997). emm sequence typing is currently 
the most widely used method to define GAS strains through sequence analysis of PCR 
products of the N-terminal hypervariable region of the M protein gene and its excellent 
typeability and concordance values (Beall, et al 1996). It has become a powerful 
epidemiological tool to study GAS M-type with identification accessible in all
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laboratories with DNA-sequencing capability. It has resulted in a dramatic increase in 
the number of identified M and emm types(Bisno, et al 2003, Cunningham 2000).
The emm gene was amplified by PCR using primers emmlb and emml. PCR was 
performed in a reaction mixture volume of 25pi under the following conditions: initial 
denaturation at 94°C for 5 min, 30 cycles of denaturation at 94°C for 1 min, primer 
annealing at 55°C for 1 min, and extension at 72°C for 1 min 45 s, and a final extension 
step at 72°C for 5 min. Size variation in emm PCR product was assessed by gel 
electrophoresis using 1.5% agarose gels. PCR products were purified using QIAquick 
PCR purification kit (QIAGEN, Valencia, CA) according to manufacturer’s protocol. 
The primers used were primer 1: TAT TCG CTT AGA AAA TTA A and primer 2 
GCA AGT TCT TCA GCT TGT TT and Sequencing primer emm seq2 TAT TCG 
CTT AGA AAA TTA AAA ACA GG. Although primer 1 may also be used for 
sequencing and these came from the CDC website:
www.cdc.gov/ncidod/biotech/strep/protocol_emm-type.htm, Sequencing was done by 
Macrogen/ Lark at the DNA level.
Purified PCR product was used as template for cycle sequencing with either emmlb or 
emml primer under the following conditions: 25 cycles of 96°C for 10 s, 50°C for 5s, 
and 60°C for 4 min. Sequence data were analyzed by BLAST search performed against 
the Centers for Disease Control and Prevention (CDC) Streptococcus pyogenes emm 
sequence database (http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm). To be 
identified as a particular emm type, the emm sequences had to have greater than 98% 
identity with the emm sequence of CDC reference strain. Reference strain sequences are 
available from CDC at URL: http://www .cdc.gov/ncidod/biotecli/strepAmmtypes.htm.
2.5.4 Exotoxin pyrogenic gene phage determination 
All strains were cultured on blood agar plates Agar plates were stored at 4°C; DNA 
lysates were stored at -20°C and bacterial strains were stored at -80°C in the freezer at 
the Microbiology Laboratory Department, University of Liverpool.
Emm sequence typing was performed as described by Beall etal on the CDC web site 
http://www.cdc.gov/ncidod/biotech/strep/protocol_emmtype.htm). DNA was extracted 
with a commercial chelex resin-based DNA extraction kit (InstaGene Matrix 1, Bio-
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Rad, France). All emm sequences used in this study are available at http 
:www.cdc.gov.Ncidod biotech.strep.strepindex.html) and were independently obtained 
in the CDC streptococcal laboratory from CDC reference strains.PCR of GAS isolates 
was performed according to recommendations of Division of Bacterial and Mycotic 
Diseases, Centres for Disease Control and Prevention (CDC), Streptococcus pyogenes 
emm sequence database (http://www.cdc.gov/ncidod/bioteclV strep/doc.htm).
The primers used for amplification of GAS at the DNA wereprimer 1 (55 
TATTCGCTTAGAAAATTAA 3’) and primer 2 (5’ GCAAGTTCTTCAGC TTG TTT 
3’). PCR products were purified with Wizard columns (Promega, Madison, Wis.) as 
described by the manufacturer. Primer 1 (F) TATTAGCTTAGAAAATTAA 5' ends of 
emmL genes GCAAGTTCTTCAGCTTGTTT 3' ends of emniL genes. The sequence 
DNA analysis were subjected to homology searches against the bacterial DNA database 
with GCG software (Wisconsin package, version 8). Sequences for new emm gene 
GenBank entries were obtained from one strand of PCR fragments. PCR fragments 
using methods and the primers used were described in Table 2.5 (Page 22).
PCR detection of the sil locus was performed with two sets of primers: silC-Fand silC-R 
for the silC while ORF and silD-F and silD-Rfor the silD ORF (Table 2.5) All PCR 
mixes consisted of a 50-jxl volume with 25 pi of 2x QIAGEN Multiple PCR Master Mix 
(QIAGEN, Courtaboeuf, France), 5 pi of 5x Q-solution, 1 pM each primer and 5 pi of 
bacterial DNA extract. PCR was performed with a Bio-Rad i-cycler thermal cycler as 
follows: DNA denaturation and polymerase activation for 15 min at 95°C; 30 cycles of 
30 s at 94°C, 90 s at 55°C, and 90 s at 72°C; and a final extension step for 10 min at 
72°C. The PCR detected the positive toxin gene profile for the GAS and SNA isolates.
The PCR was used for toxin-gene profiling (speC, spdl and sdn) using the primers aas 
shown in Table 2.5 as described by Schmitz et a/(Schmitz, et al 2003). GAS colonies 
were resuspended in 20 mL of water and boiled for 5 min at 95 °C and then centrifuged 
with brief high-speed. PCRs were setup in a total volume of 50 mL, with 1 mL of cell 
lysate as a template, 5 mL of lOx PCR buffer, 5 mL of 10xMgC12 (25mmol/L), 2 mL of 
dNTPs (10 mmol/L each), 1 mL of polymerase (3.5 U/mL; High Fidelity PCR System; 
Roche), and 1 mL of each oligo (100 pmol/L). PCR was performed by denaturing for 5
28
min at 96°C, 30 cycles for 50 s at 96°C5 annealing for 65 s at 44°C, and elongation for 
70 s at 72°C5 followed by 5 min at 72°C. The PCR detects the positive toxin gene 
profile for the studied GAS and SNA isolates.
2.5.5 Serum opacity factor (sof) determination and sequencing
All strains were cultured on blood agar plates and stored at - 20°C until characterization. 
SOF gene sequence specific typing with PCR was performed using standard protocols 
Boehringer Mannheim Hi Fidelity system described by Beall et al. 2000 (Beall et aL, 
1998; CDC web site) http://www.cdc.gov/ncidod/biotecli/sti-ep/protocol-emm type.htm).
DNA was extracted with a commercial chelex resin-based DNA extraction kit as 
recommended by the manufacturer (InstaGene Matrix f Bio-Rad, France). Conserved 
primer sets were based upon comparison of the sof gene with GenBank accession 
sequence encoding the mature protein plus 22 residues of signal sequence amplification 
PCR fragment using methods and primers described in Table 2.6(Beall, et al 2000).
2.5.6 Data analysis
The SPSS 17 statistical package was used for all analyses. Chi square or Fisher’s exact 
test was used for statistical analysis. A P value of <0.05 was considered significant.
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2.6 Objective: 5 Analyze the antimicrobial susceptibility 
pattern
Analyse the antimicrobial susceptibility pattern and genetic diversity among patients 
with GAS and SNA pharyngotonsillitis
2.6.1 Patients and methods
The susceptibility pattern was determined on a total of 24 culture isolates from patients 
with acute pharyngotonsillitis of whom 11 GAS isolates were selected from objective 4 
and all the 13 SNA isolates were collected from objective 5.
2.6.2 Antibiotic disc sensitivity test procedure
Antibiotic disc sensitivity testing using penicillin G (1 unit), amoxicillin (lOpg), 
erythromycin (5 pg), tetracycline (10 pg) and chloramphenicol (10 pg) was conducted 
on the 24 culture proven GAS and SNA isolates on the isosensitest agar supplemented 
with 5% defibrinated horse blood. The diameter of the zone of inhibited growth around 
the antibiotic disk, known as the diameter of zone of inhibition was measured to the 
nearest millimetre with a ruler and according to the standard Table by the BSAC system 
the bacteria were classified as sensitive and resistant. The range of concentrations test 
and interpretation of results was as per the BSAC guidelines on antimicrobial sensitivity 
testing (Andrews 2001b),
2.6.2,1 Reference for breakpoints
The breakpoint refers to the concentration of antibiotic dividing isolates of GAS as 
susceptible or resistant to a particular antibiotic. The interpretation of zone diameters in 
(mm) according to the BSAC standard for the six antibiotics of penicillin G, 
amoxicillin, erythromycin, chloramphenicol and tetracycline were sensitivity of >20mm 
and a resistance of <19mm (Andrews 2007).
2.6.3 Data analysis
The data was then analyzed by SPSS 17.0 software and the level of significance was 
determined as p<0.05.
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2.7 Objectives: 6 Compare the levels of selected cytokines and 
chemokines
Compare the concentrations of selected cytokines and chemokines in Yemeni children 
with ARF and RRF.
2.7.1 Sample size
The sample size was based on a study on cytokines in ARF which included 27 patients 
(12 ARF and 15 RHD) (Yegin, ei al 1997) and another study on 18 patients with RRF 
(WHO 2004). Cytokines and chemokines were analyzed from a subset of 50 patients 
analysis in the current study to compare the results from the two groups ARF (Group 
A), RRF (Group B). A total of 25 children fulfilling the diagnosis of ARF and 25 
children fulfilling the diagnosis of RRF were recruited from the patients in the private 
polyclinics and those admitted in public and private hospitals.
2.7.2 Blood collection for Cytokines
Peripheral blood was taken into sterile 5ml containing tubes, immediately centrifuged 
at 600g (+4’C) for 10 min, serum collected in tubes and kept frozen at -70°C until 
transported to Microbiology Department at University of Liverpool for analysis. 
Commercially available BD™ Cytometric Bead Array (CBA) Human Inflammatory 
Cytokines Kit were used with FCAP Array sp/tware (Cat. No. 641488)
2.7.3 FCAP Beads assay
Bead assays determined the concentrations for multiple analytes in the given sample In 
a bead assay, one or more beads with discrete and distinct fluorescence intensities were 
used to simultaneously detect multiple analytes in a small sample volume. The beads 
captured and quantified soluble analytes through a sandwich schema. A particular 
analyte in the sample was bound to a corresponding bead with given fluorescent 
characteristics. The bead was coated with capture antibodies specific for that analyte. A 
reporter antibody (different from the capture antibody) bound to the analyte and was 
conjugated with fluorescent molecules (different color from those used to distinguish 
beads). Unbound (excess) reporter antibodies and analytes were eliminated by washing. 
Samples are acquired with a flow cytometer and acquisition sq/tware capable of saving 
data in a Flow Cytometry Standard (FCS) 2.0 file format. FCAP Array jq/tware
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analyzes the FCS 2.0 files. Bead populations were found by clustering, and assigning 
beads to clusters. Reporter antibody florescence intensity within a population measured 
the analyte-specific binding.
Figure 2. 1 FCAP Bead assays
2.7.3.1 Quantitative analysis
Quantitative analysis was determined by analyte concentrations based on the known 
concentration values of a set of standards with FCAP Array sp/tware. The number of 
concentration levels was used to calibrate the standard curve and number of sample and 
standard replicates were adjusted. FCAP Array sp/hvare read the FCS 2.0 data files 
from the experiment, locates clusters (to which analytes have been assigned), and then 
determined the median fluorescence intensity (MFI) of the detector antibody for each 
analyte. The software fit a standard curve to the data from the concentration standards. 
The standard curve was used to calculate concentration values for each measured 
analytes in each sample bead capture analyte
2.7.3.2 Reagents provided
The BD CBA system uses the sensitivity of amplified fluorescence detection by flow 
cytometry to measure soluble analytes in a particle-based immunoassay. Eachbead in a 
BD CBA Kit provides a capture surface for a specific protein similar to a coated well in 
an ELISA plate. BD CBA capture bead mixture is in suspension to allow for multiple 
analytes detection in small volume sample. BD CBA Human Inflammatory Cytokines
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Kit was used to quantitatively measure the different cytokines and chemoldnes in this 
study Interleukin-Ip (IL-ip), Interleukin-6 (IL-6), Interleukin-7 (IL-7), Interleukin-8 
(IL-8), Interleukin-9 (IL-9), Interleuldn-10 (IL-10), Interleuldn-12p70 (IL-12p70), 
Tumor Necrosis Factor (TNF-a);, Interferon gamma (IFN-y), chemokines Monocyte 
Chemotactic Protein-l(MCP-l), Macrophage Inflammatory Protein-la (MIP-la), 
Macrophage Inflammatory Protein-ip (MIP-lp), Human interferon inducable protein- 
10 (IP-10) and Regulated upon Activation, Normal T-cell Expressed and Secreted 
(RANTES) protein levels in a single sample. The kit performance has been optimized 
for analysis of specific proteins in serum samples using the protocol BD™ Cytometric 
Bead Array (CBA) Human Inflammatory Cytokines Kit.
2.7.3.3 Serum Assay Procedure
10 pl/test of each Human Inflammatory Cytokine Capture Bead suspension was mixed 
and the pellet mixed beads were centrifuged and the supernatant aspirated. It was 
resuspended in serum enhancement buffer and incubated for 30 min at RT. Then 50 pi 
mixed beads were transferred to each assay tube. Reconstitute Human Inflammatory 
Cytokine Standards were reconstituted in assay diluent for 15 min and dilute standards 
were formed by serial dilutions using assay diluents. The standard dilutions and test 
samples were added to the appropriate sample tubes (50 pl/tube) and incubated for 1.5 
hour at RT. The samples were washed with 1 ml wash buffer and centrifuged with 100 
pi residual volume left after aspiration. PE Detection Reagent (50 pl/test) was added to 
the samples and incubated for another 1.5 hour’s at RT. The samples were washed with 1 
ml wash buffer and centrifuged. Then an additional 300 pi of wash buffer was added to 
each assay tube and the samples analyzed.
2.7.3.4 Cytometer Setup Bead Procedure
Three 50 pl/tube tubes A, B and C were setup and Cytometer Setup Beads were added 
to them. This was followed by adding 50 pi of FITC positive control to tube B and 50 pi 
of PE positive control to tube C and incubated for 1.5 hour’s at RT. Then 400 pi of wash 
buffer was added to tubes B and C while 450 pi of wash buffer was added to tube A.
The tubes A, B and C were used for cytometer setup. The Human Inflammatory 
Cytokines Standards were lyophilized and reconstituted and serially diluted 1:1, 1:2 and 
1:4 before mixing with the Capture Beads and the PE detection reagent.
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2.7.3.5 Preparation of Human Inflammatory Cytokines capture beads 
for serum sample analysis
The number of assay tubes (including standards and controls) required for the 
experiment were 49 known and 9 standard dilutions and 1 negative control = 59 assay 
tubes. Each capture bead suspension was vigorously vortexd for a few seconds before 
mixing. Thena 10 pi aliquot of each Capture Bead was added for each assay tube to be 
analyzed, into a single tube labeled “mixed Capture Beads” (eg, 10 pi ofIL-8 Capture 
Beads x59 assay tubes = 5900 pi ofIL-8 Capture Beads required). The mixed Capture 
Beads were centrifuged at 200 x g for 5 minutes and carefully aspirated and supernatant 
was discarded. The mixed Capture Beads pellet was resuspended in Serum 
Enhancement Buffer equal to the same volume above and vortexed thoroughly. The 
assay tubes were incubated for 30 minutes at RT and protected from direct exposure to 
light. The mixed Capture Beads were then ready to be transferred to the assay tubes 
(50pl of mixed Capture Beads/tube) and samples analyzed by flow cytometer as 
desciibed in BD CBA Human Inflammatory Cytokines Kit Assay Procedures using the 
BD FACS Calibur flow cytometers and the BD FACS Comp sq/tware BD 
FACSArray™ bioanalyzer (FCAP Array software (Cat.No. 641488)).
2.7.4 Data analysis
The profiles of a selection of 14 cytokines and chemokines in serum of children with 
ARF and RRF are described. The cytokines and chemokines IL-1J3, IL-6, IL-7, IL-8, IL- 
9, IL-10, IL-12p20, TNF-a, IFN-y, MCP-1, MIP-la, MIP-lp, IP-10 and RANTES were 
analyzed using FCAP Array Software with BD FACS Array Bioanalyzer. The analysis 
of cytokines and chemokines and their correlations included their comparisons in ARF 
and RRF patients, Data analysis was conducted using SPSS version 17 with descriptive 
statistics using median and inter-quartile ranges. The Maim-Whitney test was used to 
compare medians between ARF and RRF groups. Spearman correlation coefficient was 
conducted on the study of correlations between the different cytokines and chemokines 
and the level of significance was p = <0.05.
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Chapter 3
3 Prevalence of Rheumatic Fever and Rheumatic Heart 
Disease among Yemeni school children in Aden
3.1 Introduction
Rheumatic Heart Disease (RHD) is the leading form of acquired childhood 
cardiovascular disease and continues to be a common medical problem in 
industrializing countries. It is a major public health issue in areas where there is limited 
access to medical care of children living in poverty, overcrowding and poor housing 
conditions (Al-Eissa, et al 1993, Olgunturk, et al 2006). RHD is clearly an important 
and preventable cause of ill health and death (Nkomo 2007, Omurzakova et al 2009, 
WHO 2004).
RHD is triggered by an auto-immune reaction to an untreated throat infection with 
GAS; initially giving rise to ARF within days to weeks and then disappearing, but 
leaving behind damage to the heart valves (Carapetis, et al 2005a, Kafetzis, et al 2005, 
Majeed, et al 1992a). The cumulative damage of recurrent and persistent episodes of 
ARF results in RHD (Omokhodion 2006, Oran, et al 2000). Primary school screening 
surveys appear to be the most informative source to assess the prevalence of RHD when 
echocardiogram is available for confirmation (Padmavati 2001, Robertson, et al 2006).
The prevalence of RHD has been estimated in surveys of school-age children, with wide 
geographic variations ranging horn 0.2 per 1000 school children in Pinal Del Rio, Cuba 
(Nordet, et al 2008), 1.2 per 1000 in India (Bahadur, et al 2003), 2.3 per 1000 
schoolchildren in Mozambique (Marijon, et al 2007), 3.4 per 1000 in Egypt (Refat 
1994), 14 per 1000 schoolchildren in Kenya (Longo-Mbenza, et al 1998), 21.9 per 1000 
schoolchildren in Pakistan (Sadiq, et al 2008). The prevalence of RHD was 26/1000 in 
children in New Zealand and 8.5/1000 in Australia (Jaine, et al 2008, Parnaby and 
Carapetis 2010, White, et al 2010, Wilson 2010) and 8.4/1000 in Fiji (Steer, et al 
2009c).
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In Yemen symptomatic patients with RHD are usually detected through paediatric 
clinics and hospitals and RHD accounts for a significant cause of acquired heart 
morbidity and mortality.
The school survey presented in this chapter is the first of its kind in Yemen and aimed 
to estimate the prevalence of RHD among schoolchildren aged 5-16 years in Aden city. 
The survey was based on cardiac auscultation with echocardiographic confirmation of 
the diagnosis.
3.2 Objective
To determine the prevalence of RHD among primary school children in Aden.
3.3 Literature review
ART is a clinical syndrome without a specific diagnostic test or single pathognomonic 
feature. Dr. T. Duckett Jones proposed guidelines for ARE diagnosis (1944) that were 
revised by the American Heart Association (1992) and the World Health Organization 
(WHO 2004) (Table 3.1).
ART is unique among infectious diseases in having a tendency to recur and the only 
cardiac disease that is clearly preventable (Taranta 1967, Taranta and Markowitz 1989). 
ART still remains highly prevalent in developing nations with presence of unfavourable 
conditions such as overcrowding, poor hygiene and limited access to health care 
(Alkhalifa, et al 2008, Shulman 2007). RHD continues to be an important and 
significant cause of congestive heart failure (CHF) in Africa, Central and South 
America, and Asia (Mendez and Cowie 2001, Shaddy and Wernovsky 2005).
Disability-adjusted life years (DALYs) lost to RHD ranged from 27.4 to 173.4 per 100 
000 population in WHO Regions of America and South -East Asia with an estimated 
6.6 million DALYs lost per year worldwide (Carapetis, et al 2005a, Hart 1993).
An approach to the problem of ARP/RHD must be guided by a plan which coordinates 
medical and non-medical community leaders for mass primary prevention, providing 
care for high-risk group of susceptible children and for checking the accuracy of 
secondary prevention (Alkhalifa, et al 2008, Robertson, et al 2006). This important
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public health problem requires improvement in the detection and treatment of sore 
throats and regular screening of school-children for ARF/RHD. There is an urgent need 
for early identification of children with ARF/RHD for penicillin prophylaxis, thus 
preventing recurrence of ARF and progression of RHD (Carapetis, McDonald et al. 
2005).
It is of utmost importance to provide health education to parents, children and to 
teachers, as well as to medical and non-medical health providers in order to increase 
awareness and understanding of the disease (Steer, et al 2011). The Director of health 
care centres should facilitate the introduction of secondary prophylaxis strategies into 
existing health care systems. A simple registry program should be introduced at the 
polyclinics, hospitals and public and private hospitals in order to facilitate regular* and 
continuous follow up and secondary prophylaxis(Robertson, et al 2006,Steer and 
Carapetis 2009).
RHD is the most common acquired heart disease worldwide leading to incapacitating 
haemodynamic changes in children, adolescents and young adults (McDonald, et al 
2005). Its public health importance is not only a direct result of its high occurrence rates 
(mortality, prevalence and incidence), but also the population affected (children and 
young adults) and its economic consequences, both in health care related costs and its 
indirect cost to society, often resulting in premature death or disability (Carapetis 
2008a, Demina, et al 2005, Kaplan 2005).
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Table 3. 1 Diagnosis of Rheumatic fever
Duckett Jones criteria (1992)
Two major or one major and two minor manifestations must be present, plus evidence of 
antecedent GAS infection.
Chorea and indolent carditis do not require evidence of antecedent GAS infection.
Recurrent episode requires only one major or several minor manifestations, plus evidence of 
antecedent GAS infection.
Major manifestations:
Carditis
Polyarthritis
Chorea
Erythema marginatum 
Subcutaneous nodules 
Minor manifestations:
Arthralgia
Fever
Raised erythrocyte sedimentation rate or C-reactive protein concentrations
Prolonged PR interval on electrocardiogram
Evidence of antecedent GAS infection
Positive throat culture or rapid antigen test for GAS
Raised or rising streptococcal antibody titer
WHO criteria (2002-03)
Chorea and indolent carditis do not require evidence of antecedent GAS infection.
First episode 
As per Jones criteria 
Recurrent episode
In a patient without established RHD: as per first episode.
In a patient with established RHD: requires two minor manifestation, plus evidence of 
antecedent GAS infection. Evidence of antecedent GAS as per Jones criteria, but with addition 
of recent scarlet fever.
Modified from (Carapetis Jonathan et al 2005)
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Figure 3. 1 Figure Prerequisites for the development of ARF/RHD
ARF is an immunoinflammatory delayed non-suppurative sequelae of GAS upper 
respiratory tract infection (Kaplan 2005, Majeed 2002). RFID is the end result of a 
number of factors including neglect, late diagnosis, improper treatment, atypical 
presentations or repeated recurrences of ARF (Robertson and Mayosi 2008). In low 
income countries, it is a serious cause of chronic health problem during the school age 
period (Figure 4.1) (Guilherme, et al 2006).
Even though substantial efforts have been made to understand the pathogenesis of GAS 
infections in triggering RHD, it still remains an intricate network of events that have a 
complex immunologic basis. It is ironic that a rather innocuous “sore throat” should 
extract such a high price from the host (WHO 2004).
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The clinical manifestations of RHD reflect the response to GAS and the severity of 
ARF in an individual(Commerford and Mayosi 2006). These are determined by host 
genetic susceptibility, virulence of the infecting organism and a conducive environment 
(Stollerman 200 la). A high proportion of people with RHD do not recall a history of 
ARF (Carapetis, et al 2005b), and they are not aware of their problem until an incidental 
detection occurs during a medical check up or when the disease progresses with the 
development of symptoms and signs of cardiac failure (Giannoulia-Karantana, et al 
2001).
Genetic susceptibility and autoimmune features play an important role in RHD along 
with familial disease occurrence and the relationship with HLA antigens of the major 
histo-compatiblity complex related to racial and ethnic origin (Kudat, et al 2006, WHO 
2004). Disease susceptibility factors including the major histocompatibility antigens and 
tissue-specific antigens are presently under investigation to assess their role as disease 
determinants (Kaplan 2005).
Toll-like receptors (TLRs) are key cell-associated pattern recognition receptors (PRRs) 
in the innate immune system able to recognize a wide range of pathogens (Liadaki, et al 
2011). The classification depends on the cell surface/intracellular site and type of 
pathogen-associated molecular' patterns (PAMPs). Bacterial cell surface components 
combine with PRRs such as the ficolin family of proteins, or Mannan binding lectins 
that form complexes leading to complement activation causing phagocytosis of the 
invading pathogen, apoptosis, or modulation of inflammation. TLR2 and TLR4 are 
located on the cell surface and recognize bacterial products unique to GAS. Mutations 
and polymorphisms in TLRs have shown their essential role in human defense against 
diseases.
TLR lead to production of proinflammatory cytokines which activate macrophages and 
dendritic cells (DC) to remove the pathogens. DCs couples TLR-mediated innate 
immune recognition leading to the initiation of T and B cell activation. These molecules 
act as signals to activate adaptive immune responses (Schumann and Keitzer 2005).
DCs act as the antigen presenting cells that express CD80 and CD86 and MHC 
molecules on their cell surface allowing these cells to present processed antigens to T 
cells through the T cell receptor (TCR). Class I MHC molecules present peptides from
intracellular pathogens to CD8+ T cells, while class IIMHC molecules present peptides 
derived from extracellular pathogens to CD4+ T cells. These in turn secrete cytokines, 
as TNF-a and IFN-y that affect pathogen survival and control the immune response. 
CD4+ T cells cause expansion of CD4+ effector cells, CD8+ T cells and B cells 
(Liadald, ^ a/2011).
These molecules involved in the innate and adaptive immune responses are encoded by 
genes that may be associated with ARF/RHD. TLR2 is encoded by a gene located on 
chromosome 4 in the 4q32 region with a single nucleotide polymorphism (SNP) in exon 
3 (2258 G>A) that leads to the replacement of arginine with glutamine in codon 753. 
The polymorphism in TLR-2 genotype 753 Arg/Gln was reported to be more frequent in 
Turkish children with ARF. TLR4 polymorphisms as TLR4-D299G SNP, alone or 
together with 7X7W-T399I, were reported to be associated with an increased risk of 
recurrent GAS pharyngotonsillitis.
Ficolins are molecules that play a role in the innate immune response. They are able to 
bind to specific PAMPs and trigger the complement lectin pathway. Ficolins bind to 
collectin receptors and activate immune cells to produce cytokines like TNFa, IL-1 and 
IL-8. Three ficolin genes were found in humans that encode ficolin-1 (M-ficolin), 
ficolin-2 (L-ficolin) and ficolin-3 (H-ficolin or Hakata antigen). The role of ficolin-2 is 
involved in the clearance of the pathogen by binding to the specific GAS antigen, 
lipoteichoic acid; hence low levels predisposes the patients to recurrent GAS infections 
leading to ARF and RHD (Messias-Reason, et al 2009). Polymorphisms in the ficolin 
genes may produce different serum ficolin protein levels which lead to prolonged or 
repeated GAS infections and are important in ARF pathogenesis. Polymorphisms in the 
FCN2 gene promoter for L ficolin protein that binds to GAS also may be important. 
FCN2 gene polymorphism was shown to be associated with CRHD. CRHD patients 
express the haplotype -986/ 602/-4 G/G/A, with decreased serum ficolin-2 levels. The 
haplotype -986/-602/-4A/G/G was associated with protection against CRHD. MBL 
binds to N-acetyl-D-glucosamine present on the cardiac valves. MBL2 genotypes were 
reported to be associated with risk of carditis in patients with ARF/RHD. Haplotype 
GGA was found more frequently in CRHD patients in Brazil (Hemandez-Pacheco, 
Flores-Dominguez et al. 2003).
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MBL is a lectin pathway member of the complement system involved in innate immune 
responses that is involved in the clearance of the bacteria. MBL2 gene was reported to 
be involved in the development of valvular lesions (Chou and Tsai 2006). SNPs were 
found in the promoter site of the MBL2 gene (-550H/L, -221X/Y and +4P/Q) and in 
exonl (codons 52A/D,54A/B and 57A/D) of ARF/RHD patients (Bryant, et al 2009).
Different alleles were associated with valvular' lesions in RHD. A allele (52A, 54A and 
57A) codes for high production of MBL was reported to be linked to mitral stenosis 
while the O allele (52D, 54B and 57D) which encodes for low production of MBL was 
found in AR. Fc fragments receptor of immunoglobulin G (FcgRIIA) eliminates 
antigen-antibody complexes from the blood and protects the host against foreign 
antigens. The gene for this receptor is expressed on mononuclear phagocytes, 
neutrophils, and platelets and shows SNP in exon 4. The 131R/R genotype was reported 
to be associated with a high risk of ARF in Turkish children (Sallakci, et al 2005, 
Akcurin et al. 2005).
Several studies have reported the role of TNF-a gene polymorphisms in RHD(Berdeli, 
et al 2005)(Duzgtin, et al 2007). TNF-a gene in the alleles TNF-a -308A and -238G and 
genotype was associated with ARF/RHD in Mexico, Brazil, Egypt but not in Turkey 
(Berdeli, et al 2006, Bryant, et al 2009, Hernandez-Pacheco, et al 2003, Sallakci, et al 
2005) There may be a risk of RHD associated with polymorphisms in the TNF-a 
promoter region and TNFAIP3 (Hua, et al 2009, Mohamed, et al 2010, Settin, et al 
2007). Another study reported immunoglobulin FcRIIA gene polymorphisms with risk 
to ARF by a genetic failure of removal of immune complexes (Berdeli, et al 2004, 
Guilherme, et al 201 l).The MEFV polymorphism was reported to cause impaired 
control of Thl helper cell immune response in pathogenesis of ARF (Col-Araz, et al 
2012). Polymorphisms of the ACE gene have been shown to be related with CRHD 
(Berdeli, et al 2005, Bryant, et al 2009). These polymorphisms were observed to be 
linked to valvular* damage (Ramasawmy, et al 2007, Smeesters, et al 2009).
Extensive research is in progress to advance knowledge on the genetic and host 
susceptibility factors for ARF/RHD, disease pathogenesis and distribution and 
frequency of toxin-producing strains of GAS with a view to the development of
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vaccines against GAS disease, and these efforts should improve prophylaxis and 
treatment strategies (Medina and Chhatwal 2002, Thomas 2001).
Prevalence rates of RHD vary between and within populations which may be attributed 
to genetic predisposition and/or socioeconomic standards (Jose and Gomathi 2003, 
Marijon, et al 2007, Zhimin, et al 2006). These differences also depend on the age of 
the studied population and the survey techniques (Table 3.2).
It is estimated that at least 15.6 million people have RHD and 300,000 of 500,000 new 
individuals with ART develop RHD annually. There may be up to 233,000 deaths 
worldwide due to ART or RHD per year and 95% of these occur in developing countries 
(Oli and Asmera 2004, WHO 2004). However, the burden of RHD is likely to be 
higher than these estimates given that epidemiological data from developing countries 
are poor (Isaacura and Granero 1998, Mincham, et al 2002, Ravisha, et al 2003).
Most surveys are conducted in schools that include clinical cardiac examination with 
the subsequent assessment of RHD through performance of echocardiography and 
Doppler ultrasonography (Carapetis 2008a, Marijon, et al 2007, Meira, et al 2005). The 
utilization of these techniques is acceptable to the population and is appropriate for 
screening and has a high sensitivity and specificity (Steer and Carapetis 2009b, 
Vijayalakshmi, et al 2005). In low income countries, RHD accomits for 30% to 40% of 
cardiac patients admitted to hospital and are an important reason for heart surgery 
(Alkhalifa, et al 2008, Essop and Nkomo 2005).
RHD follows the prevalence ART which increases with age, starting in childhood and 
peaking in adulthood (Berry 1972, Chockalingam, et al 2004). This profile has been 
well documented in populations having both low and high rates of RHD (Ahmed, et al 
2005, Kumar, et al 2002, Oli and Asmera 2004).
Several reports horn South Asia, the Middle East and North Africa have highlighted 
unacceptably high sex predilection pattern of RHD with an association of severe 
manifestations in girls and women (al-Sekait, et al 1990, Diao, et al 2005, Rizvi, et al 
2004). It has been postulated that this gender preference may be explained by innate
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susceptibility, limited access to preventive health care or increased exposure to GAS 
infections (Padmavati 2001).
Table 3. 2 Prevalence of RHD per 1000 in school-aged children by ehocardiography
Reference Year of study Place
Age
(yrs)
No.
screened
RHD/
1000
No of RHD 
children
Wilson et al 2010 New Zealand 5-15 1142 26 29
Jaine et al 2008 Australia 5-14 - 8.5 _
Periwal et al 2005 India 5-14 3002 0.67 2
Sadiq et al 2002 Pakistan 5 - 15 24,980 21.9 546
Bahadur et al 2002 Nepal 5-18 9420 1.2 11
Marijon et al 2001 Mozambique 6-17 2170 2.3 5
Marijon et al 2001 Cambodia 6-17 3677 2.2 8
Mebenza et al 1998 Kenya 5-16 4848 14 59
Hasab et al 1997 Oman 5-16 9904 0.8 8
Nordet et al 2000 Cuba 5-15 25,159 0.2 6
Refat et al 1994 Egypt 6-12 8000 3.4 27
Mahmodi et al 1992 Iran 7-18 167,786 0.14 23
Khalil et al 1992 Sudan 5-15 13,332 3 40
Al-Sekait et al 1990 Saudi Arabia 6-15 9418 2.4 22
References: (Alkhalifa, et al 2008, Carapetis, et al 2005a, Marijon, et al 2007, Nordet 
2000, Sadiq, et al 2008, Steer and Carapetis 2009b)
The most common valvulopathies in RHD are mitral regurgitation, which is the 
predominant cardiac lesion, and mitral stenosis. Mitral stenosis becomes more common 
with advancing age (Choudhary, et al 2001, Mahmoud U Sani 2007).
It is well known that low income, poverty, overcrowding, poor housing conditions and 
inadequate sanitation increase the impact of the disease (Abella-Reloza 1998, Jose and 
Gomathi 2003, Paul 1930). In addition, inadequate expertise of primary healthcare 
providers, shortage of health care resources and low disease awareness in the 
community further affect both the occurrence and recurrence of the disease. Another 
contributing factor is the fear of allergic reactions to penicillin for primary and 
secondary prophylaxis. This is of great concern as prophylaxis is needed to minimize
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the risk of exposure of children and adults to GAS (Cilliers 2006, Kumar; et a! 2002, 
Lennon 2004, Robertson, et al 2005).
Although, in most developing countries, cost-effective strategies for ARF/RHD control 
programmes are available they remain under-utilised (Cilliers 2003, McDonald, et al 
2005). RHD is now very rare in developed countries and remains mainly a disease of 
poverty. The diagnosis of RHD may subject the patient to high cost cardiac surgery, 
although tills may not be available for populations of low socioeconomic settings 
(Demina, et al 2005, Hillman, et al 2004).
3.3.1 Components of a ARF/RHD Prevention Programme
Penicillin remains the drug of choice in primary and secondary prophylaxis of 
ARF/RHD since there are no reports of resistance of GAS isolates to penicillin 
(Carapetis, et al 2005a, Robertson, et al 2006, Steer and Campetis 2009a). Primary 
prevention is the first line of treatment for acute GAS pharyngotonsillitis with 
appropriate antibiotics. Primary prophylaxis is to prevent subsequent attacks of GAS 
pharyngotonsillitis which could trigger ARF and recurrence with increasing severity for 
cardiac disease (Steer, et al 2011).
Antibiotic therapy stalled within 9 days of onset of acute pharyngotonsillitis is effective 
to prevent ARF. Oral penicillinV for 10 full days is still the first line treatment in 
patients with good compliance. In patients with poor compliance to an oral regimen, 
they can be given a single intramuscular dose of benzathine penicillin G (BPG) at time 
of GAS diagnosis. Patients who show hypersensitivity to penicillin may be treated with 
eiythromycin (Madden and Kelly 2009). First generation cephalosporins maybe used 
but 5% of patients allergic to penicillin may also show allergy to cephalosporins. If 
eiythiomycin resistance is documented then alternatives include clarithromycin or 
azithromycin. Some measures likely to be effective but difficult to implement include 
decreasing overcrowding and improving access to medical care and antibiotics (Warren 
2010).
Secondary prophylaxis is given to patients after the initial attack of ARF. They are 
predisposed to recurrent attacks of ARF with high risk to develop carditis, if not yet 
developed or worsen with an existing RHD (Kerdemelidis, et al 2010). The choice of
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antibiotics is similar to the primary prophylaxis.Secondary antibiotic prophylaxis is only 
effective with good compliance and given as intramuscular BPG every 4 weeks to 
ensure adequate serum penicillin levels. In high risk areas of ARF tire BPG dose should 
be given every 3 weeks for better prevention of recurrent ARF(Commerford and 
Mayosi 2006). Unless patients are compliant with oral regimens, these can also be 
effective.
The duration of secondary prophylaxis depends on clinical symptoms of the disease and 
presence or absence of heart valvular defects Patients with history of ARF without 
car’ditis should be treated until the age of 21 years or 5 years after their last attack. 
Patients with RHD should be treated until 40 years of age or 10 year’s after their last 
attack of ARF. Patients without CRHD are recommended to receive at least 10 years of 
therapy or until well into adulthood (Gerber; et al 2009). Patients who live in areas with 
continuous high exposure to GAS may require lifelong prophylaxis (Seckeler and Hoke 
2011). It is also recommended to continue prophylaxis after heart valve replacement 
surgery, as any of the four cardiac valves can be affected by ARF. Patients with RHD 
require antibiotic prophylaxis to prevent endocarditis before minor surgical and dental 
procedures with short term antibiotics to be continued for one week after the procedures 
(Ananda and Purushottam 2008, Carapetis, et al 2007).
Screening surveys in combination with a national registry form the framework of a 
ARF/RHD prevention programme. Although primary prophylaxis preventing initial 
attacks of ARF is ideal, it is rather difficult to implement in large populations, hence 
secondary prophylaxis to prevent recurrent attacks of ARF remains the most practical 
solution in underprivileged countries (Tandon 2004).
A registry program has been shown to be inexpensive and to facilitate the delivery of 
secondary prophylaxis through continuous and regular* follow up (Bassilf et al 2002, 
Kumar; et al 2002, Marijon, et al 2007). It can be conducted in school health centres, 
maternal and child health services and paediatric clinics. There is no registry program in 
operation in Yemen.
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3.4 Patients and methods
This was a cross sectional survey of school children in Aden, Aden city has 59 primary 
public schools with 1796 classrooms segregated by gender, of which 47683 are male 
and 40952 female students. A cross-sectional survey of RED was conducted on a 
representative sample of 6000 school children aged 5-16 years of both sexes from 
February 2004 through April 2005,
3.4.1 Sample size
The sample size for the survey was based on data obtained from previous studies that 
reported prevalence rates per 1000 school children of 3.6 in Sana’a, Yemen. If the RHD 
prevalence accepted was 3.6/1000 taking the Cl of 95%, power 80%, and a precision of 
±10%, then the number of students which would be a representative of one million was 
6000. The target population was drawn from 12 governmental primary schools of eight 
districts at Aden selected by systematic sampling,
A written approval acceptance form of school visits was obtained from the Director of 
the Ministry of Education, the School Health Care Doctor and eight School Vice- 
Directors. Informed verbal or written consent was obtained from the parents. All 
students enrolled underwent a careful cardiacauscultation in a quiet room by the 
principal investigator and two paediatric specialists. They were examined in both the 
supine andleft lateral decubitus positions. A social worker recorded their identification 
data.
3.4.2 Clinical asssessment
Children diagnosed with organic/pathological murmurs were auscultated for a second 
time by the same investigator to confirm the clinical diagnosis (Chapter 2).During the 
clinical examination if a pathological murmur was diagnosed; the patient was offered 
echocardiography. In students with doubtful murmurs for a second examination were 
also given appointment for echocardiography. Children with pathological murmurs 
were then given appointments for echocardiography in a specialty hospital to which 
they were taken by bus after obtaining a second informed consent from their 
parents/guardians. These children also had a complete blood count, ASO and CRT 
investigations which were done in a specialized diagnostic centre.
48
Two-dimensional and colour flow Doppler echocardiography was used for detecting 
abnormal blood flow and valvular regurgitation. Independent echocardiography was 
peifoimed by two paediatric cardiologists who were present for all the echo Doppler 
examinations. The echocardiography Doppler findings were then discussed by the two 
cardiologists and a consensus diagnosis of RED was achieved prior to the enrolment 
into the further components of the study. The diagnosis of definite RHD was based on 
the modified Duckett Jones’ criteria which included the presence of a significant 
organic mitral or aortic murmur.
Echocardiographic evidence of significant valvular incompetence was defined as the 
presence of evidenceof mitral or aortic valve regurgitation seen in two Doppler 
echocardiography planes, accompanied by at least two ofthe following three 
morphologic abnormalities of the regurgitantvalve: restricted leaflet mobility, focal or 
generalized valvularthickening, or abnormal subvalvular thickening (Ferrieri 2002, 
Folger, et al 1992). These features had tobe identified concordantly by each 
cardiologist.
A diagnosis of suspected RED was made in the presence of significant mitral or aortic 
oiganic miumuis with trivial or simple mitral (MR) or aortic valvular regurgitation 
(AR) without morphologic abnormalities of the regurgitant valve in the presence of 
normal heart chambers. Mitral valve prolapse (MVP) was categorized as CED, if it was 
a mitral valvulopathy with an underlying non-rheumatic structural abnormality; and as 
RED when MVP was associated with MR and thickened valves.
3.4.3 Socio-economic assessment
Regarding the demographic characteristics, overcrowding was defined as > 4 members 
per bedroom(Sana’a, Yemen: Ministry of Planning 2006). The housing conditions 
were classified as “good” when the house was made of stone with > four rooms and had 
a water supply; “satisfactory” if the house was made of stone and had water supply but 
was small; and “bad” if was made of other materials (e.g. wood) and had no water 
supply. Water supply included treated pipe water or untreated water from protected bore 
holes, springs and sanitary wells, either in the home or within 15 minutes walking 
distance.
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The socio-economic status was assessed by obtaining the income of each household 
member for one month and calculating the total monthly money income of the 
household/total members in the household. Family income was graded as low (<5000 
Yemeni Riyals (YR), intermediate (5000 - 10,000 YR) and high (>10,000 YR) and 
around 340 Riyals equal to a £1(MOPIC2006),
A questiomiaiie which included demographic details, past medical hi story j family 
socio-economic background and income per capita was completed for all students. 
Prophylactic benzathine penicillin G every three weeks was prescribed to suspected and 
confirmed patients with RED. This prophylactic treatment was to be undertaken 
regularly in primary health centres in their neighbouring districts.
3.4.4 Statistical analysis
Data was analyzed using the Statistical Package for Social Sciences (SPSS-PC) version 
17. Statistical analysis included quantitative descriptive analysis and summary statistics 
(mean, percentages, standard deviations, 95% Cl and rates) stratified by gender, age and 
valvulopathies. Analysis was based on chi-square tests and Fisher’s exact tests.
3.5 Results
3.5.1 General characteristics of children in the survey 
A total of 6000 primary school children of both sexes in twelve schools representing 
7.4% of the school population underwent clinical screening followed if necessary by 
Doppler echocardiography. The primary level starts from class 1 to class 6 which 
includes children from approximately 5 to 12 year’s of age while the preparatory level 
from class 7 to class 9, includes children from 13 to 16 year's.
The male to female ratio was 1.1:1 with a mean (SD) age of 11.2 (3.1) years. Children 
10-16 years old comprised 53% of the participants. About half, 3203 (53.4%) children 
attended primary school and 2797 (46.6%) preparatory school. Males comprised 1562 
(49%) and 1506 (53.8%) participants who attended primary and preparatory level, 
respectively (Table 3.3).
The prevalence of RHD was probably underestimated since 514 had an organic murmur 
and out of them 168/514 (32.7%) parents of children (of whom 105 were females
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comprising a female-to-male ratio of 1.7: 1) considered to have organic murmurs 
refused permission for further investigation. An important limitation of the study was 
that only 346 of the 516 children with a clinically detected cardiac abnormality 
consented to echocardiography; one-third refused. This systematic error could partly 
explain the lack of gender association in our study.
Table 3. 3 Characteristics of 6000 study participants
Variables n = (%)
Age/years Mean (SD) 11.16 (3.1)
Age groups (years) 5-10 2817 (47.0%)
>10-16 3183 (53.0%)
Gender Male: female (male %) 3068:2932 (51.1%)
Education Primaiy 3203 (53.4%)
Preparatory 2797 (46.6%)
Class and sex Primary (male %) 1562/3203 (48.8%)
Preparatory (male %) 1506/2797 (53.8%)
School Almasmoum 297 (5.0%)
Alshukany 699(11.6%)
Basateen 432 (7.2%)
Fatehli 322 (5.4%)
Gala 513 (8.6%)
IbnZaidoon 570 (9.5%)
Kadicia 265 (4.4%)
Raydan 452 (7.5%)
Rowdah 522 (8.7%)
SevenJuly 744 (12.4%)
Shamsan 686(11.4%)
Wahdda 498 (8.3%)
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n= 587 (9.8)
Screened 
n = 6000
Murmur 
n=587 (9.85
=514 (8.
Organic
5413
Murmur on 
auscultation
Non-organic 
n=73 (1.2%)
Doppler
Echocardiogram
Other 
cardiac 
defects 
n=22 (0.4)
Rheumatic heart 
disease
Congenital heart 
disease
Mitral valve 
prolapse 
n=36 (0.6)
Suspected 
rheumatic 
heart disease
Refused
Definitive 
rheumatic 
heart disease 
n= 219(3.7)
Figure 3. 2Flow diagram of total participants in the study
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3.5.2 Cardiac findings of screened children
Heart murmurs were documented in 587 (9.8%) students. Of these 514 (8.6%) were 
deemed to be organic murmurs. One hundred and sixty eight (2.8%) parents refused 
fuithei investigations oi did not attend school during the day of the echocardiography 
examinations.
Cardiac defects were diagnosed by echocardiography in 346 (5.8%) children. RHD was 
diagnosed in 288 (4.8%), 219 (3.7%) with definite RHD and 69 (1,2%) with suspected 
RHD. The overall prevalence of definitive RHD comprised 36.5/1000 children (95% Cl 
32%-41.6%) (Table 3.4).
Childien with suspected RHD were discharged from the study. These children with 
suspected RHD were given prophylaxis with antibiotics as penicillins or if allergy give 
eiythiomycin and were instructed to attend health services and to be assessed every 6 
months with a repeat echocardiography one year later. Fifteen students were diagnosed 
with ARF including three with recurrent rheumatic fever (RRF) and RHD. These were 
referred for hospital admission.
Table 3.4RHD among the school children screened
Variables n(%)
Children screened 6000
Murmur 587 (9.8)
Organic 514 (8.6)
Non-organic 73 (1.2)
Echocardiography Done 346 (5.8)
Refused 168 (2.8)
Rheumatic heart disease 288 (4.8)
Definitive 219 (3.7)
Suspected 69 (1.1)
Congenital heart disease 58 (1.0)
Mitral valve prolapse 36 (0.6)
Others* 22 (0.4)
* Other CHD included 7 PDA, 4 ASD, 4 PS, 3 AS, 2 VSD, 1 TOF and 1 TA
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Congential heart diseases (CHD) included seven patent ductus arteriosus (PDA), four 
atiial septal defects (ASD), four pulmonary stenosis (PS), three atrial stenosis (AS), two 
ventricular septal defects (VSD), one Petrology of Fallot (TOF) and one tricuspid 
atresia (TA).
3.5.3 Prevalence of cardiovascular disease 
The survey documented 277 students with echocardiographically confirmed 
cardiovascular' disease (219 with definitive RED, 36 with MVP and 22 with CHD) 
There was a higher prevalence of RHD in preparatory than in primary school 
children(59.3 vs 16.6/1000,/? = 0.001)
The mean age (SD) of children with and without definite RHD was 14 (1.8) and 10.8 
(3.2) respectively (p = 0.001). The prevalence of RHD among males was 40.4/1000 
(95% Cl 33.7-48.0) which was higher than females 32.4/1000 (95% Cl 26.3 - 39.5), but 
this was not statistically significant (p=0.97) (Table 3.5).
Table 3.5Pievalence of Cardiovascular Diseases per 1000 school children by the 
education level and sex
Cardiovascular defects N
CHD
11 (°/oo)
RHD
n (%o)
All
n (%o) 95% Cl
Education
-Primary (1-6 class) 3203 32(10.0) 53 (16.6) 85 (26.5) (21.3-32.8)
-Preparatory (7-9 class )** 2797 26 (9.3) 166 (59.3) 192 (68.6) (59.6-78.8)
Sex
-Male*** 3068 40 (13) 124 (40.4) 164 (53.5) (45.9-62.2)
- Female 2932 18(6.1) 95 (32.4) 113 (38.5) (32.0-46.3)
All cardiac defects 6000 58 (9.7) 219(36.5)* 277 (46.2) (41.1-51.9)
^Prevalence of RHD 36.5/1000 school children ** p = < 0.0001 comparing CHD and 
RHD between primary and preparatory levels ***p = <0.005 when comparing CFID and 
RHD between males and females
Echocardiographic evidence of CHD was obtained in 58 (1%) children resulting in a 
prevalence of 9.7/1000 (95% Cl 7.4 - 12.6%). The male to female ratio of CHD was 
2.2: 1 but this difference was not statistically significant (p = 0.08).
54
Thirty-six children with CHD had mitral valve prolapse, which was three times more 
common in males than females (27 versus 9) (p < 0.02). The main types of other CHD 
are listed in Table 3.4. The majority had MVP followed by PDA, then by ASD and PS.
c 4.00
o 3.00
5 2.00
Age in years
□ Normal
□ CHD 
■ RHD
Figure 3. 3Distribution of RHD and CHD by age
3.5.4 Medical background
A history of RHD was obtained from more than one family member in 53 (24.2%) of all 
children with RHD. RHD was diagnosed in 20 siblings of the children with definite 
RHD. One family had four siblings affected, another three siblings in two families, two 
siblings in two families and one sibling in six families all attending the same schools. In 
addition there was a positive family history of one of the parents or a close relative in 33 
children. Only 36 (16.4%) out of 219 children with RHD were aware of their 
cardio\ascular disease before the study and 18 (8.2%) were on irregular secondary 
rheumatic prophylaxis.
j>.5.5 Socio-econornic status of children with and withoutcardiac 
defects
Low income was observed most frequently among children with RHD (49.3%), 
followed by children with CHD (44.8%), compared with children without these
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conditions (21.6%) X2 for trend (13.2). Similarly poor housing conditions was reported 
most frequently in children with RHD (39.3%) followed by CHD (32.8%), compare to 
(21.6%) in normal children X2 for trend (12.9).
An overcrowding index was assessed by dividing the total number of family members 
by the number of bedrooms used and overcrowding considered when there were four or 
more persons per bedroom. A higher overcrowding index was reported in children with 
RHD (64.8%) while in CHD it was 48.3% and those without any cardiac defects 37.1% 
X2 for trend (22.2). The difference between low income, bad housing conditions and 
overcrowding between the three groups were all statistically significant (p^O.OOl) 
(Table 3.6).
Table 3.6Socio-economic status among children with cardiovascular disease
Socio-economic status
Cardiovascular defects
p valueCHD
n = 58
RHD
n = 219
No detects
n =5723
Income Low 26 (44.8%) 108 (49.3%) 1236 (21.6%) 0.001
Middle 22 (37.9%) 62 (28.3%) 2175 (38%)
High 10(17.2%) 49 (22.4%) 2312(40.4%)
Housing Bad 19 (32.8%) 86 (39.3%) 1234(21.6%) 0.001
conditions Satisfactory 21 (36.2%) 82 (37.4%) 2225 (38.9%)
Good 18(31%) 51(23.3%) 2264 (39.6%)
Overcrowding Yes 28 (48.3%) 142 (64.8%) 2123 (37.1%) 0.001
No 30(51.7%) 77 (35.2%) 3600 (62.9%)
3,5.6 Cardiovascular disease by age and sex
There was a higher frequency of heart disease among males than females >10 years old 
(145 (52.3%) and 104 (37.5%)), respectively compared with that among children < 10 
years old, (19 (6.9%) and 10 (3.6%)) for males and females, respectively (p = 0.04). 
Older children were more likely to have confirmed RHD (p < 0.05) (Table 3.7).
Table 3.7Children with cardiovascular disease by sex and age
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Sex Age CHD
n(%)
RHD 
n (%) P value
Male n=164 40 (24.4) 124 (75.6)
5-10 year (19) 9 (47.4) 10(52.6)
*11-16 year (145) 31 (21.4) 114(78.6) 0.02
***Female n=113 18(15.9) 95 (84.1) 0.06
5-10 year (10) 7 (70%) 3 (30%)
11-16 year (104) 11 (11.5) 92 (88.5) 0.001
**A11 (277) 58 (20.9) 219(79.1) 0.001
*p = 0.02 between CHD and RHD and sex in the 11--16 year age
* P 0*001 between CHD and RHD in both age groups 
*** P = 0*06 between male and female in CHD and RHD
3.5.7 Blood investigations in children with RHD
Ninety-three school children (42.5%) with RHD had a positive CRP and 139 (63.5%)
had raised ASO titers > 200 Todd units, of whom 27 (12.3%) had ASO titers over 600 
Todd units. (Table 3.8).
Table 3. SBlood investigations in 219 children with RHD
Blood Test RHD n (%)
ASO Todd units
(normal~<200) <200 80 (36.5)
> 200 - 400 62 (28.3)
>400 - 600 50 (22.8)
>600 27 (12.3)
CRP
(normal=< 1 mg/dL) Normal 126 (57.5)
Raised 93 (42.5)
The median CRP was 3 mg/dL (IQR 2-5 mg/dL) among patients with a single valve 
involvement and 6 mg/dL (IQR 4-8mg/dL) with multiple valve involvement. A higher
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proportion of students with multiple valve involvement 21 (65.6%) had a raised CRP 
level than students with single valve involvement 11(35.4%) and the difference was 
statistically significant (p^O.OOl).
Table 3. 9C-reactive protein levels among patients with valve involvements
CRP Single valve Multiple valves
mg/dL n=54 n=39 P
<5 43 (70.5) 18(29.5) 0.001
>5 11 (34.4) 21 (65.6)
3.5.8 Cardiac valve lesions in school children with RHD 
The commonest valves affected among children with RHD were the mitral valve in 209 
(95.4%) and the aortic valve in 44 (20.1%). The mitral valve was predominantly 
involved m more than half of the children, with isolated MR in 109 (50.9%), combined 
MVP with MR in 57 (26.6%) and combined MR and AR in 39 (17.8%). Isolated aortic 
valve regurgitation was diagnosed in nine patients (2.3%) and pure mitral stenosis was 
detected in five (1.9%) 11-16 year' old students, four boys and one girl (Table 3.9).
Although the proportion of males with RHD was higher than in females, the difference 
was not statistically significant. Valvulopathies were more frequent in 11 -16 years old 
children (P< 0.001). In the 13 children with RHD < 10 years of age isolated MR with no 
evidence of other valvulopathies was the only finding.
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Table 3. lOType of cardiac valve lesions in children with RHD by sex and age
Sex
Age
5-10 year
n(%)
11 — 16 year***
n(%)
Male 11= 124 (%) *
Mitral regurgitation 10 (8.1) 48 (38.7)
Aortic regurgitation 7 (5.7)
Mitral stenosis 4 (3.2)
Mitral regurgitation+ aortic regurgitation 21 (17.0)
Mitral regurgitation + mitral valve prolapse 34 (27.4)
Sub total 10 (8.1) 114(91.9)
Female n=95 (%) **
Mitral regurgitation 3 (3.2) 48 (50.5)
Aortic regurgitation 2(2.1)
Mitral stenosis 1(1.1)
Mitral regurgitation+ aortic regurgitation 18(19.0)
Mitral regurgitation + mitral valve prolapse 23 (24.2)
Sub total 3 (3.2) 92 (96.8)
""P h-lld2 between valvulopathies and both age groups in males
•*p = 0.4 between valvulopathies and both age groups in females 
:**P = 0-001 between valvulopathies and both age groups in both sexes
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3.6 Discussion
RHD remains a major contributor to cardiovascular disease in children and adults in low 
and middle income countries accounting for recurrent hospital admissions, premature 
disability and early death (Canter, et al 2004, Golbasi, et al 2002, Olgunturk, el al 2006, 
Sadiq, et al 2008).
This school survey is the first to assess the prevalence of RHD among school children in 
Aden. The lack of similar surveys was largely due to limited Rinding for public health 
issues. The prevalence of RHD reported in this study in Aden is 36.5/1000 school 
children and is one of the highest reported in the world among the school surveys that 
have used echocardiography (Al-Munibari, et al 2001) . Despite the high prevalence, it 
is likely that this is an underestimate of the true prevalence in this population, as 
students with poor health are more likely to be kept at home than healthy children.
A large proportion of the participants were diagnosed for the first time. This is 
attributed to some families being totally unaware of their children’s illness or its 
severity and as they lack access to proper diagnostic tests. This may be explained by 
limited financial resources for families to access health services and thus they seek 
medical advice mostly for emergency purposes only.
This high prevalence confirms that RHD is an alarming public health program in 
Yemen with long-term health and economic consequences. General health screening 
programs and a preventive RHD prophylactic program are an urgent and essential 
necessity which should be undertaken as a regular basis.
Routine screening programs should lead to earlier detection and monitoring of 
asymptomatic and symptomatic cardiac lesions in patients through primary school 
surveys which are the mainstay of childhood screening programs around the world 
(Carapetis 2008a, Chen, et al 2003, Finau and Taylor 1988, Jose and Gomathi 2003).
In this study there was an inconsistent sex pattern among patients with RHD. Previous 
studies have reported that females are more likely to experience RHD than males. This 
might reflect behavioural patterns such as being more often housebound and to have 
closer involvement with mother and child care, thus increasing their exposure to GAS
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infections and overcrowding. Females also face constraints due to socio-cultural norms 
in health care seeking thus limiting their access to preventive medical care. However, 
this is not a universal pattern, as other studies have not confirmed these sex differences 
as was the case in this study (Thakur, et al 1996, Vashistha, et al 1993). It is difficult to 
determine whether the lack of gender differences was due to similar backgrounds
among males and females, or a preferential pattern of healthy school children being 
overrepresented in schools.
The prevalence of RHD was probably underestimated since 514 had an organic murmur 
and out of them 168/514 (32.7%) parents of children (of whom 105 were females 
comprising a female-to-male ratio of 1.7: 1) considered to have organic murmurs 
refused permission for further investigation. An important limitation of the study was 
that only 346 of the 516 children with a clinically detected cardiac abnormality 
consented to echocardiography; one-third refused. Refusal means that the parents did 
not agree for the child to have an echocardiogram performed or the child did not attend 
school on the day the echo was performed. The availability of a portable 
echocaidiographic machine in the field might have minimised some of this loss. The 
majority of those for whom echocardiography was refused were female (62.5%) and the 
explanation given by their parents was reluctance to accept that the child might have a 
heart disease. If it had been proved by echocardiography, it would affect the family’s 
reputation and damage the child’s prospects of marriage. Some families were suspicious 
of the fact that the echocardiogram, an expensive investigation, was free of charge.
They might have thought that it was not for the purposes of research but for some other 
unspecified reason.
The more frequent refusal of females to accept the echo could have led to a systematic 
enoi. This systematic error could partly explain the lack of gender association in our 
study. In other settings females are reported to have a higher prevalence of RHD.Their 
higher refusal rate could have preferentially lead to the exclusion of selected 
participants aware of their illness and thus an under representation of the true 
prevalence of RHD in females.
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As accepted, the long term characteristic of RHD results in an increasing prevalence 
with age. In various school surveys the highest prevalence is reported between 11 and 
16 years with mean ages of 10 and 11 year's, which was confirmed in this study. 
Similarly, rates were not different among boys and girls as reported from other 
developing countries (Bahadur, et al 2003, Refat 1994, Rizvi, et al 2004, Sadiq, et al 
2008). The lower prevalence rate of RHD in primary schools indicates that there is an 
opportunity for the early identification of patients and commencement of secondary 
prophylaxis at this age (Grover, et al 2002, Veasy, et al 2004).
RHD is a disease of poverty and has been nearly eradicated in industrialized countries 
due to improved housing and economic conditions and health care facilities (Kutumbiah 
1958, Steer, et al 2002, Taranta and Markowitz 1989, Vendsborg, et al 1968). 
Socioeconomic and environmental factors play an indirect but important role in the 
magnitude and severity of ARF and RHD (Kurahara, et al 2006, Leirisalo, et al 1980, 
Mena, et al 2005). Overcrowding, poverty and poor housing conditions were 
documented in 56.1%, 71.4% and 3.3% of school children, respectively, which is 
similar to that reported in the literature (Alkhalifa, et al 2008, Longo-Mbenza, et al 
1998, Steer, et al 2002). These factors facilitate the high prevalence and spread of 
streptococcal infections, and may also enhance their virulence and rheumatogenicity 
(Groves 1999, Lennon 2004, Schaffer, et al 2003).
Previous reports indicate that the mitral and aortic valves are the usual valves affected 
in RHD, with isolated involvement of mitral valve regurgitation in more than half of the 
patients (Bitar, et al 2000, Carapetis, et al 2005a, Hillman, et al 2004, Khriesat, et al 
2003). This is consistent with this study with 49.8% of the children presenting with a 
mitral valve lesion (Table 4.9).
Rapid progression of the disease in children and adults leads to severe haemodynamic 
compromise with combined mitral and aortic valve involvement (Schaffer, et al 2003, 
Tani, et al 2004, Venugopalan, et al 2002).This was also documented in 17.8% of the 
study participants with valve disorders with no sex predilection.
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In developing countries including South Africa, Egypt and India, isolated mitral stenosis 
is commonly reported among female adolescents and young women (Andy and Soomro 
2001) ,but was not detected among females in this study. However, there were only five 
cases of mitral stenosis in this study altogether (4 males and 1 female).
It is important to differentiate rheumatic mitral valve prolapse from degenerative or 
myxomatous mitral valve disease. Rheumatic prolapse always involves the anterior 
leafletwhereas myxomatous prolapse involves the posterior leaflet (Pomerantzeff et al 
2000). Myxomatous leaflets are thick, huge with significant systolic bulge toward the 
left atrium. In contrast, the leaflets in rheumatic carditis with MR have minimal 
thickening or bulge (Essop and Nkomo 2005). MVP may have a variable course; the 
pathologic changes in the valves and chorda tendineae cordis may occur at different 
stages after the inflammation or may disappear with the inflammation (Talwar, et al 
2005, Zhou and Lu 1997).
The mechanisms involved in combined mitral valve regurgitation and mitral valve 
prolapse appeal’ to differ when associated with rheumatic as opposed to a congenital 
floppy mitral valve origin (Kaymaz, et al 2005, Perier 2004). Mitral valve abnormalities 
with lesultant anterior leaflet thickening of mitral prolapse are reported to occur in 
severe mitral regurgitation due to the result of annular dilatation and chordal elongation 
in patients with RHD, and are not caused by congenital abnormalities of the mitral 
leaflets per se (Essop and Nkomo 2005, Kaymaz, et al 2005).
The posterior leaflet of the mitral valve is protected from involvement and rupture in 
patients with rheumatic mitral valve disease due to its leaflet thickening and retraction 
and chordal elongation (Kalangos, et al 2000, Jonkaitiene, et al 2005, Turn, et al 1989).
In this study, a combination of mitral regurgitation with mitral valve prolapse involving 
the anterior leaflet with minimal thickening was diagnosed in 26.6% of the children in 
total, which is comparable to Wou et el (30%), but significantly lower than Lembo et el 
(80%) (Avierinos, etal 2002, Cheng 1997, Gersh, et al 1985).
These complex lesions need to be further investigated, for example with follow-up 
studies to predict the effect of mitral valve prolapse on the outcome of children with 
RHD. Furthei consideration should be given to include MVP as one of the common
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cardiac valve lesions in ARF/RHD and specifically correlate its origin of occurrence 
whethei it still stands as a primary or a secondary abnormality and determine its course 
of development with the progress of the disease.
CRP is not specific enough to diagnose a specific disease but it serves as general marker 
for infection and inflammation (Elliott et al 1997). The CRP test does not indicate 
where the inflammation is located or what causes it. Higher-than-normal levels of CRP 
may indicate ARF. CRP is useful mainly in monitoring inflammatory conditions since 
CRP drops as inflammation subsides (Yeh 2004). CRP increases above 10 mg/L in an 
inflammatory or infectious disease (Cengic, et al 2002). When CRP drops below 
lOmg/L it indicates the patient does not have clinical active inflammation (Reitzenstein, 
et al 2010). CRP appeal's and disappears more rapidly than ESR changes (Sarzi-Puttini 
and Atzeni 2004). Normal values may vary from laboratory to laboratory from CRP 0- 
1.0 milligrams per deciliter (mg/dL), or less than 10 mg/L (SI units) (Cengic, et al 2002, 
Rerkasem, et al 2002, Ridker, et al 2003). The highest values for CRP were up to 
lOmg/dL equivalent to lOOmg/L in this study.
High CRP concentrations indicate an acute phase response to a previous inflammatory 
process and also a reaction to existing damaged tissue. High concentrations of CRP 
weie obseived in 39.3% of the students with RHD. A higher proportion of students 
with multiple valve involvement 21 (65.6%) had a raised CRP level than students with 
single valve involvement 11(35.4%) (p-0.001). The severity of valvular involvement 
may result in increased production of CRP (Golbasi, et al 2002). Thus CRP monitoring
should be included in the follow up of individuals affected with not only ARF but also 
in chronic RHD.
The occurrence of RHD in more than one family member has long been reported but 
specific patterns of inheritance have not yet been identified. HLA Class II associations 
with RHD are more evident and consistent among clinically homogenous patients 
(Guedez, et al 1999). Interesting trends and associations between DR6 haplotypes and 
RHD have been reported (Guedez, et al 1999). A significant increase in fiequency of 
DRB1*0701 allele in RHD patients has been detected (Kudat, et al 2006). Carreno et al 
(2000) documented increased frequency of HLA-DR4 and HLA-DR2 with RHD in both 
white and black patients respectively (Carreno-Manjatrez, et al 2000). Sudies in
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Brazilian patients have implicated DR1 and DRw6. DR7 and Dw53 . These conflicting 
results have raised speculation that the observed associations might be of Class II genes 
close or in linkage disequilibrium with a putative RF-susceptibility gene (Kaplan 2005, 
Quinn, et al 1967). RED was diagnosed in more than one family member in 53 (24.2%) 
of the children with RHD, all of whom were also attending the school which included 
20 siblings. One family had four' siblings affected; three were in two families, two 
siblings in two families and one sibling in six families. In addition in 33 children, there 
was a positive family history of RHD in one of the parents or a close relative. There are 
no recent studies documenting the familial occurrence of ARF with or without RHD. 
Reports of familial RHD exist from the 19th century and early 1940s (Davis, et al 1954, 
Saksena, et al 1969, Wilson and Morton 1937, Winter 1972)
Piioi to the survey only 36 (16.4%) of the parents were aware of their children having 
RHD and they only volunteered this information after the echocardiography. Parents of 
students with known RHD wanted to have a follow up echocardiography to know if the 
damaged valve had resolved and thus were subjected to echocardiography examination 
for reassurance.
Eighteen of these children were taking secondary prophylaxis on an irregular basis 
while the other eighteen had refused prophylactic treatment due to their parents’ fear of 
penicillin hypersensitivity reactions and long term compliance. Health professionals 
should stress the consequences of RHD with the families and create a good parent- 
doctor relationship to gain their confidence and provide continuous reassurance (Davis 
1970, Kurahara, et al 2006).
There is an urgent need for the early identification of children with ARF/RHD so that 
penicillin prophylaxis is commenced thus preventing both recurrence of ARF and 
progression of cardiac valve lesions (Kimbally-Kaky, et al 2002, Lue, et al 1988, Ralph, 
et al 2006, Stollerman 2001a). Shortage of resources for providing quality health care, 
inadequate expertise of primary health care providers and a low awareness of 
ARF/RHD all impact on the expression of the disease and put a large burden of a 
severely disabling condition on a young productive population (Kumar, et al 2002,
Kung, et al 2005).
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3.7 Conclusions
There is a high prevalence of RHD among Yemeni school children (36.5/1000) which is 
higher than in neighbouring countries. RHD is a major and serious health problem in 
Yemen. The prevalence of RHD increased with age, having a high preponderance in 10- 
16 years old students. There was no sex specific difference. MR either isolated or 
combined with other RHD valve lesion was the most common lesion followed by MR 
combined with MVP. The disease was reported in one or more than one family member 
m 24.2% of siblings. This survey identified new cases of RHD who were likely to go 
undetected until severe progressive damage had occurred.
3.8 Recommendations
Schools can be used to educate and motivate teachers, parents and children about the 
importance and treatment of sore throat It is time for the public health authorities to 
understand the burden of this hazardous preventable heart disease and realise the cost 
incurred by the curative health care of patients with RHD. Sufficient human and
financial resources need to be provided to promote a successful program for control of 
ARF and RHD.
A major goal of the Ministry of Public Health in Sana’a should be the development of 
national ARF and RHD prevention strategies tailored towards the local characteristics 
of the population. The success of the programme will depend on the cooperation, 
effectiveness and dedication of health personnel, policy health makers, educational 
administrators, community leaders and as an increased awareness of the risk by parents.
It is of utmost importance to introduce primary and secondary prophylaxis at a public 
health level. The strategy of primary prophylaxis programs needs to be effective and 
successful. It should take into consideration certain requirements that might pose some 
difficulties in successful achievement. The prerequisites are that patients with sore 
throat will attend a health center for care; primary health care providers should have the 
ability to diagnose GAS pharyngotonsillitis and when diagnosis is made the respective 
patients must be treated adequately and should adhere to the treatment regimen. It 
should be emphasized that such prophylactic programs should be started and continued
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to further promotion of investigation and treatment of GAS pharyngotonsillitis in 
settings with feasible facilities.
Secondary prophylaxis programs should be continued and strengthened due to their 
feasibility and cost-effectiveness. Benzathine penicillin G injections given every 2 to 4 
weeks are superior to daily oral penicillin. The duration of prophylaxis depends on the 
severity of RHD and the patient’s age. Secondary prophylaxis is recommended for at 
least 5 years for patients with a history of ARF but without carditis and a minimum of 
10 year's or until age 21 year's whichever* is longer, with even longer duration for CRHD 
patients. Secondary prophylaxis requires a successful delivery through effective 
coordination of a central registry program with the public health authorities. It should 
include strategies for increasing and continuous adherence to secondary prophylaxis, 
screening programs through clinical and echocardiography examination to enhance 
early detection of ARF and RHD. Health education and health promotion programs 
should be conducted regularly to increase awareness of GAS sore throat and its 
complications of ARF and RHD for primary health care providers, teachers, patients 
and their families.
3.9 Limitations of the study
The availability of a portable echocar'diography in the field work could have minimized 
the loss of participants after the clinical examination. The prevalence of RHD among 
the school children was probably underestimated since of the 514 children with an 
organic murmur, 168 (32.7%) refused to come for the echocardiography appoinment. 
The majority of refusals were females 150 (29.2%) and the explanation for refusal given 
by their parents was reluctance to accept the fact that their child might turn out to have a 
heart disease. If it was proved by echocardiography, it would affect their familial 
reputation and hinder the marital status of their children. Some families were suspicious 
as to why echocardiography, an expensive investigation, was free of charge. They may 
have thought that it was not done for the intention of research but for other unspecified 
reasons.
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Chapter 4
4 Prevalence of Group A beta hemolyitc streptococcal 
infections among Yemeni school children with acute 
pharyngotonsillitis
4.1 Introduction
Group A beta hemolyitc Streptococcus (GAS) is the most important human pathogenic 
bacterium of the genus Streptococcus, encountered in paediatric clinical practice (Dale 
2008, Kaplan, et al 2001, Martin and Green 2006).
GAS is the most common cause of bacterial pharyngotonsillitis accounting for 10 to 
30% of episodes m children and 5 to 10% of episodes in adults (Barzilaf et al 2001, 
Bisno 2001, Rajkumar and Krishnamurthy 2001). A clinician has to decide if a child 
with acute sore throat has a GAS infection or a viral infection and whether to prescribe 
antimicrobial therapy (Loganathan, et al 2006, Menon, et al 2008).
Due to lack of epidemiological data from low income countries, the global burden of 
GAS disease is not yet well established. GAS disease may be influenced by multiple 
factors and the strains responsible for ARP/RHD exhibit geographical variations 
(Pichichero 1998, Tanz, et al 2006).
This study estimated the prevalence of GAS infections among Yemeni children with 
pharyngotonsillitis.
4.2 Objective
To determine the prevalence of GAS infection among children with pharyngotonsillitis 
in Aden, Yemen.
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4.3 Literature review
GAS colonizes superficial tissues leading to pharyngotonsillitis or impetigo and is 
associated with the development of the non-suppurative sequelae ARF, RHD, acute 
glomerulonephritis and reactive arthritis (Bassilf et al 2002, Rajkumar and 
Krishnamurthy 2001). GAS occupy a narrow ecological niche with humans as the 
primary biological host and the sole environmental reservoir. The bacteria are able to 
replicate and withstand adverse conditions facilitated by the presence of virulence 
factors that promote survival (Martin, et al 2004).
Changes in the disease epidemiology of GAS might be associated with the introduction 
and reappearance of serotypes against which a population lacks immunity or to specific 
serotypes becoming more prevalent within populations at risk (Martin and Green 2006). 
Despite the advent of antimicrobials, GAS infections and their sequelae still pose a 
significant public health problem in many countries (Leung and Kellner 2004, 
McDonald, et al 2006, Smeesters, et al 2006).
4.3.1 Biology of GAS
Louis Pasteur’ first described Sfreptococcus pyogenes, as ‘chains of beads’ in 1879 and 
Rossenbach (1884) proposed the name Group A Streptococcus. Schotmuller (1903) 
reported distinct changes in blood media with clear zones of lysis called Group A 
Streptococcus p-haemolyticus(Carapetis, ef a/2005b, Cumringham 2000). Rebecca 
Lancefield in 1920 discovered the GAS group polysaccharide and the cell wall M 
protein which are used to separate serotypes (Facklam 2002). In 1930, Fred Griffith, 
worked on die T protein and in 1990, together with Lancefield, developed the classic 
scheme for the pathogenic and phenotypic GAS characterization used globally 
(Efstiatiou, et al 2003, Tagg, et al 1990). There was a resurgence of severe clinical GAS 
infections and RHD during 1980 and 1990 in many countries highlighting the 
importance of strain characterization (Dale 2008, Kaplan, et al 2001, Krause 2002).
4.3.2 Serological classification of GAS
GAS is serologically classified into specific types based on the detection of T and M 
cell wall piotein antigens. T protein forms the basis of the agglutination typing system 
but its function is unknown. M protein is the basis of the precipitation typing system
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and has major significance in the pathogenicity of the organism (Bantes, et al 2002). It is 
quite difficult for the organism to survive in normal human blood without the M protein 
against which a type specific antibody can be produced (Cunningham 2000). One 
hundred and three different M types have been validated and internationally recognized 
with only one M-type antigen usually expressed by each strain. Currently a molecular 
approach for the identification of emm (M protein) genes is available (Beall, et al 2000).
Approximately 50% of GAS strains produce an enzyme that causes mammalian serum 
to increase m opacity, called serum opacity factor (SOF) (Oehmcke, et al 2004). 
Antibody to OF is specific in its inhibition of the opacity reaction of the M type 
producing it, a characteristic that is useful as a supplementary aid to the typing scheme 
(Almengor, et al 2006, Gillen, et al 2002, Kanellopoulou, et al 2000). The typing of 
strains is usually based on the M and T proteins and production of SOi^Prakash and 
Dutta 1991, Shah, et al 1995). Genotypic methods such as emm and ^o/gene sequencing
and vir typing, are newer highly discriminatory methods (Lechot, et al 2001, Oehmcke, 
et al 2004).
Modern techniques have advanced understanding of the virulence factors for GAS and 
the genomes of several GAS types are now determined (Tail, et al 2007). The 
prevalence of highly virulent clones vary across populations and further epidemiologic,
laboratory and molecular studies are necessary for its full characterization (Johnson, et 
al 2006).
4.3.3 Prevalence
The prevalence of severe GAS-associated disease worldwide is estimated to be 18T 
million cases, with T78 million new cases annually (WHO 2004). It is estimated that 
517, 000 deaths occur each year due to GAS-associated diseases. The prevalence of 
GAS pharyngotonsillitis varies across countries, season, age and quality of health care 
(Katz, et al 2002, Nanda Kumar, et al 1992).
GAS carnage in the throats of asymptomatic primary school children ranges from 10% 
to 50%. Recovery rates from children with GAS pharyngotonsillitis vary from 0.3 to 
37% in locations such as Kuwait, Egypt, Ethiopia, Tunisia and India, with peaks in late 
winter and early spring (Durmaz, et al 2003, Mclsaac, et al 2000, Nanda Kumar, et
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a/1992, Nandi, et al 2002b, Steinhof£ et al 1997). However, this is likely to be an 
underestimate as some patients may not seek medical advice for a sore throat due to 
economic or cultural reasons.
GAS pharyngotonsillitis is common in children between 3-15 year’s of age with a 
peak age of 11 years (Ebell, et al 2000). It is likely that there are no differences by sex 
(Barzilai, et al 2001). Most children have at least one episode of pharyngotonsillitis per 
year' with 15% - 25% of these being caused by GAS (Bisno 1996, Kaplan, et al 2001, 
Martin and Green 2006).
GAS is highly transmissible and spreads rapidly in overcrowded settings through 
respiratory droplets or close contact within pupils, families and guests (Barzilai, et al 
2001). The predominant serotypes constantly change in terms of their severity, 
virulence and sequelae.. ARF attacks vary with the severity of the host’s immune 
response and the virulence of the GAS strain (Martin and Barbadora 2006, Veasy, et al 
2004). Different emm types in GAS isolates have varied genotypes and variable virulent 
antigens (Bisno, et al 2003, Chaussee, et al 2008, Martin, et al 1994). GAS produce 
several surface-exposed and secreted proteins that are important for virulence at 
different stages during a GAS infection (Beyer-Sehlmeyer, et al 2005, Johnson, et al 
2006). Variation in GAS virulence is associated with their M protein content and their 
degree of hyaluronate encapsulation (Bisno, et al 2003, Martin and Green 2006,
Metzgar and Zampolli 2011). Certain environmental conditions may affect the 
transcription of emm in GAS (Beyer-Sehlmeyer, et al 2005). Bacterial growth in high 
salt, ambient atmosphere, or restricted iron cause a decreased activity of the virulence 
factors compared with growth in active carbon dioxide atmosphere (Rothbard and 
Watson 1948, Stollerman 1975)
GAS strains causing throat infections do not all lead to ARP but some strains that do so 
are unusually virulent (Bisno, et al 1977, Erdem, et al 2007, Robinson and Kehoe 1992, 
Stollerman 1993). Virulent fresh GAS isolates attenuate quickly during convalescence 
from pharyngotonsillitis, and also when grown on blood agar plates, losing their M 
protein content and hyaluronate capsules and resistance to phagocytosis (Martin, et al 
1983, Stollerman 2001b). These attenuated strains of GAS survive commonly as 
carriers in the throats of children and remain transmissible (Kaplan 1980, Stollerman
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2001a). Thus throat cultures from sporadic pharyngitis or asymptomatic carriers show 
varied pathogenicity of GAS strains (Johnson 1992, Stollerman 2001b). During severe 
epidemics of pharyngotonsillitis some GAS strains with virulent serotypes became 
prevalent leading to ART and their virulence can be identified (Majeed, et al 1992b, 
Steer, et al 2009d). Some affected patients may not remember having an acute episode 
of GAS pharyngotonsillitis (Kaplan 1980). So by the time the diagnosis of ARP is 
confirmed, the infecting GAS clones may have gone or the persisting strain may have 
become attenuated and the M type may not be recognized, or new GAS strains may be 
acquired during the latent period (Adanja, et al 1991, Martin, et al 1994).
The resurgence of ARP in the developed world was attributed to the epidemiologic 
changes in the virulence of circulating GAS strains, possibly host susceptibility and the 
changing patterns of antibiotic use (Bisno 1990, Chang 2011, Cunningham 2000, 
Kaplan 1991).
4.3.4 Clinical Diagnosis
It is difficult to differentiate the clinical features of GAS from viral upper respiratory 
infections or other causes of pharyngotonsillitis (Magdy Attia 1999, Santos and Berezin 
2005). Headache, nausea, vomiting and abdominal pain may be seen in children with 
GAS (Meland, et al 1993, Shet and Kaplan 2004).The presence of cough, running nose, 
hoarseness, diarrhoea and conjunctivitis usually favour' viral infections but in patients 
with GAS pharyngotonsillitis, respiratory symptoms may be more common than 
previously thought (Leung and Kellner 2004).
Tonsils are reddened and swollen and exudates appear* on the posterior pharyngeal and 
tonsillar pillars with fine petechial lesions on the roof of the mouth. Around 50% of 
GAS pharyngotonsillitis in children present with tender anterior cervical lymph nodes.
Several clinical prediction rules with scoring points have been proposed to aid primary 
health workers in the diagnosis of GAS pharyngotonsillitis (Edmonson and Farwell 
2005). One of these scoring systems is the Mclsaac modification of the Center criteria 
(Mclsaac, et al 2000). This scheme is based on the following criteria and points:
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Table 4. IMcIsaac Scoring System
Mclsaac Score Score
history of fever or temperature >38°C +1
absence of cough +1
tender anterior cervical adenopathy _l_l
tonsillar swelling and exudates +1
age <15 years +1
age > 45 years -1
Maximum 5 points
Children with no points are unlikely to have GAS infection and do not need to be tested. 
Those with 1-3 points should be tested and treated based on the test result. Those with 
4-5 points have a high likelihood of having GAS and may be treated empirically or 
treated if the test is positive (Edmonson and Farwell 2005, Mclsaac, et al 2000).
Clinical scoring systems can help to determine which patients should undergo 
diagnostic testing and potentially reduce unnecessary use of antibiotics (Warren, et al 
1998).
Leung and Kellner reported that the sensitivity and specificity of the Mclssac scoring 
system was 80% (Leung and Kellner 2004). In a community based study Mclssac et al 
(2000) found that the sensitivity was 92.6% and the specificity 72.3%, while in a family 
medicine centre it was 96.9% and 67.2% respectively (Mclsaac, et al 2000). Another 
study by Hall et al reported that the sensitivity of rapid antigen detection tests increased 
with the number of the scores, 47% with score of 1, 65% with a score of 2, 82% with a 
score of 3 and 90% with 4 and 5. Diametto et al stated that the sensitivity increased 
from 0 to 97% for those with 1 to 5 criteria (Hall, et al 2004, Leung, et al 2006).
4.3.5 Diagnosticstrategies
Data from low income countries suggest that the frequency of the classical clinical 
presentation of GAS pharyngotonsillitis in children is estimated to be low (Kaplan, et al 
2001). This may be attributed to regional differences in the organism and host response 
or limited access to health care. Re-evaluation of the clinical criteria is required taking 
into consideration the continuous changes that occur with the epidemiology and
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demographic characteristics of GAS infection in a specific community. Hence, GAS 
pharyngotonsillitis in these settings may not be diagnosed in patients presenting with 
atypical clinical features and this reduces the clinician’s confidence to diagnose GAS on 
clinical grounds. Under such circumstances microbiological studies are required to 
reach a correct diagnosis.
4.3.6 Rapid antigen detection test
In patients with acute pharyngotonsillitis, a rapid antigen detection test (RADT) can 
provide results within 10 to 15 minutes (Cohen 2004, Tanz, et al 2009). Most of the 
RADT have a specificity of 90% and a sensitivity > 90% (Araujo Filho, et al 2005, 
Camurdan, et al 2008, Mayes and Pichichero 2001, Santos and Berezin 2005). Due to 
the high specificity of the RADT, a positive test is accepted to be diagnostic for GAS 
(Cohen, et al 2004, Tanz, et al 2009). Conversely, a negative RADT should be 
confirmed by a throat culture in the presence of a suggestive clinical diagnosis 
(Johansson 2003, Leung, et al 2006). The rapid identification and treatment of patients 
with pharyngotonsillitis can reduce the risk of spread of the infection, shorten the 
symptom duration, decrease the occurrence of complications, reduce school 
absenteeism and misuse of antibiotics (Camurdan, et al 2008, Kaplan 2004, Kim 2009).
4.3.7 Throat culture
GAS pharyngotonsillitis is usually diagnosed in symptomatic patients by swab culture, 
which remains the reference standard. Culture has 90% - 97% test accuracy (Johansson 
2003, Shet and Kaplan 2004, Tanz, et al 2009). A disadvantage of culture is the delay in 
confirming a diagnosis as it usually takes 24 - 48 horns to obtain a definitive result and 
further typing with latex agglutination kits (Martin and Green 2006). In a child with 
compatible history and clinical evidence of pharyngotonsillitis, a positive culture 
confirms a GAS diagnosis (Tanz, et al 2009). However in low income countries 
bacteriological culture is not readily available and primary health care providers depend 
on a clinical diagnosis to prescribe treatment (Lindbaek, et al 2005).
4.3.8 Treatment
It is essential to treat GAS pharyngotonsillitis with appropriate antibiotics. Appropriate 
treatment results in the resolution of clinical manifestations within 24 to 48 hours
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(Mclssac et al 2004). Penicillin remains the drug of choice and its efficacy for 
preventing ARF is well established (Dale 2008, Linder, et al 2005). This antibiotic has 
low cost, few side effects, narrow antimicrobial spectrum, and there is so far no 
documentation of penicillin resistance in GAS (Martin and Green 2006). Intramuscular 
benzathine penicillin G is preferred for patients who are unlikely to complete a 10-day 
oral course of pencillinV (Brahmadathan and Gladstone 2006).
Amoxicillin has been reported to be effective in treatment of GAS and a better solution 
for children, with easier dosing and better taste and less side effects (Brook 1989, 
Leelarasamee, et al 2000). In patients allergic to penicillin or amoxicillin, erythromycin 
remains the first choice with high efficacy (Bingen, et al 2000). In communities with 
erythromycin resistance to GAS, azithromycin or clarithromycin may be used (Cohen 
2004, Leung and Kellner 2004). Oral cephalosporins are more effective in the 
eradication of the GAS carriage than penicillin but have more side effects, are more 
expensive and thus their routine use cannot be endorsed (Camurdan, et al 2008, Kim 
2009, Wong and Chung 2002).
4.4 Patients and methods
4.4.1 Sample size and strategy
The principal investigator (PI) was informed about all Yemeni children with acute 
pharyngotonsillitis attending public, private and school polyclinics by the attending 
physicians. The PI then went to the reported site and recruited the required patients.
The PI generally visited five to six clinics per day. The patients who fulfilled the 
inclusion criteria of age 1—16 years, both sexes, symptoms of sore throat with evidence 
of fever, anterior tonsillar exudates and anterior cervical adenitis were selected, after 
obtaining verbal consent from their parents or through the health social worker at the 
school. Patients with coryza, cough, conjunctivitis and those who had used antibiotics 
in the two-week period prior to onset of current illness were excluded.
A sample size of 730 children was estimated. This was based on published prevalence 
figures for GAS 45% from neighbouring countries with similar climatic conditions at 
95% Cl and accepting a maximal error of + 2 in the estimate with a power of 80% to 
determine the prevalence of GAS sore throat infections.
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4.4.2 Collection of throat swab
Two throat swabs were collected by rubbing sterile cotton tipped swabs over the 
tonsillar- area without touching the tongue or lips. The first swab was tested by a RADT 
to detect GAS antigens in pharyngeal swabs. Results were obtained in 10 - 15 minutes 
and graded as positive, negative or non-specific.
The second swab was rolled on a Strept Selective Agar plate containing 5% sheep 
blood. There was a laboratory technician who helped with these cultures. The plates 
were incubated at 35°C under anaerobic conditions for 24 to 48 hours and checked for 
{3 haemolytic streptococi. Bacitracin was placed culture plates with a sub-culture of the 
initial isolateand those that gave a zone of inhibited growth around the disc of > 15 mm 
diameter were considered potential GAS. Bacitracin sensitive GAS that were isolated 
from patients with a negative RADT were subsequently tested for the Lancefield group 
by the latex agglutination test, the Oxoid streptococcal grouping kit, used for the 
identification of the streptococcal group and reagents provided for groups A, B, C, D, F 
and G (Diagnostic Reagents Streptococcal Grouping Kit Code: DR0585).
4.4.3 Treatment of patients
The patients were treated with penicillin if positive by either RADT or culture. If 
patients had a positive clinical Mclssac score but RADT was negative, they were given 
an appointment to return after 48 hours for their culture results and then received their 
treatment. School children were revisited by the PI within the next 48 hour's with the 
culture results. Patients were given penicillin for 7-10 days either orally or 
parenterally based on their clinical condition. Those having history of pencillin allergy 
were treated with erythromycin for 7 days.
4.5 Results
4.5.1 General characteristics of the participants 
A total number of 730 children were enrolled, with a mean (SD) age of 11.8 (3.4) years 
between August 2006 and July 2007. The predominant age was 11-15 year’s which 
included more than half of the patients (406, 55.6%), followed by 6-10 years’ old
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children (163, 22.3%). Male comprised 319 (43.7%) and female 411 (56.3%) of the 
children with pharyngotonsillitis, with a ratio of 1:1.3. The participants recruited from 
schools comprised 553 (75.8%) of the patients and those recruited from a public clinic 
were 96 (13.1%) and those from a private clinic comprised 81 (11.1%).
A history of prophylactic penicillin was recorded in 83 (11.4%) of the participants who 
were either previously diagnosed as ARF or RHD, A history of tonsillectomy in another 
family member was obtained in 95 (13.1%). A history of ARF and RHD was elicited in 
62 (8.5%) and 49 (6.7%), respectively and a family history of ARF and RHD was 
reported in 44 (6%) and 45 (6.2%), respectively.
A greater proportion of the patients (536, 73.3%) were enrolled during the winter 
months (October to February) while the lowest frequency (194 (26.7%)) occurred in the 
summer (March to September) (Table 4.1). 297 (40.7%) children reported having 5-8 
acute pharyngotonsillitis attacks per year* followed by 224 (30.7%) with 9 to 12 attacks 
per year*.
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Table 4. 2Demographic characteristics of participants with acute pharyngotonsillitis
Demographic factors n-730(%)
Sex Male 319(43.7%)
Female 411 (56.3%)
Age (years) Mean (S.D.) 11.8(3.4)
Age group (years) 0-5 69 (9.5%)
6-10 163 (22.3%)
11-15 406 (55.6%)
> 15 92 (12.6%)
Season Winter (October —February) 536 (73.3%)
Summer (March- September) 194 (26.7%)
Medical history Plistory of ARF 62 (8.5%)
Histoiy of RFID 49 (6.7%)
Family history ARF 44 (6%)
RHD 45 (6.2%)
Tonsillectomy 95 (13.7%)
Sore throat episodes reported/year <4 205(28.1%)
5-8 297 (40.7%)
9-12 224 (30.7%)
>12 4 (0.5%)
Prophylactic penicillin 83(11.4%)
Clinic location School 553 (75.8%)
Private 81 (11.1%)
Public 96(13.1%
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4.5.2 Acute pharyngotonsillitis attacks among participants by age 
and sex
The frequency of pharyngotonsillitis episodes per year varied by age and sex. Females 
had a mean (SD) 7.3 (3.5) episodes which was higher than that for males who had a 
mean (SD) 6.7 (3.5) episodes (p=0.02). There was no statistically significant difference 
in the number of episodes of pharyngotonsillitis in the different age groups.
Table 4. 3Pharyngotonsillitis episodes reported by sex and age group
Variable
Pharyngotonsillitis episodes per year
Mean (SD)
Gender Female 7.3 (3.5) 0.02
Male 6.7 (3.5)
Age groups (years) <5 7.1 (3.1) 0.06
6-10 6.6 (3.3)
11-15 7.4 (3.7)
>15 6.5 (3.3)
4.5.3 Culture and RADT results
RADTs followed by culture on sheep blood agar* media were performed on all patients 
with clinical manifestations of acute pharyngotonsillitis (figure 4.1). A total of 267 
(36.6%) patients had positive RADT.
GAS cultures were positive in 238 (89.1%) patients with positive RADT compared to 
33 (7.1%) patients with negative RADT. Among the patients with negative RADT but 
positive cultures, 20 (60.6%) were GAS positive by culture. The cultures were positive 
for streptococci other than GAS in 13 (39.4%) patients with acute pharyngotonsillitis. 
Cultures were contaminated in 10 patients with positive RADT but were included in the 
analysis as having GAS since the RADT is only capable to detect the carbohydrate 
antigen only for GAS. There were 39 contaminated cultures of patients with negative 
RADT and these were excluded Rom the study.
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There were a total of 49 cultures that were contaminated because of overgrowth with 
other bacteria. The likely reason is laboratory plate contamination. We attempted 
unsuccessfully to recover GAS from these cultures.
The proportion of contaminated cultures in the RADT positive cases was 10/267 
(3.7%), significantly less than the 39/463 (8.4%) contaminated cultures in the RADT 
negative group (p^O.02). If the all contaminated cultures are excluded horn the analysis 
the sensitivity of the RADT is 92.6% and specificity 95.3%. If the contaminated 
cultures are all included and assumed to be GAS positive (for the RADT positive 
samples) and GAS negative (for the RADT negative samples) the sensitivity and 
specificity would be little changed at 92.9% and 95.6%. In contrast, if the worse case 
scenario is assumed, contaminated culture were included and assumed to be GAS 
culture negative (for the RADT positive samples) and GAS culture positive (for the 
RADT negative samples) the sensitivity and specificity would be 89.1% and 86.5%.
The true sensitivity and specificity is likely to rest between these values with a bigger 
variation in the possible specificity.
Overall a total of 691 patients with acute pharyngotonsillitis of both sexes had valid 
GAS information and were included in subsequent analysis.
4.5.4 Composite diagnosis
A composite diagnosis was formed with the terms “with” GAS and “without” GAS 
pharyngotonsillitis. Patients with GAS pharyngotonsillitis included all patients with 
positive RADT and patients with negative RADT but positive culture for GAS 
comprising a total of 287 (41.5%) patients. Patients without GAS pharyngotonsillitis 
were defined as patients who had both negative RADT and negative GAS culture, or a 
negative RADT with a positive culture for other non GAS bacteria. A total of 404 
patients were classified as not having GAS pharyngotonsillitis (Figure 4.1).
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Latex test
Culture
Contaminated
Negative
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Contaminated
RADT
n=730
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n=730
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Without GASWith GAS
Figure 4. IFlow chart of participants with acute sore throat. ^Contaminated cultures 39 
(8.4%) were excluded from the detailed analysis
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4,5.5 Demographic characteristics of patients with and without 
GAS pharyngotonsillitis
Patients with GAS pharyngotonsillitis were more frequently observed among 11-15 
years old children (p-0.001) (Table 4.3). Acute pharyngotonsillitis with GAS was more 
frequent among females than males (219 (54.2) and 185 (45.8%), respectively), but this 
was not statistically significant.
Children with GAS reported a higher frequency of pharyngotonsilltiis episodes per year 
with a mean (SD) 8.2 (3.6) compared to children without GAS pharyngotonsillitis who 
had a mean (SD) 6.2 (3.2) episodes per year. The difference between the children with 
and without GAS pharyngotonsillits was statistically significant (p=0.001) (Table 4.3).
Table 4. 4Demographic characteristics in 691 children with and without GAS
Variable
With GAS
n=287(%)
Without GAS
n=404(%) P
Age (years) <5 17 (5.9%) 51 (12.6%)
6-10 51 (17.8%) 105 (26%)
11 -15* 196 (68.3%) 182 (45%) 0.001
>15 23 (8%) 66(16.3%)
Sex Male** 113(39.4%) 185 (45.8%) 0.1
Female 174(60.6%) 219 (54.2%)
Pharyngotonsillitis episodes * *:i“ Mean (SD) 8.2 (3.6) 6.2 (3.2) 0.001
*p-0.001 The age difference in children with and without GAS was statistically
significant in the 11 - 15 years group
**p- 0.1 The differences between sexes in patients with GAS and without GAS 
was not significant statistically
* * *p=0.001 Pharyngotonsillitis episodes was statistically significant in children with
and without GAS
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4.5.6 Seasonal variation of GAS pharyngotonsillitis
Cases of GAS pharyngotonsillits were observed all year round. A total of 209 (72.8%)
patients with GAS had throat infections during the winter months which were higher
than in the summer months. However, a higher proportion of patients had GAS
pharyngotonsillitis during the months of November to February with a peak in January
71 (25%), followed by December 53 (19%), February 44 (15%) and November 41
(14%).
□ Without GAS pharyngotonsillitis 
■ With GAS pharyngotonsillitis
Sept Oct Nov Dec Jan Feb Mar April May June July
Figure 4. 2Distribution of patients with and without GAS pharyngotonsillitis by 
months (2006-2007)
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4.5.7 Clinical symptoms of patients with and without GAS 
pharyngotonsilltis
A history of sudden onset with fever, pain on swallowing, headache and nausea were 
obtained with a higher frequency in the patients with GAS pharyngotonsillitis than in 
children without GAS (p=0.001). In contrast the presence of cough, rhinorrhoea and 
hoarseness were more frequent in patients without GAS pharyngotonsillitis (p=0.001) 
(Table 4.4).
Table 4. 5 Clinical symptoms of patients with and without GAS Pharyngotonsillitis
History of
With GAS
n=287
Without GAS
n=404
OR (95% Cl) P
Sudden onset 267 (93) 307 (76) 4.2 (2.5-7.0) 0.001
Sore throat 285 (99.3) 400 (99) 1.4 (0.3-7.8) 0.7
Fever 280 (97.6) 293 (72.5) 15.2 (6.9-33.1) 0.001
Headache 149 (51.9) 150 (37.1) 1.8 (1.4 —2.5) 0.001
Pain on swallowing 279 (97.2) 349 (86.4) 5.5 (2.6-11.7) 0.001
Vomiting 34(11.8) 42 (10.4) 1.2 (0.7-1.9) 0.6
Nausea 123 (42.9) 114(28.2) 1.9 (1.4-2.6) 0.001
Abdominal pain 20 (7) 13 (3.2) 2.3 (1.1-4.6) 0.03
Cough 27 (9.4) 144 (35.6) 0.2 (0.1-0.3) 0.001
Rhinorrhoea 10(3.5) 88(21.8) 0.1 (0.1-0.3) 0.001
Hoarseness 10 (3.5) 81 (20.0) 0.2 (0.1-0.3) 0.001
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4.5.8 Clinical signs of patients with and without GAS 
pharyngotonsillitis
Erythema with exudate in the anterior tonsillar pillar was observed in 251 (87.5%) 
children, red uvula in 113 (39.4%), petechiae on the soft palate in 90 (31.4%) and tender 
anterior lymph nodes in 196 (68.3%) patients with GAS pharyngotonsillitis. In contrast 
erythema with exudate in the anterior tonsillar pillar in 235 (58.2%), red uvula in 38 
(8.9%), petechiae on the soft palate in 18 (4.5%), tender anterior lymph nodes in 57 
(14.1%) were less frequent inpatients without GAS pharyngotonsillitis (p=0.001). Skin 
rash was observed in 2 patients with GAS and in 4 patients without GAS (Table 4.5).
Table 4. 6Clinical signs of patients with and without GAS pharyngotonsillitis
Clinical signs
With
GAS n=287
Without
GAS
n=404
OR
( 95% Cl) P
Erythema 284 (99) 393 (97.3) 2.7 (0.7 — 9.6) 0.14
Oral ulcers 1(0.3) 10(2.5) 7.3 (0.9-57) 0.06
Anterior tonsillar erythema 251 (87.5) 235 (58.2) 5.0 (3.4-7.5) 0.001
Exudates 277 (96.5) 363 (89.9) 3.1 (1.5-6.4) 0.002
Anterior tonsillar exudate 209 (72.8) 187(46.3) 3.1 (2.3-4.3) 0.001
Red uvula 113 (39.4) 38 (9.4) 6.6(4.4-10.1) 0.001
Soft palate petechiae 90 (31.4) 18(4.5) 9.8(5.7-16.7) 0.001
Anterior cervical lymph node 196(68.3) 57(14.1) 13 (9.0-19) 0.001
Skin rash 2 (0.7) 4(1.0) 1.9 (0.8-4.5) 0.15
A logistic regression model with the best fit based on the clinical criteria to identify 
children with GAS infections is shown in Table 4.6, The clinical characteristics 
independently associated with GAS pharyngotonsillitis included fever (AOR=6.1), 
anterior tender cervical lymphadenopathy (AOR=13.1), petechiae on soft palate 
(AOR-4.2) and the presence of a red uvula (AOR=4,0). Conversely, clinical symptoms
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less likely to be associated with GAS pharyngotonsillitis were rhinorrhoea (AOR= 0.4), 
hoarseness (AOR=0.6) and cough (AOR= 0.4) (Table 4.6).
Table 4. TLogistic regression analysis of clinical criteria of acute pharyngotonsillitis to 
identify children with GAS
Clinical criteria OR AOR 95% Cl P value
Fever 15.2 6.1 2.7-14 0.001
Anterior cervical lymph node 13.1 9.1 6-13.7 0.001
Soft palate petechiae 9.8 4.2 2.3-7.9 0.001
Red uvula 6.6 4.0 2.6-6.2 0.001
Cough 0.2 0.4 0.2-0.6 0.001
Anterior tonsillar erythema 5.0 3.4 1.9-6.0 0.001
Nausea 1.9 1.9 1.3-2.7 0.001
Headache 1.8 1.7 1.2-2.4 0.003
Rhinorrhoea 0.1 0.4 o to 1 o ha 0.002
Hoarseness 0.2 0.6 0.3-0.9 0.002
Anterior tonsillar exudate 3.1 1.8 1.0 - 3.0 0.034
Sudden onset 4.2 1.2 — —
Pain on swallowing 5.5 2.1 - -
Sore throat 1.4 0.3 - —
Vomiting 1.2 0.9 - —
Abdominal pain 2.3 1.9 - -
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Figure 4. 3 Clinical characteristics of patients with and without GAS
4.5.9 Mclssac clinical score (Mclsaac et al. 2000)
The Mclssac score was assessed among patients with positive RADT having negative 
throat cultures in comparison with patients with positive RADT and positive throat 
cultures. The results are shown in Table 4.7. The difference was statistically significant 
between the two groups (p=<0.02).
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Table 4. SMcIssac score in patients with positive RADT and negative/positive cultures
Mclssac score
Positive RADT 
Negative culture 
n=29
Positive RADT
Positive culture
n=238
Total
n~267
1 0 2 (0.8%) 2 (0.75%)
2 0 2 (0.8%) 2 (0.75%)
3 11(38%) 17 (7.2%) 28(10.5%)
4 13 (44.8%) 76 (32%) 89 (33.3)
5 5 (17.2%) 141 (59.2%) 146 (54.7%)
p <0.02 Mclssac score was significantly different between patients with positive
RADT and negative culture compared to those with both positive RADT and culture
The Mclssac score was also assessed among patients with positive RADT having 
negative throat cultures compared to patients with negative RADT and positive throat 
cultures. The results are in Table 4.8. The difference was not statistically significant 
between both groups.
Table 4. 9McIssac score in patients with positive RADT and negative cultures and 
negative RADT with postive cultures
Mclssac score
Positive RADT 
Negative culture 
n=29
Negative RADT 
Positive Culture
n=20
Total
n=49
1 0 1 (5%) 1 (2%)
2 0 1 (5%) 1 (2%)
3 11(38%) 5 (25%) 16 (32.7%)
4 13 (44.8%) 7 (35%) 20 (40.8%)
5 5 (17.2%) 6 (30%) 11 (22.5%)
p<0.5 Mclssac score was not significant between the two groups
Among patients with a positive RADT having negative cultures 10 (12.5%) were 
receiving prophylactic benzathine penicillin compared with 42 (17.6%) patients with 
positive RADT and positive throat cultures receiving prophylactic benzathine penicillin. 
There was no significant difference in the proportion of RADT positive patients 
receiving penicillin prophlaxis with either positive or negative cultures.
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Table 4. lOPositive RADT in patients with negative or positive cultures in 52 patients 
on antimicrobial prophylaxis
Antimicrobial
prophylaxis
Positive RADT
Negative culture
n=29
Positive RADT
Positive culture
n=238
Total
n=267
No 19(65.5%) 196 (82.4%) 215 (80.5%)
Yes 10(34.5%) 42 (17.6%) 52 (19.5%)
p< 0.4 — the difference in RADT between positive and negative cultures in patients on 
penicillin prophylaxis was not significant
The Mclssac clinical score was assessed according to the presence or absence of GAS 
pharyngotonsillitis and the sensitivity and specificity were calculated (Table 4.10). A 
ROC curve was drawn to identify the optimal cut off that resulted in the highest 
combination of sensitivity and specificity (Figure 4.4). The sensitivity and specificity at 
the cut off point of 3 which is currently recommended showed a sensitivity of 98.6% 
but a very low specificity of 17% in this analysis. A sum score of 4 had a sensitivity of 
93% and a specificity of 82% while a sum score of 5 was 66% sensitive and 89% 
specific.
The estimate of the area under the smooth ROC curve (AUC) is 0.839 and its 95% 
confidence interval is 0.808 and 0.869
Table 4. 11 Sensitivity and specificity of Mclssac score in children with /without GAS
Mclssac score
Cut off points
Total
With GAS
N=287
Without GAS
N=404
Sensitivity pecificity
>1 13 287 404 100 1
>2 61 285 393 99 3
>3 279 283 334 99 17
>4 102 266 72 93 82
5 236 190 46 66 89
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Figure 4. 4ROC curve of Mclssac score to identify Definitive GAS pharyngotonsillits
4.5.10 Characteristics of patients who had GAS with positive 
and negative RADT
The RADT was interpreted as positive in 267 (93%) patients of whom 238 had positive 
GAS cultures and in 19 who had negative GAS cultures. The RADT was false negative 
in 20 (7%) patients with culture confirmed GAS pharyngotonsillitis. The mean age (SD) 
of patients with RADT true positives was 12 (3.2) and the mean age (SD) for RADT 
false negative was 13 (1.3) (p=0.005).
Males had 111 (98.2%) RADT true positives and 2 (1.8%) false negatives compared to 
156 (89.7%) females having RADT true positives and 18 (10.3%) false negatives.The 
difference between males and females was statistically significant (p=0.004).
Mclssac scoring with a 5 cut off point was observed in 153 (57.4%) patients with GAS 
pharyngotonsillitis who had true positive RADT and in 20 (100%) patients with GAS 
false negative RADT (P=0.01) as shown in Table 4.10.
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Table 4, 12Clinical characteristics of patients with GAS and positive or negative RADT
RADT
Variable True positive 
n=267
False negative 
n=20
P
Age (year's) Mean (SD) 12 (3.2) 13 (1.3) 0.005
Sex Female 156 (89.7%) 18 (10.3%) 0.004
Male 111 (98.2%) 2(1.8%)
Mclssac score 1 3 (1.1%) 0
2 3 (1.1%) 0
3 22 (8.2%) 0
4 86 (32.2%) 0
5 153 (57.4%) 20 (100%) 0.01
4.6 Discussion
Globally GAS accounts for 10% to 30% of acute pharyngotonsilltis and is the only type 
of sore throat that requires antibiotic treatment to prevent ARP and reduce the 
occurrence of local non suppurative complications (Johansson 2003, Park, et al 2006, 
Tanz, et al 2009). Despite its clinical significance and the high prevalence of 36.5 cases 
of RHD per 1000 population among Yemeni school children (see Chapter 3), there is no 
information on the prevalence of GAS pharyngotonsillitis in Yemen.
This is the first major study of the prevalence of GAS isolated from Yemeni children 
with acute pharyngotonsillitis. The prevalence of GAS pharyngotonsillitis in children 
was 41.5%, which is higher than the rates reported from both neighbouring countries 
and other parts of the world. Studies include India (4.2% -13.7%; (Menon, et al 2004), 
Tunisia (17.7%; (Mzoughi R2004), Egypt (17% -24%), China (21.4%; (Meng-Hsun 
Lin2003), Brazil (24%; (Santos and Berezin 2005), Canada (34.8%; (Mclsaac, et al 
2000) and Turkey (35.9%) (Rimoin, et al 2008). These variations in the prevalence of 
GAS pharyngotonsillitis might be attributed to the differences in geographical sites and 
the methods of diagnosis. This finding of high prevalence confirms that GAS is an 
important cause of pharyngotonsillitis among Yemeni children and requires prompt 
diagnosis and appropriate antibiotic therapy to shorten the symptom duration and reduce 
the risk of ARP and RHD.
91
In general the literature does not demonstrate a gender association with the risk of GAS 
pharyngotonsillitis (Danchin, et at 2007, Rimoin, et al 2005). In this study even though 
pharyngotonsillitis was more frequent among females, this was not a statistically 
significant association. It is a comparable observation to two similar studies in India 
(Nandi, et al 2002b) and Brazil (Santos and Berezin 2005). In contrast to China there 
was a higher prevalence in males than females (Meng-Hsun Lin2003). The differences 
in these results may be attributed to the peculiarities in the study location.
Age is reported to be an important factor in the aetiology of GAS pharyngotonsillitis. 
This study found the highest prevalence of GAS pharyngotonsillits was in the 11 - 15 
years group (68.3%) versus an overall prevalence of (41.5%) in all age groups. The 
prevalence varies in different age groups from one study to another as reported in 
Rimion’s study, although this is partly due to use of different age groups. A peak age of 
5-9 years was reported in Egypt, Brazil and Croatia, and in China it was 6-11 years 
(Meng-Hsun Lin2003), while in Latvia it was 10-12 years of age (Bassili, et al 2002, 
Rimoin, et al 2008).
Comparison with studies in other low income countries is currently difficult due to the 
limited data on the age distribution of GAS pharyngotonsillitis in children. But the 
occurrence of GAS pharyngotonsillitis in an older age group among Yemeni patients 
could be explained by the probability that it coincides with the age of transfer from the 
primary to preparatory classes with more overcrowding and increased rate of sore throat 
infections among older students.
The lowest frequency of GAS pharyngotonsillitis was detected among 68 (9.8%) 
children less than 5 year's of age in this study. This result was still higher than the WHO 
report on the clinical evaluation of GAS pharyngotonsillitis among children under 5 
years that foimd low rates of 4.6%, in Egypt, 3.6% in Croatia and no case below 5 years 
in Brazil (Rimoin, et al 2005). The low frequency in this age group in this study might 
be attributed to the fact that children may not present with the classical symptoms of 
GAS infections making the clinical diagnosis difficult. Hence in this group the 
diagnosis would be better based on the diagnostic laboratory tests in conjunction with 
clinical findings.
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The frequency of acute sore throat attacks are reported to be higher in low income 
countries than high income countries. Danchin et <3/(2007) in Australia reported one- 
third of children experiencing a confirmed GAS positive culture sore throat every year . 
They estimated that approximately 7 sore throat episodes occur per child per year with 
13.5 % of these being caused by GAS (Pichichero 1998, Sauver, et al 2006). These 
results are similar to this study with the majority having 6 episodes although we 
obtained a higher rate of 19.9% GAS pharyngotonsillitis.
There are inconsistent reports of seasonal variation in GAS pharyngotonsilltis. In 
temperate regions the general observation is that the peak is during winter and early 
spring while in the tropics it is in late autumn and early winter and and declines in 
summer (Brahmadathan and Gladstone 2006, Kaplan 2004, Sauver, et al 2006). The 
results of this study revealed a high occurrence of GAS pharyngotonsillitis of 84.7% 
during the cool months of November, December, January and February with the peak in 
January. These results are similar' to a study in Latvia which showed a similar high 
frequency between December to February (Rimoin, et al 2008). In Brazil, the peak was 
during the cool months of March to August (Santos and Berezin 2005). This study was 
quite different, however, from a study in Tunisia where the isolation rate of GAS 
peaked twice during the year from October to December and in June (Mzoughi R2004). 
In Egypt and Croatia the pealc was from September to November (Gove, et al 1998, 
Rimoin, et al 2008). These differences might be explained by the variations in climatic 
conditions of each country.
The accurate diagnosis of GAS pharyngotonsillitis is repeatedly reported to be quite 
difficult since the symptoms and signs of sore throat due to GAS or non GAS infections 
overlap widely and make it unreliable to base a diagnosis only on clinical assessment 
(Bisno, et al 2003, Gieseker, et al 2003). In this study, the clinical characteristics of 
fever, sore throat, anterior tonsillar’ erythema and exudates with enlarged anterior tender 
lymph nodes were detected with a higher frequency in children with GAS 
pharyngotonsillitis compared with those without GAS pharyngotonsillitis.
In contrast, the symptoms of cough, hoarseness and rhinoirhea favoured the diagnosis 
of those without GAS pharyngotonsillitis that are more likely to be due to a viral
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aetiology (Bisno, et al 2002, Johansson 2003). These clinical characteristics were not 
significantly different from the reports from various countries history of fever, absence 
of cough, tender cervical lymph adenopathy, tonsillar exudates and age <15 years 
associated with GAS infection (Lazar R. 2004, Lindbaek, et al 2005, Magdy Attia 
1999).
Some symptoms and signs of GAS pharyngotonsillitis may vary by site and clinical 
status. Even though the clinical symptom of difficulty in swallowing was statistically 
associated with GAS pharyngotonsillitis in Brazil, Egypt and Latvia (Rimoin, et al 
2008) but there was no clinical association among Yemeni patients with GAS 
pharyngotonsillitis. A significant association of skin rash with GAS pharyngotonsillitis 
had been reported which was not evident in this study (Gieseker, et al 2003, Santos and 
Berezin 2005). The patients with GAS pharyngotonsillitis in this study who presented 
with petechial lesions on the soft palate comprised 31.4% which was three times higher 
than the literature reports of 10% (Bisno, et al 2002). The presence of red erythematous 
uvula was also observed with higher frequency in this study when compared to other- 
reports (Bisno, et al 2003, Kaplan 2005).
The presence of red erythematous uvula and petechiae on the soft palate were 
significantly more cormnon in patients with GAS pharyngotonsillitis compared with 
those without GAS (P-O.OOl). In various other literature reports, these two specific 
significant signs did not help to differentiate between the clinical predictor variables of 
acute pharyngototnsillitis due to GAS and those without GAS (Martin, et al 2004, 
Steinhoff, et al 1997).
It is recommended that further studies should be conducted with the possibility of 
introducing these two particular signs into a scoring system to improve identification of 
GAS pharyngotonsillits. Moreover the re-evaluation and improvement in this scoring 
scale based on clinical criteria alone would of great help in underdeveloped countries 
with poor financial resources that limits the widespread use of laboratory test to confirm 
GAS diagnosis in patients with acute pharyngotonsillitis.
In patients with acute GAS pharyngotonsillitis, the recommended strategy is that if the 
RADT is positive it is considered reliable and appropriate treatment is given (Armengol,
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et al 2004, Giesekei; et al 2003, Mclsaac, et al 2000). This is because the occurrence of 
false-positive results is unusual and so therapeutic decisions can be taken with 
confidence without requiring a throat culture confirmation (Chapin, et al 2002, Fox, et 
al 2006). There were 33 patients with negative RADT on whom backup throat cultures 
were performed of whom 20 (60.6%) patients showed positive GAS cultures while 13 
(39.4%) patients grew cultures positive for Non-GAS isolates.This is comparable to the 
study of Mels sac et al in Canada and Edmonson in US A who confirmed that 70% with 
negative RADT required backup cultures (Edmonson and Farwell 2005, Mclsaac, et al 
2004). If the RADT is negative a confirmatory culture is required to avoid the risk of 
missing GAS pharyngotonsillitis that may necessitate treatment especially in regions 
with high prevalence of ARF and RHD.
RADT is unlikely to yield a positive result in children with low Mclssac scores <2 
where if a backup culture is done it will have a great likelihood of giving a negative 
result. We found that a false negative RADT was significantly more common in older 
children, females and in those children with a Mclssac score of 5. A similar study by 
Edmonson and Farwell (2005) in Wisconsin USA detected difference in age but there 
was no sex difference.
The Mclssac score of clinical criteria for GAS diagnosis of acute pharyngotonsillitis 
used in this study showed that the usual cut off point of 3 was unreliable. The 
application of the cut off point of 4 or more had a higher sensitivity (93%) and 
specificity (82%) [Figure 4.4]. These results suggest that RADT could be selectively 
used in children with Mclssac Score of 4 and above with a positive result removing the 
need of a backup culture for confirmation of the diagnosis.
Throat culture has long been accepted as the gold standard for GAS diagnosis of acute 
pharyngotonsillitis. RADT has been recently introduced to overcome the time delay in 
throat cultures (Bassili, et al 2002, Van Howe and Kusnier 2006). RADT has an 
advantage in that by confirming the presence of GAS carbohydrate antigen on a throat 
swab with results available within 10 — 15 minutes in the clinic, they provide an 
effective way to differentiate between patients having acute pharyngotonsillitis that 
need antibiotics and those who do not (Leung et al 2006, Park, et al 2006).
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RADT has been utilized in different populations and it has been shown that a 
significantly increased number of patients were treated for GAS pharyngotonsillitis on 
time when compared to the use of traditional cultures (Gerber and Shulman 2004, 
Gonzalez-Rey, et al 2003, Van Howe and Kusnier 2006). The use of RADT can reduce 
the home stay of the patient and allow their early return to school and further reduce the 
acute disease state (Mclsaac, et al 2004). It will further decrease the number of 
consultations with general practitioners and paediatricians (Amujo Filho, et al 2005).
Furthermore the prompt management of GAS pharyngotonsillitis with antimicrobial 
therapy will help to reduce the risk of spread to close contacts and may also hasten 
clinical improvement and prevent the suppurative and nonsuppurative sequelae which 
are key therapeutic goals (Cooper, et al 2001, Harrow and Buescher 2002, Shet and 
Kaplan 2004). RADTs, however, are quite expensive (De Socio, et al 2004). This 
limitation needs to be taken into consideration before they are widely distributed and 
applied as a routine practice in poor developing countries for the diagnosis of patients 
with acute pharyngotonsillitis due to GAS.
There were differences in the symptoms and signs of GAS pharyngotonsillitis in this 
study when compared to those in other countries. However, it is rather difficult to create 
and follow a strict single prediction rule for all countries with the changing 
epidemiology of GAS infections.
It is of great concern to correctly diagnose GAS pharyngotonsillitis so as to minimize 
the inappropriate use of antibiotics and occurrence of antimicrobial resistance (Dey et 
al 2005, Ebell, et al 2000, Hsin Chi 2003). However, it is essential to conduct further 
studies in neighboring regions to assess the valid clinical indicators for GAS 
pharyngotonsillitis especially in countries with high prevalence of ARF and RHD.
It is of paramount importance to instruct parents with children suffering acute sore 
throat to seek medical advice through visits to health care facilities. It is also essential to 
increase awareness regarding the importance of GAS pharyngotonsillitis and its 
implications through a school health programme.
96
4.7 Conclusions
A high prevalence of GAS pharyngotonsillitis was detected particularly in the 11 - 15 
year age group but there was no significant difference between both sexes. A high 
proportion of GAS pharyngotonsillitis was observed during the winter with the highest 
peak in January. The cut off point for Mclssac score of a value of 4 and above 
demonstrated better diagnostic accuracy for GAS pharyngotonsillitis.
The clinical characteristics associated with GAS pharyngotonsillitis included fever, 
anterior tender cervical lymphadenopathy, petechiae on the soft palate and the presence 
of a red uvula. The clinical symptoms less likely to be associated with GAS 
pharyngotonsillitis were rhinorrhea, hoarseness and cough.The RADT was positive in 
93% of the patients of whom 89% had positive GAS, The RADT was false negative in 
7% of patients with GAS pharyngotonsillitis. The Mclssac score was significantly 
different between patients with positive RADT having negative throat cultures 
compared to positive RADT and positive culture.
Two additional signs, petechiae on the soft palate and a red erythemaous uvula were 
significantly associated with GAS pharyngotonsillitis. In fixture studies it is important to 
include and further assess these two clinical findings in the predictive clinical criteria 
for GAS pharyngotonsillitis in children. This tool will enhance a simple and practical 
approach for the primary care physician and paediatricians in the identification and 
management of GAS pharyngotonsillitis.
4.8 Recommendations
RADT has an advantage over throat cultures with immediate positive results for GAS 
pharyngotonsillitis. This allows decisions to be taken on the spot and antibiotics 
prescribed but its high cost may limit its practical use in poor underdeveloped 
countries.In Yemen it is essential to implement a public health program for the 
appropriate diagnosis and management of GAS pharyngotonsillitis together with control 
and prevention of ART and RHD.
GAS pharyngotonsillitis is a major problem in Yemen and the main indication for 
antibiotic treatment in sore throats among children and families. It would be beneficial
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to introduce a clinical scoring system based on epidemiological criteria without 
corroborative laboratory investigations. If this was linked to specific management 
recommendations for patients with sore throat and could reliably identify GAS infection 
this would be a practically important development. In health centers where laboratory 
facilities exist, clinical scoring systems can be used to select cases for confirmation of 
diagnosis either using culture or rapid antigen tests.
When antimicrobial therapy is required, the safest, narrowest-spectrum, and most cost- 
effective drugs should be used, e.g.penicillin. Efforts are required to be directed at 
health policy and educational approaches for the continuous training of health care 
providers on adherence to clinical guidelines and to improve practice on antibiotic 
prescribing for acute pharyngotonsillitis in children. Public health authorities must be 
involved in providing medical and financial resources and necessary laboratory 
facilities for the proper diagnosis of GAS. It is essential to establish a public health 
program that will focus on the establishment of registers in primary prophylaxis to 
prevention of ARF/RHD and compliance associated with improvement in clinical 
follow-up of patients receiving secondary prophylaxis regimens. These are the major 
priorities for control of GAS diseases. Future strategies need substantial commitment 
from the policy health makers and the Ministry of Public Health to concentrate on 
ensuring that programs are properly resourced, but not overly ambitious in their early 
stages, and are systematically evaluated.
4.9 Limitations of this study
During the collection of the throat samples, they were ideally taken straight away to the 
central diagnostic laboratory for culturing. Sometimes due to transport problems there 
was a delay in culturing the isolates that might have lead to some negative cultures in 
positive RADT isolates.
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Chapter 5
5 Non-group A beta-haemolytic streptococci, 
Lancefield groups C, G and B
5.1 Introduction
Non-Group A (3-haemolytic streptococci (SNA), particularly Lancefield groups C 
(GCS), G (GGS) and B (GBS), although initially recognized as animal pathogens, are 
part of the normal human flora (Facklam 2002, Kalia, et al 2001, Vieira, et al 1998). 
GAS is a completely human adapted organism but the human strains of GGS and GCS 
are more likely to be related to their animal origins (Pinho, et al 2006, Vandamme, et al 
1996, WHO 2005). Human seemed to have acquired some strains of GGS and GCS 
during the process of animal domestication (Lindbaek, et al 2005, Meland, et al 1993, 
Turner, et al 1993).
Recently the pathogenic potential for humans of SNA have been clarified, as they have 
been implicated in acute pharyngotonsillitis in children and adults (Darrow and 
Buescher 2002, Johansson 2003).
A higher rate of isolation of these organisms has been described in recent years. This 
may be related to the improved diagnostic methods, an increase in virulence or an 
expanding population of compromised hosts (Pinho, et al 2006). It is not possible to 
differentiate between infections caused by GAS, GBS, GCS or GGS solely on the 
clinical presentation (Davies, et al 2006, Kalia, et al 2001).
Tlris aim of this study was to determine the prevalence of (SNA) pharyngotonsillitis 
among Yemeni children attending schools and clinics in Aden city.
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5.2 Objective
To determine the prevalence of (SNA)ainong children with acute pharyngotonsillitis
5.3 Literature review
Bacterial genome typing has demonstrated that human phenotype GCS and GGS are 
closely related and members of one species, Streptococcus, dysgalactiae subsp. 
equisimilis GCS/GGS (Davies, etal 2006, Faden 2005, Pinho, et al 2006). Human 
strains of GCS and GGS tend to have large colonies (Lopardo, et al 2005). They are 
often termed 'pyogenes-like’, because they share virulence factors, including 
haemolysins, extracellular enzymes and M-proteins that have structural, biologic and 
immunochemical features similar to GAS (Liu, et al 2006, Zaoutis 2004).
The reported prevalence of GCS/GGS carriage and related disease varies worldwide. 
Most studies originate from temperate climate regions with limited data available from 
low resources and tropical regions (Steer, et al 2009b). Reported rates for pharyngeal 
carriage of GCS ranged from 0% to 12% in a Finnish community, 0% to 9.3% in Indian 
school children and 20% in an Aboriginal population (Haidan, et al 2000, Kalia, et al 
2001, Menon, et al 2008). GGS throat carriage was reported to be more common than 
GAS in Tunisian, Bangladeshi and Nigerian schoolchildren (Ahmed, et al 2003, 
Hashikawa, et al 2004, McDonald, et al 2006, Zaoutis 2004).
The age distribution of GCS/GGS throat carriage is similar' to that of GAS, with the 
highest recovery rates in 5 to 9 year- arrd 10 to 14 year* old children (Portillo, et al 2003, 
Steer, et al 2009b). Among symptomatic patients with sore throat, those with positive 
cultures for GCS and GGS are significantly more likely to have fever, exudates, anterior 
cervical adenopathy and higher mean serum ASO titres than those with negative culture 
(Benjamin and Perriello 1976, Bisno 2001, Gerber 1996, Gerber and Shulman 2004). 
SNA cannot be detected using the current RADTs for GAS (Facklam 2002, Leung and 
Kellner 2004).
SNA are Gram-positive bacteria that grow as pairs or chains of variable length in 
culture. On sheep blood agar they appear as transparent to opaque, round, small 
colonies surrounded by a zone of complete haemolysis ([3 of red cells (Vieira, et a/1998,
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Zaoutis 2004). p- haemolysis is characteristic of GAS but strains of GBS, GCS and 
GGS are most often also f3 -haemolytic (Liu, el at 2006, Vandamme, et al 1996). 
Bacitracin susceptibility is a widely used screening method for GAS identification. 
About 3% -5% of GBS, GCS and GGS are also susceptible to bacitracin (Brahmadathan 
and Gladstone 2006, Lopardo, et al 2005).
Although there are no published cases of ARF proven to have been caused by 
GCS/GGS, the M protein of GCS/GGS share the surface-exposed, conserved domain 
region common to the M proteins of GAS types epidemiologically associated with ARF. 
This may play a role in clinical disease, tissue tropism and suggests the potential for 
rheumatogenicity (Davies, et al 2006, Haidan, et al 2000, Liu, et al 2006).
Interestingly, however, investigators in Australia recently reported a high carnage rate 
of GCS and GGS in an Aboriginal population that had a high rate of ARF but a low 
incidence of GAS disease. It has been demonstrated in vitro that GCS and GGS have 
the potential to elicit an autoimmune response that may trigger ARF (Haidan, et al 
2000).
5.4 Patients and methods
All Yemeni children with acute tonsillitis attending public polyclinics and primary 
elementary schools who fulfilled the inclusion criteria of age 1- 16 year’s of age, both 
sexes, symptoms of sore throat with evidence of fever, anterior tonsillar' exudates and 
anterior tender cervical adenitis were recruited after obtaining a verbal consent from 
their guardians. Patients with coryza, cough, conjunctivitis and use of antibiotics in the 
last two-weeks were excluded from the study. The patients included in this objective 
were recruited from the participants of chapter 4
5.4.1 Diagnostic methods
The process followed the same procedures as described in objective 2. Bacitracin 
sensitive (3 haemolytic streptococci that were isolated from patients with a negative 
RADT were subsequently tested with the Oxoid streptococcal grouping kit, used for the 
identification of the streptococcal group according to the manufacturer’s instructions
101
5.4.2 Statistical analysis
Statistical analysis included quantitative descriptive analysis and summary statistics for 
describing the prevalence of SNA. Univariate analysis were based on “odds ratio” and p 
values <0.05. Analyses were further based on chi-square tests, exact Fisher tests 
followed by logistic regression analysis for categorical variables.
5.5 Result
5,5,1 Baseline characteristics of children with SNA- positive 
cultures, GAS-positive cultures and negative cultures
A total of 13 patients had positive cultures for SNA comprising 1.9% of 691 children 
with acute pharyngotonsillitis and 4.3% of the 300 children with positive cultures.
Six of the 13 SNA pharyngotonsillitis cases were male comprising 5% of the total 119 
male patients with positive cultures. There were 7 females with SNA pharyngotonsillitis 
representing 3.9% of 181 females with positive cultures (Table 5.1).
The mean (SD) age of the patients with SNA pharyngotonsillits was 13.1 (1.5) years 
compared to a mean (SD) of 11.4 (3.8) years for all children and 12 (3.1) years for 
children with GAS pharyngotonsillitis. The difference in means between patients with 
SNA pharyngotonsillitis and those with positive GAS and negative GAS cultures was 
statistically significant (p=0.001). The predominant age group affected in children with 
SNA positive cultures was between 11-15 years in 92.3% of the children compared to 
68.3% in children with positive GAS and 45% with negative cultures (Table 5.1).
All the 13 SNA patients were diagnosed during the winter months of December and 
February compared to 84.7% of children with GAS pharyngotonsillitis (Figure 5.1).
A history of ARF and RHD were elicited in 2 (15.4%) and 11 (84.6%) children with 
SNA pharyngotonsillitis compared to 41 (5.9%) and 46 (6.5%) patients with GAS 
pharyngotonsillitis (p=0.001).
A positive family history of ARF and RHD was obtained in 2 (15.4%) and 11 (84.6%) 
patients with SNA pharyngotonsillitis compared to 32 (4.6%) and 43 (6.2%) of patients 
with GAS pharyngotonsilitis (p-0.001). The mean (SD) frequency of
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pharyngotonsillitis episodes experienced by the patients with SNA pharyngotonsillitis 
was 10.2 (1.9) episodes compared to 8.2 (3.6) episodes for children with GAS 
pharyngotonsillitis (p^O.OOl).
All the 13 patients with SNA pharyngotonsillitis with recurrent episodes of sore throat 
were on parenteral benzathine penicillin injections on an irregular basis with the 
exception of one who received injections every 21 days. All patients with positive SNA 
pharyngotonsillitis gave a history of receiving prophylactic benzathine penicillin.
A higher proportion of children (10, 76.9%) with SNA pharyngotonsillitis than children 
with GAS pharyngotonsillitis (188, 65.5%) were diagnosed from the schools (TableS.l).
Table 5. 1 Baseline characteristics of children with non-GAS compared to those with 
positive GAS and negative cultures
Demographic Total Non-GAS GAS Negative
factors cultures P
n=691patients n=13 (%) n=287(%) n=391(%)
Sex Male 6 (46.2%) 113 (39.4%) 179 45.8%) 0.2
Female 7(53.8%) 174 (60.6%) 212 54.2%)
Age (years) Mean (S.D.) 13.1 (1.5) 11.4 (3.8) 12(3.1) 0.001
Season Winter (Oct -Feb) 13 (100%) 241 (84.7%) 323 80.2%) 0.001
Medical history History of RF 2(15.4%) 41 (5.9%) 20 (4.9%) 0.001
History of RHD 11 (84.6%) 46 (6.5%) 26 (6.6%) 0.001
Family history RF 2(15.4%) 32 (4.6%) 12(3.1) 0.001
RHD 11 (84.6%) 43 (6.2%) 3 (0.8)
Pharyngotonsillitis
episodes/year
Mean (SD) 10.2(1.9) 8.2 (3.6) 6.2 (3.2) 0.001
Drug history Prophylactic
penicillin
13 (100%) 80 (27.9%) 29 (7.4%) 0.001
Clinical location School 188 65.5%) 10 (76.9%) 322 82.4%) 0.001
Public 31 (10.8) 2(15.4%) 45 (11.5%)
Private 68 23.7%) 1 (7.7%) 24 (6.1%)
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Figure 5. 1 Distribution of patient with GAS and SNA pharyngotonsillitis and negative 
cultures by months
5.5.2 Clinical symptoms of patients with GAS and non-GAS 
pharyngotonsillitis
A history of sudden onset of sore throat, fever and pain on swallowing was documented 
in all the thirteen (100%) patients with positive throat cultures for SNA 
pharyngotonsillitis compared to those with GAS PT in 93%, 99% and 97.6%, 
respectively
Headache was reported in 10 (76.9%) versus 149 (51.9%), nausea in 7 (53.8%) versus 
123 (42.9%) and vomiting in 2 (15.4%) versus 34 (11.8%) patients with SNA and GAS 
pharyngotonsillitis, respectively (Table5.2)
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Table 5. 2Clinical symptoms of patients with GAS and SNA Pharyngotonsillitis
History of SNA
n=13 GAS n=287 OR (95% Cl) P
Sudden onset 13 (100) 267 (93) 1.0
Sore throat 13 (100) 285 (99.3) - 1.0
Fever 13 (100) 280 (97.6) - 1.0
Headache 10(77) 149 (51.9) 0.3 (0.08-1.1) 0.07
Pain on swallowing 13 (100) 279 (97.2) - 1.0
Vomiting 2(15.4) 34(11.8) 0.6(0.1 —3.1) 0.6
Nausea 7(53.8) 123 (42.9) 0.5 (0.2-1.6) 0.3
5.5.3 Clinical signs of patients with GAS and SNA 
pharyngotonsillitis
The clinical signs of red uvula (OR= 0.3) and petechiae on the soft palate (OR=0.2) in 
patients with positive SNA and GAS pharyngotonsillitis revealed statistical significance 
of (p=0.05 and p^O.008) between the two groups as shown in Table 5.3
Table 5. 3 Clinical signs of patients with GAS and SNA pharyngotonsillitis
Clinical signs GAS
n=287
SNA
n=13
OR (95% Cl) P
Erythema 284 (99) 12 (92.3) 12(1.1-140) 0.05
Anterior tonsillar erythema 251 (87.5) 13 (100) - 1
Exudates 277 (96.5) 13 (100) - 1
Anterior tonsillar exudate 209 (72.8) 13 (100) - 1
Red uvula 113 (39.4) 9 (69.2) 0.3 (0.1-1) 0.05
Soft palate petechiae 90 (31.4) 9 (69.2) 0.2 (0.06 - 0.7) 0.008
Anterior cervical lymph node 196(68.3) 13 (100) - 1
The best fitting logistic regression model based on the clinical criteria to distinguish 
children with SNA and GAS is depicted in Table 5.4. The clinical characteristics 
independently associated with SNA were erythema (AOR=14.5, p=0.05) and petechie 
on the soft palate (AOR = 3.4, p=0.008).
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Table 5. 4 Logistic regression analysis of clinical criteria of acute pharyngotonsillitis to 
identify children with GAS and non-GAS
Clinical criteria OR AOR 95% Cl P value
Headache 0.4 2.9 0.8-11 0.1
Erythema 0 14.5 1 -210 0.05
Soft palate petechie 0.3 0.2 0.06-0.6 0.008
5.5.4 Mclssac score in patients with SNA and GAS 
pharyngotonsillitis
All the thirteen patients with non-GAS pharyngotonsillitis had a Mclssac score of 5 
presenting with all the definitive clinical criteria suggestive for GAS acute 
pharyngotonsillits. The RADT was negative in all these patients whereas the cultures 
grown both on sheep and on horse blood agar culture media were all positive for non- 
GAS. Bacitracin disc were added to these culture isolates that were all observed with an 
inhibition zone of > 15mm,
Table 5. 5 Diagnostic tests of isolates with non-Gas and GAS pharyngotonsillitis
Mclssac score
Cut off points
GAS
N=287
Non-GAS
N=13 P
1 2 0
2 2 0
3 17 0
4 76 0
5 190 13 0.1
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5.5.5 Culture isolates of GBS, GCS and GGS by age and sex 
The latex agglutination test for Lancefield group was performed on the 13 non-GAS 
isolates of which 1 (7.7%) isolate was GBS, 6 (46.2%) isolates were GCS and the other 
six (46.2%) were GGS.
The predominant age of occuiTence for SNA was 13 years in almost half of the patients. 
Six patients with GCS, five patients with GGS and one patient with GBS were within 
the age group of 11 - 15 years.
The patient who had GBS infection was a female while the isolates of GCS and GGS 
were equally distributed between both genders.
Table 5. 6 Culture isolates of GBS, GCS and GGS between different ages and sex
Variables GBS N=l(%) GCS N=6(%) GGS N=6 (%)
Age (years) Mean (SD) 11(0) 13.7(1.2) 12.8(1.6)
Sex Female 1 (100) 3 (50) 3 (50)
Male 0 3(50) 3(50)
5.5.6 Clinical symptoms and signs of patients with the different 
strains of SNA
The clinical manifestations and signs of patients with SNA within the three different 
SNA strains of GBS, GCS and GGS are shown below for completness. Frequencies are 
too small for further statistical analysis.
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Table 5. 7Clinical symptom/sign of patients with GBS, GCS ,GGS pharyngotonsilltiis
Clinical findings GBS N=l(%) GCS N=6(%) GGS N=6 (%)
Symptoms
Sudden onset 1(100%) 6(100%) 6(100%)
Sore throat 1(100%) 6 (100%) 6(100%)
Fever 1(100%)
Headache 1(100%) 4 (66.7%) 5 (83.3%)
Pain on swallowing 1(100%) 6 (100%) 6(100%)
Nausea - 4 (66.7%) 3 (50%)
Vomiting - - 2 (33.3%)
Signs
Erythema 1(100%) 6(100%) 6(100%)
Anterior tonsillar exudates 1(100%) 6(100%) 6 (100%)
Ant cervical lymph node 1(100%) 6(100%) 6(100%)
Red uvula - 5 (83.3%) 4 (66.7%)
Petechiea of soft palate - 5 (83.3%) 4 (66.7%)
RADT Negative Negative Negative
5.6 Discussion
Thirteen patients were diagnosed with SNA based on clinical throat isolates comprising 
a prevalence of 1.9% of the total 691 patients with acute pharyngotonsillitis, but from 
the total 300 positive cultures the prevalence was 4.3%. The result of this study were 
not different from the 3% rate of isolation of SNA pharyngotonsillitis in children having 
acute sore throat reported by Zaoutis in USA 3.1% GCS (65/2085) and 2.6% GGS 
(38/1449) and Mzoughi in Tunisia 3% (14 GCS and GGS / 474 patients) but it was 
higher than what was reported by Wong et al in Hong Kong 0.3% GCS (5/1449)
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(Mzoughi R2004, Wong and Chung 2002, Zaoutis 2004). In addition Thangam Meneon 
et al in India reported 5 GCS and 3 GGS (8/310 patients) and Tewodros in Ethiopia 6 
GCS and 2 GGS (8/143 patients) comparable with six patients each of GCS and GGS in 
this study (12/300 patients) (Menoi% et al 2004, Tewodros, et al 1992).
Patients with SNA pharyngotonsillitis had a male to female ratio of 1.2:1 and 12 
(92.3%) fell in the age range of 11 - 15 years. This age range is higher than the age 
range of 0 - 5 years and 5-9 years reported in two Egyptian studies in children 
(Bassili, et al 2002, Tamburlini and Ronfani 1998). The mean age for SNA in this study 
was 13 whereas Faden et al reported a median of 17 years (Faden 2005). Various 
reports showed an increasing prevalence of SNApharyngotonsillitiswith increasing age 
in paediatric age groups (Hofkosh, et al 1988), A trend of increasing prevalence with 
age was reported as follows: 12% in 3-6 years age group , 20% in 6-12 years, 40% in 
12-18 years and 61% in those more than 18 year's of age(Cimolai et al 1990, Gove, et 
al 1998, Mzoughi R2004, Wong and Chung 2002).
The number of sore throat episodes reported in SNA pharngotonsillitis per year in males 
was higher than in females. It is difficult to comment on gender differences due to the 
small sample size of the study.Bassili et al in Egypt reported that the peak of non-GAS 
pharyngotonsillitis occurred in March and April which is in disagreement with this 
study where the peak was in December and January. These differences may be 
explained by the difference in the site of study and geographical climate (Bassili, et al 
2002, Davies, et al 2006).
All 13 patients with SNA pharyngotonsillitis had a score of five on the Mclssac scoring 
system criteria with a clinical score of 100%. This is in contrast to Lindbaek in Norway, 
who found that only 45% of the patients with SNA met three or four of the criteria 
(Lindbaek, et al 2005).The RADT were negative in patients with SNA which was in 
line with the reports of many authors (Gerber and Shulman 2004, Lopardo, et al 2005). 
Latex agglutination test was further conducted on clinical isolates of patients with 
Mclssac score of five and negative RADT. Six patients had GCS and six had GGS.
Only one patient was indentified with SNA GBS. Mzoughi in Tunisia and Meland in
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Norway did not reveal GBS strain among their patients (Meland, et at 1993, Mzoughi 
R2004).
The clinical manifestations of patients with non-GAS pharyngotonsilliits in this study 
were similar to those with GAS pharyngotonsillitis and did not reveal any difference. 
This similarity was reported by Bassili et al in Egyptian children (Bassilf et al 2002) 
and in various other studies (Faden 2005, Gerber and Shulman 2004, Liu, et al 2006, 
Portillo, et al 2003).Symptomatic patients with sore throats and positive cultures for 
GCS and GGS were more likely to present with fever, pain on swallowing, erythematic 
and exudates on anterior pillar regions. Ths is in line with the results of Benjamin et al 
in Virginia, Tunner et al in Columbia and Meland et al in Norway (Benjamin and 
Perriello 1976, Meland, et al 1993, Turner, et al 1997). Lindbaek et al found that pain 
on swallowing was not significantly associated with GCS and GGS pharngotonsillitis 
which was quite different from the findings in this study, where 100% of the patients 
presented with pain on swallowing (Lindbaek, et al 2005)
The finding of GCS and GGS in patients with acute pharyngotonsillitis with underlying 
history of ARE and RHD may be proposed to be a prerequisite to further prove its 
autoimmune pathogenicity. Hiadan and colleagues in the Aboriginal population of 
Australia suggested that GCS and GGS pharyngeal carriage may be capable of causing 
ARP by conducting a in vitro research on mice. They demonstrated entry into the 
pharyngotonsillar cells with an increase in the ASO titre and a high invasive reactivity 
eliciting an autoimmune response with human heart myosin, a major cardiac antigen in 
ARE and RHD (Haidan, et al 2000). They proposed that these SNA C and G may be 
capable of causing ARE by acquiring rheumatogenic factors horn GAS by horizontal 
transfer of genetic material (Johnson, et al 2006).
A few other studies have suggested that there could be a link between SNA and ARE 
and RHD, but there are no reports to this date confirming that SNA are implicated in the 
pathogenesis of ARE and RHD in humans (Saslaw and Jablon 1960, WHO 2004, 
Zaoutis 2004).
It is important to document that in these thirteen patients with SNA pharyngotonsillitis,
2 patients gave a history for ARE and 11 patients were echo proven cases of RHD. A
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positive family history of ARF/RHD was also obtained in one, or more than one, family 
member in all these patients with SNA pharyngotonsillitis. It is possible that these 
positive throat cultures for SNA, particularly GCS and GGS, in these patients who also 
gave a positive history of ARF and were echocardiographically proven cases of RHD 
may suggest the possibility of their clinical association with ARF and RHD. Stronger 
evidence for this rheumatogenic potential could have been obtained if these patients 
were followed up during the course of their acute pahryngotonsillitis and observed to 
see if during this sore throat attack they developed any recurrence of ARF. All these 
patients were on secondary prophylaxis with benzathine pencillin.
This is the first study conducted in Yemen to document the SNA pathogens in children 
with acute pharyngotonsillitis mainly GCS and GGS. Even though SNA GCS and GGS 
may share many of the cell surface and extracellular pathogenic factors associated with 
GAS, they need further investigations (Kalia, et al 2001, Portillo, et al 2003, Zaoutis 
2004).Global differences are emerging in the epidemiology of GAS and SNA infections 
and their sequelae and this requires comparisons to be made in different countries.
The most productive way is likely to be gene expression profiling of both bacteria and 
patients and their immune responses in areas where ARF/RHD still remain major health 
issues.The question needs to be resolved because current approaches to controlling 
ARFand RHD in some communities have clearly been ineffective. Resolving these 
uncertainties is likely to require collaborative studies. This would help to broaden the 
spectrum of causative bacteria and have an immediate effect on primary prevention 
strategies and possible vaccine development.
5.7 Conclusion
GCS, GGS and GBS are an infrequent cause of pharyngotonsillitis compared with GAS. 
The clinical criteria for diagnosing SNA did not differ from that characteristic for GAS 
pharyngotonsillitis and the reference standard for provisional diagnosis is the throat 
culture. In the presence of Mclssac clinical score of five points and negative RADT, it is 
recommended to conduct a throat culture that should be followed by Lancefield 
Grouping latex agglutination test for identifying SNA types.
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5.8 Recommendations
Further epidemiological studies on exudative pharyngotonsillitis in countries such as the 
Yemen should include grouping of GAS isolates to differentiate them from SNA 
isolates. Such studies will help to broaden knowledge on the spectrum of causative 
bacteria and improve understanding of possible characteristics and virulence factors 
potentially leading to ARF pathogenesis.
The question of whether SNA could be involved in eliciting an autoimmune response 
leading to ARF must be taken into consideration. Studies should be designed in which 
patients with SNA are monitored during the course of their illness in order to diagnose 
the development of ARF and RHD. The successful prevention of ARF/RHD may 
require thorough treatment not only of GAS but also of SNA pharyngotonsillitis which 
would have an immediate effect on primary prevention strategies and vaccine 
development.
5.9 Limitations of this study
This prevalence of SNA pharyngotonsillitis among children with acute sore throat could 
be an underestimate of the SNA contribution since the latex agglutination test for 
LancefieldStreptococci Grouping kits was not available during the time of the field 
work and there is high probability that cases may have missed. In particular* (3- 
haemolytic Streptococci isolated from throat swabs that were bacitracin resistant were 
not pursued in this study.
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Chapter 6
6 Emm serotypes, exotoxin genes and serum opacity 
factor gene of GAS and SNA pharyngotonsillitis
6.1 Introduction
GAS isolates are characterized by numerous typing schemes that measure their genetic 
diversity (Sobhan, et al 2008). The M protein, a primary virulence factor, is a long 
coiled protein projecting from the GAS cell wall surface (Darmstadt, et al 2000, 
Fischetti 1989, Manjula, et al 1984, Pancholi and Fischetti 1992). The basis for 
determination of the M type depends on the type of amino acid at the amino-terminal 
portion of the protein and this has a high degree of variability (Lancefield 1962, Relf et 
al 1996, Yoonim, etal 2005, Zimmerlein, et al 2005).
The emm gene code for the M protein is referred to as the emm gene sequence and this 
is another method for typing GAS (Martin and Green 2006, Sunaoshi, et al 2009). This 
can be performed using the automated DNA sequencing with an expanding reference 
database (Beall, et al 2000, Espinosa, et al 2003).
Molecular* epidemiology is a sensitive method that is essential to detect the genetic 
relatedness of different GAS pathogens or other disease agents (Massey, et al 2001, 
McDonald, et al 2007b, Olive 2007, Sobhan, et al 2008). The distribution and genetic 
variations of these important pathogens should be regularly monitored to better 
understand the epidemiology of specific GAS and non-GAS strains (Alberti, et al 2003, 
Sakota, et al 2006, Seppala, eta/1994b, Shulman, et al 2009).
The most important new insight has probably been the recognition that numerous 
diseases are caused by a limited number of clonal groupings and molecular* types 
(Carapetis, et al 2005b, Seppala, et al 1994a). Molecular epidemiology also gives a 
global overview of changes in disease patterns and would help to distinguish the details 
of person-person transmission (Brandt, et al 2000, Single and Martin 1992).
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This study was undertaken to detennine the genotypes and exotoxin and sof genes of 
GAS and SNA among a group of patients with ARF and RED in Aden.
6.2 Objective
To determine the prevalence of emm serotypes, exotoxin gene and serum opacity factor 
gene among GAS and SNA isolated from children with pharyngotonsillitis in Aden, 
Yemen
6.3 Literature review
6.3.1 GAS classification and emm typing
GAS strains are now commonly classified on the basis of sequence variation in the emm 
gene, which encodes the M protein (Bisno, et al 2003, Steer, et al 2009b). This emm 
region shows the highest level of polymorphism known for GAS genes (Koh, et al 
2008, Rogers, et al 2007). Currently GAS are referred to as emm types rather than M 
types due to the limited availability of M antisera required to characterise the new emm 
types (Beall, et al 2000, Facklam, et al 1999). This methodology has lead to the 
description of almost 200 different GAS sequence types and clarified the understanding 
of the phylogenetic relationships between different GAS serotypes (Bernard, et al 2002, 
Kim and Lee 2004a, Metzgar, et al 2009, Nandi, et al 2008). This type-specific epitope 
shows strong host protective immunity for many M proteins (Kaplan, et al 2001,
Rogers, et al 2007).
The emm sequence typing is based on the 5’ end of the central emm gene within the 
emm chromosomal region present in all isolates. A unique emm type is defined as 
having 95% sequence identity to any other known emm type over 160 bp near the 5’end. 
In other words two isolates are considered to share the same type of sequence if they are 
95% identical between their 5’end 160 nucleotide as specified (Beall, et al 2000). There 
is a very strong correspondence between M type, as determined by serology, and the 
emm type that meets the stated definition (Jing, et al 2006, Tyrrell, et al 2002).
There has been a need to reassess the typing strategies for GAS during the resurgence of 
ARF and emergence of severe GAS infections (Doktor, et al 2005, Efstratiou 2000).
The nucleotide sequence at the 5' ends of emm genes has now been reported for many
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strains (Beres, et al 2004, Durmaz, et al 2003). GAS infections are said to be in a 
continuous epidemiological change leading to the appearance and reappearance of 
serotypes to which the population lacks immunity (Enright, et al 2001). The differences 
in the strains may be explained by the geographical separation, the anatomical site of 
isolation and the time examined (Colman, et al 1993, Dey et al 2005).
GAS strains responsible for ART have distinct biological characteristics (McDonald, et 
al 2008, Stollerman 2001b). These strains are not all pathogenic and their ability to 
cause ARF depends on different biological properties such as the type and amount of M 
protein production and the epidemiological background that enhance person to person 
contact (Abdissa, et al 2006, Beres, et al 2002, Lamagni, et al 2005). There is a surface 
exposed antigenic site present on the M protein to which the IgG immunoglobulin 
released by ARF patients binds (Norrby-Teglund, et al 1996, Timmer, et al 2006). GAS 
strains responsible for ARF do not produce alphalipoproteinase serum opacity factor 
(SOF) and are heavily encapsulated with formation of mucoid colonies on blood agar 
plates (Gillen, et al 2008). It is still not clear whether each of these strains exhibit a 
unique rheumatic antigen (Erdem, et al 2009, McDonald, et al 2007b, Shulman, et al 
2004).
There are various other genotypic methods used for the GAS typing. VirTyping 
measures restriction fragment length polymorphisms within the emm chromosomal 
region (Ramachandran, et al 2004). Pulsed-field gel electrophoresis (PFGE) and 
arbitrary-primed PCR can provide high resolution levels between strains by measuring 
multiple loci for differences that are not necessarily under selection (Gonzalez-Rey, et 
al 2003, Martin and Green 2006). Even though various genotypic methods have been 
developed to determine the level of clonal relationship in GAS, the emm type was found 
to correlate with clone complex. Surveillance of M types causing ARF will be important 
during the development of future M type specific GAS vaccines (Espinosa, et al 2003).
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6.3.2 Streptococcal M-protein
The GAS M-protein is one of the best characterized determinants of bacterial virulence. 
The M protein is a filamentous molecule with two protein chains in a coiled-coil 
configuration that extends to about 60 mn above the GAS surface (Bisno, et al 2003, 
Lancefleld 1928). GAS may be divided into serotypes on the basis of antigenic 
differences in the M protein molecule with more than 100 known serotypes 
(Cunningham 2000, Lancefield 1962). The M protein coats GAS and acts as the primary 
antigen and determinant of type-specific immunity in man (Lancefield 1957).
M protein functions by preventing phagocytosis of the bacteria by PMNs allowing the 
bacterium to avoid the host immune response (Cunningham 2000). The protein is 
essential for the persistence of GAS in infected tissues and its survival in blood due to 
its anti-phagocytic fmiction. Resistance to a GAS infection appears to be mediated, in 
part, to type-specific antibodies to M molecule (Guilherme, et al 2006).
The M protein is thought to play a major role in the development and progression of 
GAS disease (Cunningham 2000, Johnson, et al 2006). The surface-exposed, conserved 
C repeat domain of M protein in some GAS serotypes may be a virulence determinant 
for ART (Guilherme and Kalil 2010, Robinson and Kehoe 1992). Specific regions of M 
protein serve as shared antigens, and cross-reactivity between these epitopes and human 
proteins lead to autoimmune RHD (Guilherme, et al 2006, Lancefield 1962). Thus, M 
protein is a major GAS virulence and immunological factor and antibody to this protein 
gives protection to the human host. This has made M phenotyping and genotyping the 
best epidemiological tool to detect outbreaks of GAS, and for measuring the general 
threat presented by GAS at any given time and place (Guilherme and Kalil 2010, 
Metzgar and Zampolli 2011, Smeesters, et al 2009). The M protein is the subject of 
intensive investigation and its potential as a vaccine against GAS infections (Steer, et al 
2009d)
GAS are classified into Class I and II based on their M-protein reaction with a 
monoclonal antibody. The majority of Class I reactive M-proteins are associated with 
ARP including M types such as 1, 3, 5, 6, 14, 18, 19 and 24. Class II strains have non­
reactive M proteins that produce an apolipoproteinase called opacity factor (Nwankwu 
and Njoku-Obi 1990). Children may be exposed to several GAS throat infections but
116
reinfections with the same serotype are less common due to the presence of homologous 
anti-M antibodies after an infection (Courtney, et al 2009). Some reports have identified 
certain M strains to be repeatedly associated with ARF while other prevalent strains do 
not cause ARF even in susceptible hosts. Not all strains of rheumatogenic types are 
equally pathogenic(Jolmson, et al 2006, Menon, et al 2004)
6.4 Multilocus sequence typing
Multilocus sequence typing (MLST) is a new molecular epidemiological technique that 
helps to identify the global spread of virulent or antibiotic resistant isolates of bacterial 
pathogens and with the capacity for the typing information to be shared through the 
internet (Brian G 1999, Enright and Spratt 1999). MLST is a nucleotide sequence-based 
method that characterizes the genetic relationships between the organisms of a bacterial 
species (Enright, et al 2001). The nucleotide sequence of 450—500-bp internal fragments 
of seven housekeeping genes are determined for each isolate (Maiden, et al 1998). An 
allele is assigned for each locus according to the sequence. This length of DNA 
fragment can be sequenced on both strands using a single pair of primers and provides 
enough variation to identify many different alleles in most bacterial pathogens within 
the population (Urwin and Maiden 2003). Housekeeping loci are used for analysis 
because they are present in every organism, their products serve a vital function and the 
mutations within them are assumed to be selectively neutral (Meisal, et al 2010).
MLST is highly discriminatory as the accumulation of nucleotide changes in 
housekeeping genes is a relatively slow process (Richardson, et al 2011). The allelic 
profile of a bacterial isolate is sufficiently stable over time for the method to be ideal for 
global epidemiology (Urwin and Maiden 2003). The technique can identify clones, 
groups of isolates that are descendants of a recent common ancestor and have shared 
alleles at each of the housekeeping loci (Bessen, et al 2008). Currently the database 
contains the allelic profiles of isolates that represent the global diversity of GAS and 
other bacterial isolates (McGregor, et al 2004b). It has the advantage of being applied 
directly to clinical material and does not require laboratories to obtain the reference 
isolates of each of the important clones of a bacterial pathogen.
The major advantage of this approach is that sequence data are unambiguous and
electronically portable, allowing electronic databases and molecular typing band global
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surveillance studies of GAS and other bacterial pathogens (Cooper and Fell 2004, 
Maiden, etal 1998).
6.4.1 Emm genotyping system for GAS
A genetic marker for GAS is the emm pattern based on the chromosomal arrangement 
of emm genes that encodes surface protein fibrils. M protein is composed of two 
polypeptide chains. The chain comprises four repeat blocks A-D. The C (carboxy) 
terminal is highly conserved among GAS strains (Jenkinson and Lament 1997). The N 
(amino) terminal portion extends into the environment with a series of 11 amino-acids 
that vary among different clinical isolates. This hypervariable region of the protein has 
antigenic differences that form the basis for the Lancefield classification of GAS (Beall, 
et al 1998, Facklam, et al 1999, Lancefield 1962). The classification has been expanded 
after cloning of the M-protein (emm) gene and the standardisation of the emm typing 
system (Beall, et al 2000, Facklam, et al 2002, Johnson, et al 2006).
PCR was introduced by Podbielski et al in 1991 to study the M protein gene family 
emm in GAS (Podbielski, et al 1991). This DNA sequencing has been used to describe 
more than 200 GAS sequence types. It also gave information on the phylogenetic 
associations between different serotypes of GAS (Brahmadathan and Gladstone 2006). 
Emm usually refers to the M protein gene although it may refer to any of three emm-Wks 
genes that are present at the vir locus (Shet and Kaplan 2004).
Only a few reference laboratories are able to prepare the type-specific M-typing 
antisera. It is frequently difficult to detect M proteins in this way due to the 
unavailability of typing reagents (Reed, et al 1980). No attempt has been made to 
produce them commercially due to their great expense. It is also believed that many 
GAS isolates are nontypeable because of the lack of M expression or lack of reactivity 
of expressed M protein with available antisera (Moses, et al 2003, Shet and Kaplan 
2004).
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6.4.2 emm GAS strains with “Rheumatogenic” characteristics 
GAS strains have been evaluated by sequence analysis of emm gene-specific PCR 
products (emm typing). This methodology has allowed the recognition of several 
previously unknown GAS types in different geographic areas, demonstrating the 
usefulness of emm typing for detecting genetic diversity among GAS isolates and for 
tracing GAS infections (Doktor, et al 2005, Espinosa, et al 2003). GAS strains of 
certain emm! M protein serotypes vary in their rheumatogenic potential (Dey, et al 
2005, Erdem, et al 2009).
It is probable that not all GAS strains of rheumatogenic serotypes are equally 
pathogenic (Yoonim, et al 2005). The tendency of a given strain to provoke ARE 
depends on the type and production of M protein and conditions that favour person to 
person transmission (Kurahara, et al 2006, Shulman, et al 2006). Some strains are 
strongly and repetitively associated with outbreaks of ARE whereas other prevalent 
GAS strains do not provoke the disease or reactivate it in susceptible hosts (Ekelund, et 
al 2005, Lazar R. 2004, McDonald, et al 2007b). These rheumatogenic variations are 
responsible for the temporal and geographical variations of ARE/RHD (Bisno, et al 
2003, Steer, e? a/2009b).
The predominant serotypes associated with outbreaks of ARE in the United States and 
United Kingdom betweenl939 and 1971 were rheumatogenic strains of Ml, M3, M5, 
M6, M14, M18, M19, M24 and M29. During the period 1970 to 1989, Ml, M3, M5, 
M6, and Ml 8 were the reported predominant rheumatogenic strains. The rheumatogenic 
strains M9, M22 and M33 were reported in the years 1970 to 1980 (Kaplan 2005).
Substantial heterogeneity in the M types was reported in India but the five most 
prevalent types were emm 74, emm 11 and StI129 with some areas having emm 5, emm 
6, emm 18, emm 19,and emm 24 (Sagar, et al 2008, Sakota, et al 2006). In Australia 
emmlA' and A3765 were reported as rheumatogenic but with lower prevalence of emm 
1, 3, 12, 14, 18, 24, 75 and 89 (McDonald, et al 2007b, Richardson, An/2010). In New 
Zealand rheumatogenic strains were diverse and emm 6,53,55, 58, 66, 74,75,76,92 
and99 were associated with ARE (Dierksen, et al 2000, Safar, et al 2011).
119
There is supporting evidence of the concept of rheumatogenicty based on global 
epidemiologic studies but the nature of these strains needs to be further studied in 
countries with high prevalence of ARF and RHD to elucidate new rheumatogenic 
strains. It has been emphasized that changes in genotypic prevalence of GAS occurs 
which may account for the predominantly type-specific nature of immunity exhibited by 
individuals to GAS (McGregor, et al 2004a, Surdeanu, et al 2000) .
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Figure 6. 1 Virulence factors of GAS From Cunnigham et al (2002)
6.4.3 Serum opacity factor (SOF) and serum opacity factor (sof) 
gene
GAS has some surface adhesion molecules that can interact with extracellular host 
proteins such as fibronectin (Maxted, et al 1973). This interaction is important for the 
adherence of GAS to the epithelial host cells that makes it a prerequisite for 
colonization and subsequent disease(Courtney, et al 2006, Gillen, et al 2008). Serum 
opacity factor (SOF) is a large extracellular and surface-bound protein capable of 
binding bronectin which is encoded by the sof gene(Johnson 1993). SOF is unique 
among GAS (Rosales, et al 2009). Almost half of the GAS strains produce an
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apoproteinase, an enzyme that causes mammalian serum to increase in opacity (Bianco, 
et al 2006). The opacity factor enzymes are type specific for M types (Han, et al 
2009).Opacity factor antibodies can be used in the inhibition tests (Timmer, et al 2006).
The two functional domains of SOF are located on separate regions of the 
protein(Johnson 1993). The variable N-tenninus of the enzyme domain of SOF is 
responsible for cleaving the ApoAl portion of high-density lipoprotein (Rosales, et al 
2009). The conserved C-terminus involves the fibronectin-binding domain of the SOF 
protein via the repeated homologous chains. SOF is a virulence determinant in GAS that 
expresses a class IIM protein (Gillen, et al 2008). The GAS isolates that possess the 
class IIM protein are the only ones able to express SOF (Brandt, et al 2001, Courtney, 
et al 1999). Some GAS strains are more likely to cause ARF and certain characteristics 
of individual GAS genotypes are associated with rheumatogenicity based on 
epidemiologic data (Carapetis 2008b). These include a high M protein content and 
mucoid colonial morphology indicative of a large capsule and lack of in vitro 
production of SOF (Courtney, et al 2009, Johnson, et al 2006).
Virtually all rheumatogenic emm types (1, 3, 5, 6, 14, 17, 18, 19, 24, 27 and 29) express 
a class IM protein and are SOF negative except emmll. Whatmore in 1995 
demonstrated extensive genetic variation within certain individual M types and distinct 
emm sequence clusters associated with SOF status and previous rheumatogenecity, 
concluding that SOF-positive and SOF- negative M types represent distinct 
evolutionary lineages (Whatmore, et al 1995). These findings support the concept that 
there are specific rheumatogenic GAS strains that are encapsulated and associated with 
increased virulence and rheumatogenicity (Gillen, et al 2008, Shulman, et al 2006).
This complementary molecular methodology (sof typing) is also based upon sequence 
analysis of a hypervariable virulence gene (Perea-Mejia, et al 2006), Plowever, recent 
studies have demonstrated that multiple sof-gens types do occur within a single Ml emm 
type, and that a single sof sequence can be associated with more than one emm type 
(Beall, et al 2000, Jeng, et al 2003). Therefore, although SOF-inhibition serotyping 
remains a useful GAS classification tool, it must be interpreted carefully, with the
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understanding that in some instances the SOF-inhibition type will not accurately predict 
MJemm type, especially when strains from diverse sources are analysed (Wolfe 2000).
Fibronectin-binding protein (FnBP) has been reported to be vital for endothelial 
invasion (Massey et al 2001, Peacock, et al 1999). FnBP forms a link between bacterial 
pathogens and the cell of the host (Peacock, et al 2000). Sof is a unique bifunctional 
protein anchored to the cell surface of many GAS strains, so/is linked to a second gene 
encoding a new streptococcal fibronectin-binding protein(s/AY). Serum opacification is 
encoded by sof gene alone and sfbX encodes a fibronectin-binding function. SfbX 
protein was found to bind immobilized fibronectin and to partially inhibit GAS 
adherence to fibronectin. The sof and sfbX genes were found to be expressed on the 
same transcription unit. The sfbX gene was found to be present only in ^/-positive 
strains where both genes influence the type of tissues and disease manifestations 
associated with sqfpositive GAS(Jeng, et al 2003). The presence ofprtF, sof and 
other genes encoding extracellular matrix binding proteins with GAS may be associated 
with antibiotic sensitivity and resistance patterns (Dicuonzo, et al 2002, Oehmcke, et al 
2004)
Thus SOF is required for the virulence of GAS(Courtney, et al 2006, Timiner, et al 
2006). The fibronectin-binding repeats of this streptococcal protein are highly 
conserved, required for fibronectin-binding by SOF and are capable of provoking an 
immune response not observed as a result of natural GAS infection (Courtney, et al 
2009, Kreikemeyer, et al 1999). Some studies have suggested that the fibronectin- 
binding repeats of GAS Sfbl (protein F) are protective (Oehmcke, et al 2004, Towers, et 
al 2003). Thus fibronectin-binding repeats of sof may prove to be a useful target for a 
vaccine against GAS (Goodfellow, et al 2000, Schulze, et al 2003).
6.4.4 Pyrogenic exotoxin superantigens
GAS produces a variety of exotoxins including streptococcal pyrogenic exotoxins 
(SPE). These belong to a larger group of pyrogenic toxin superantigens (PTSAgs) that 
stimulate T cells by binding to both regions on major histocompatibility complex 
(MHC) class II molecules and specific Vp chains of the T-cell receptor (Ferretti, et al 
2001). This reaction is called superantigenicity (Fraser and Proft 2008). Extensive T-
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cell proliferation results in massive cytokine release. Structural and immunological 
characterization of the SPEs has revealed that they are low-molecular-weight proteins 
(24,000 to 28,000) that are relatively heat and protease resistant (Arcus, et al 2000,
Proft, et al 2003). Other novel GAS superantigens made by virulent streptococci have 
been described (Green, et al 2005, Nakagawa, et al 2003, Norrby-Teglund 2001).
GAS strains possess mobile genetic elements like plasmids, bacteriophages, transposons 
and insertion sequences (Ferretti, et al 2001). The prophages or prophage-like elements 
comprise a small fraction of the GAS genome but may be responsible for 70% of the 
variation in the formation of GAS strains (Nagiec, et al 2004).
GAS phages are considered to contribute to the characteristics of virulence and 
resistance (Smoot, et al 2002b). Many prophages encode one or two proven 
extracellular virulence factors and antibiotic resistance determinants (Kotb, etal 1990, 
Nandi, et al 2002a). These may play a role in the expression and horizontal transfer of 
genes (Beres and Musser 2007, Yang, et al 2006).
Prophage-encoded virulence factors are divided into two groups (McCormick, et al 
2001, Schafer and Shell 1995). The first group belongs to the pyrogenic toxin 
superantigens that consist of the streptococcal superantigen and the streptococcal 
pyrogenic exotoxins (SpeA, SpeC, SpeK, SpeH, Spel, SpeM, and SpeL) (Chatellier, et 
al 2000, Schlievert 1993). The other group is composed of DNases (Spdl, Spd3, Spd4, 
Sda, and Sdn) and phospholipase A2 (Proft, et al 2001, Vitali, et al 2009).
6.4.5 Streptococccus invasive locus (sit)
Hidalgo-Grass et al., (2002) identified a DNA locus named sil in the invasive serotype 
Ml 4 clone causing necrotizing fasciitis in Israel. Thus, sil may regulate virulence genes 
in GAS strains of different genetic backgrounds causing diverse types of human disease 
(Bidet, et al 2007, Billal, et al 2008, Hidalgo-Grass, et al 2004). The role of the 
superantigen-like activity of M-protein fragments, as well as the streptococcal 
pyrogenic exotoxin, in the pathogenesis of ARF is still the focus of study.
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6.4.6 Pulsed field gel electrophoresis (PFGE)
PFGE is another powerful subtyping molecular method for epidemiologic investigations 
of GAS. PFGE is based on restriction length fragment polymorphisms of the whole 
microbial genome and allows the detection of variations among strains (Ghourchian and 
Elyasvandi 2005). Despite its usefulness, the results from PFGE generated between 
laboratories are not comparable unless a standardized protocol is followed(Bianco} et al 
2006). The typing patterns are then analyzed with computer software that permits their 
comparison online (Rydberg, et al 1994, Tenover, et al 1995).
PFGE of bacterial DNA provides genotyping information with a pattern of DNA 
fragments (Riapis, et al 2006). It is used to assess similarity among GAS. PFGE shows 
that within an outbreak of infections, single genetic events may occur randomly for 
months. The difference in PFGE patterns of 1 - 3 bands can result from a single genetic 
event. If the GAS isolates have bands that differ by 1-3 bands, they should be 
considered “closely related,” those that differ by 4-6 bands “possibly related,” and 
those that have six or more differing bands are distinct strains as outlined in Table 6.1 
(Tenover, et al 1995). PFGE banding patterns (pulsotypes) are analyzed by visual 
inspection (Haukness, et al 2002, Riapis, et al 2007).
Table 6. 1 Criteria for interpreting PFGE patterns (Tenover et al, 1995)
Category
No. of genetic 
differences 
compared with 
outbreak strain
Typical no. of 
fragment differences 
compared with 
outbreak pattern
Epidemiologic
interpretation
Indistinguishable 0 0 Isolate is part of the 
outbrealc
Closely related 1 2-3 Isolate is probably 
part of the outbreak
Possibly related 2 4-6 Isolate is possibly 
part of the outbreak
Different >3 >7 Isolate is not part of 
the outbreak
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6.4.7 Future GAS Vaccine
Most of the recent isolates within emm types 1-89 share identical M type-specific 
sequences with corresponding reference strains that were isolated 20-70 years ago 
(Georgousakis, et al 2009, Nir-Paz, et al 2009). Despite considerable emm type 
heterogeneity, the majority of pharyngitis isolates are concentrated within relatively few 
M serotypes (Pichichero 2004, Steer, et al 2009d). An effective M protein-based 
vaccine encompassing the most prevalent serotypes may impact very significantly on 
GAS pharyngotonsillitis and its complications (Shulman, et al 2004, Steer, et al 2009b)
The 26-valent M-protein vaccine that is currently undergoing clinical trials includes 
immunogens for 86% of pharyngeal isolates and a highly conserved epitope 
(streptococcal protective antigen) that may protect against additional types. This vaccine 
includes 35-50 amino acid N-terminal segments of emm types 1-3, 5-6, 11-14, 18, 19, 
22, 24, 28, 29, 33, 43, 59, 75-77, 89, 92, 101 and 114 (Dale 2008, Kotloff 2008, 
Loughlin 2007, Nir-Paz, et al 2009).
Continuous research is undertaken in the development of GAS vaccine for ARF 
prevention during over the past 40 years (Bryant, et al 2009). A 26 valent -vaccine 
based on emm types and M subtypes collected across GAS diseases from the US was 
evaluated in a clinical trial(Dale, et al 2005). Reports showed this 26-valent vaccine 
was associated with 79% emm coverage in the US, 69% in Europe, 40% in Fiji, 33% in 
New Zealand, 76% in Brussels and 32% in Brasilia (Hu, et al 2002, Lee, et al 1995, 
McNeil, et al 2006, Metzgar and Zampolli 2011, Nir-Paz, et al 2010, Shulman, et al 
2009). Reports on this vaccine revealed seroresponse to 84.5% of GAS pharyngeal 
isolates, 92.5% isolates linked with ARF and 87.6% of invasive disease isolates and 
100% of strains causing necrotizing fasciitis in US (Steer, et al 2009a).
Overall, the 26 emm types in the experimental multivalent vaccine accounted for less 
than 65% of all isolates in Africa, Asia, Middle East and Pacific region (Abdel-Aal, et 
al 2010, McNeil, et al 2005).This vaccine will not be applicable for countries with high 
risk of ARF due to tire lack of data on rheumatogenic GAS strains(Seckeler and Hoke 
2011). GAS vaccines, should be evaluated for their efficacy against GAS isolates of 
greatest importance to less developed countries (Dale, et al 2005). Moreover GAS 
vaccines face a number of challenges among which is the avoidance of cross-reactivity
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with human tissue. It will take several more year's for a possible GAS vaccine to be 
clinically effective and affordable in underdeveloped countries but it still remains a 
priority (Seckeler and Hoke 2011). The more urgent requirement is to implement 
available public health control measures against GAS diseases worldwide with special 
emphasis in low income countries.
6.5 Patients and methods
Thirty four throat culture isolates from patients with GAS and SNA pharyngotonsillitis 
required for the phenotype and genotype study were selected from a pool of samples 
described in chapters four and five who gave a history of ART and were echo- 
cardiography-proven cases of RHD.
There was limited funding available for isolate typing and so it was only possible to 
type a small number of isolates. The strains that were chosen for typing with positive 
RADT and positive cultures were among the patients who gave a positive history of 
ARP and were echocardiographic proven cases of RHD. They showed raised anti­
streptolysin body titers (>400 Todd units) with positive C-reactive protein (>50mg/L).
In this part of the study there were no controls that makes it somewhat difficult to 
detennine if the genotype and phenotype of strains associated with GAS and SNA 
pharyngotonsillitis and a history of RHD reflected the general bacterial population 
circulating in the Yemen or a specific subset of this. Future studies should include a 
control group.
These included 21 patients with GAS and 13 patients with SNA pharyngotonsillitis. The 
34 isolates were stored at -70°C until characterization. The GAS DNA extraction was 
performed according to the protocols described in Chapter 2. PCR amplification was 
carried out using specific “M” primers. The resulting PCR products were purified and 
sequenced on an automated sequencer. The nucleotide sequence with the N-terminal 
hypervariable portion of the M protein was subjected to homology searches against 
sequences in the Gen Bank molecular data bank.The emm sequence typing was 
performed as described by Beall et al on the CDC website
http://www.cdc.gov/ncidod/biotech/strep/protocol_em??? type.htm).The programs check 
the degree of similarity and attempt to obtain > 95% identity with the 5’ terminal portion
of a known emm genotype. This was followed by giving the nucleotide sequence the 
respective emm designation.
A PCR-based method was developed to determine the presence of phages and phage- 
associated virulence genes of em?72 genotypes,jpeC, spell, sdn, silC, silD,sofand 
sfbXgQriQS. The oligonucleotide primers and PCR conditions are listed in Table 6.2. The 
PCR-based method for the presence of the prophage-associated-w> genes: speC, spdl, 
sdn and the primer pairs for virulence genes were replicated from Matsumoto 
(Matsumoto, et al 2003). Multiplex PCR was used for toxin-gene profiling as described 
by Schmitz (Schmitz, et al 2003). PCR detection of the streptococcus invasive locus 
(sil) was performed with multiple sets of primers (Zimmerlein, et al 2005).
6.5.1 PFGE interpretation
Interpretation of PFGE results was based on published guidelines (Tenover, et al 1995) 
as described in Table 6.1. The PFGE patterns were designated by their serial number 
identification in the study (Haukness, et al 2002).
6.6 Results
6.6.1 GAS and SNA pharyngotonsillitis
34 samples were subjected to PFGE, emm typing, and nucleic acid amplification for the 
pyrogenic exotoxin superantigen gene and serum opacity factor gene. These included 21 
(61.8%) samples with GAS positive cultures and 13 (38.2%) with SNA positive cultures 
of GBS, GCS and GGS pharyngotonsillitis.
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Figure 6. 2Distribution of 34 isolates of GAS and SNA by month (2006-2007)
6.6.2 GAS genotypes
Eleven (52.4%) GAS pharyngotonsillitis isolates encoded as emm 87, 6 isolates (28.8%) 
were emm\2 genotype, 3 (14.3%) were emm2% and one (4.8%) emmS genotype (Table 
6.2).
Table 6. 2Distribution of GAS genotypes and emm sequence type
Strain Emm type
No of emm 
isolates
n=21(%)
GAS 87 11 (52.4)
12 6 (28.8)
28 3 (14.3)
5 1 (4.8)
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6.6,3 SNA GBS, GCS and GGS genotypes
Four isolates (30.8%) of GCS pharyngotonsillitis were st2917 and two (15.4%) of the 
GCS isolates were emm stCK249 genotypes. Two (15.4%) GGS isolates were emm 
stG7882.2 genotypes, and the other four GGS were st2917, st7406, stG652.5 and 
stKNB7. One GBS isolate was stG4974. (Table 6.4)
Table 6. SDistribution of SNA serotypes and emm typing
Strain Emm type
No of emm isolates
n=13(%)
GBS st4974 1 (7.7)
GCS st2917 4 (30.8)
stCK249 2(15.4)
GGS stG7882.2 2 (15.4)
st2917 1 (7.7)
st7406 1 (7.7)
stG652.5 1 (7.7)
stKNB7 1 (7.7)
6.6.4 Pyrogenic exotoxin superantigen genes in patients with GAS 
and SNA pharyngotonsillitis
The presence of pyrogenic exotoxin superantigenes among patients with GAS and SNA 
pharyngotonsillits is shown in Table 6.5. The sof and sfbX exotoxin gene amplification 
was positive in all the 21 (100%) patients with GAS but negative in all patients with 
SNA pharyngotonsillitis (pA).001).
The superantigen gene specC was positive in 20 (95.2%) patients with GAS 
pharyngotonsillitis and negative in 13 (100%) patients with SNA pharyngotonsillitis 
(p=0.001). The silC virulence gene was positive in 21 (57.1%) GAS patients and 11 
(77%) SNA patients with pharyngotonsillitis (p=0.048). The presence of the pyrogenic 
exotoxin superantigen gene spdl, silD, and sdn were positive in a higher proportion of
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patients with GAS than SNA but the difference was not statistically significant between 
the two groups (p=<0.5) (Table 6.5).
Table 6. 4Distribution of pyrogenic exotoxin superantigen genes among patients with 
GAS and SNA Pharyngotonsillitis
Exotoxin
superantigen
gene
GAS
n=21(%)
SNA
n=13(%) P
sof 21 (100) - 0.001
sfbX 21 (100) - 0.001
speC 20 (95.2) - 0.001
spdl 21 (100) 13 (100) 1.0
sdn 12(57.1) 6 (46.2) 0.7
silC 21 (100) 11 (77) 0.048
silD 17(81) 11 (77) 1.0
Figure 6. 3Distribution of pyrogenic toxin superantigen genes among isolates of GAS 
and SNA
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6.6.5 Pyrogenic exotoxin superantigen genes in patients with GAS, 
GBS, GCS and GGS pharyngotonsillitis
The sof and^/h/Ygene was detectable in all patients with GAS and negative in all patients 
with GBS, GCS and GGS pharyngotonsi 11 itis (p=0.001).
The pyrogenic exotoxin superantigen gene specC was positive in 20 (95.2%) patients 
with GAS pharyngotonsillitis but negative in all patients with GBS, GCS and GGS 
pharyngotonsillitis This difference of presence of specC among the four groups was 
statistically significant (p=0.001).
Table 6. 5Distribution of pyrogenic exotoxin superantigen genes among patients with 
GAS, GBS, GCS and GGS pharyngotonsillitis
Exotoxin
Superantigen
GAS
=21(%)
GBS
n=l (%)
GCS
n=6 (%)
GGS
n=6 (%) P
sof 21 (100) - - - 0.001
sfbX 21 (100) - - - 0.001
speC 20 (95.2) - - - 0.001
spdl 21 (61.8) 1(100) 6(100) 6(100) 1.0
sdn 12(57.1) - 6(100) - 0.001
silC 21 (100) - 6 (100) 4(67) 0.005
silD 17(81) - 6(100) 4(67) 0.1
The exotoxin superantigen gene sdnN was positive in 12 (57.1%) patients with GAS 
and 6 (100%) patients with GCS pharyngotonsillitis. Patients with GBS and GGS 
pharyngotonsilltis were all negative for sdnN superantigen gene. This difference of the 
presence of 5^77 was statistically significant (p=0.001).
The pyrogenic exotoxin superantigen gene silC was positive in all 21 (100%) patients 
with GAS and all 6 (100%) patients with GCS pharyngotonsillitis. It was positive in 4 
(67%) of patients with GGS pharyngotonsillitis. The presence of silC exotoxin super­
antigen gene showed a statistical significant difference within the groups (p=0.005).
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6.6.6 Virulence prophage exotoxin superantigen gene among emm 
genotypes of GAS, GBS, GCS and GGS patients with 
pharyngotonsillitis
The emm genotypes observed among GAS isolates was emm%l in 11 patients, emm\2 in 
six patients, emml% in three patients and emm5 in one patient. All the eleven patients 
with emm%l GAS pharyngotonsilitis were positive for the pyrogenic exotoxin 
superantigens sof sfbX,speC, sdn, spdl, silC and silD.
emmll genotypes of GAS were present in six strains positive for the pyrogenic 
exotoxin superantigens genes of sof sfbX, speC, spdl, silC and silD. None of the emm 
12 genotype was positive for sdn pyrogenic exotoxin superantigen.
The emm2% genotype was identified in three isolates positive for the pyrogenic exotoxin 
superantigens gene sof, sfbX, spec, spdl and silC. One GAS isolate with emm5 genotype 
had positive pyrogenic exotoxin superantigen genes of sof, spdl, sdn and silC.
One GBS isolate emm st4974 had pyrogenic exotoxin superantigen gene positive for 
spdl and silD. GCS was identified with four isolates of st2917 and two stCK249 that 
were all positive for pyrogenic exotoxin superantigen gene of spdl, sdn, silC and silD.
There were six isolates with GGS serotypes. Four GGS identified as emm st652.5, 
st2917, st7406 and stKNB7 were positive for spdl, silC and silD exotoxin superantigen 
genes. GGS was also identified as emm stG7882.2 in two isolates that were positive for 
pyrogenic exotoxin superantigen gene spdl only.
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Table 6. 6Distribution of the virulence genes among GAS and SNA pharyngotonsillitis 
isolates divided by emm genotype
Serotype emm type N Sof sfbX, speC Spdl sdn silC silD
GAS emmS 1 + + + + +
emm 12 6 + + + + + +
3 + + + 4“ +
emm%l 11 + + + + + + +
GBS st4974 1 + +
GCS st2917 4 + + + +
stCK249 2 + + + +
GGS st2917 1 + + +
st7406 1 + + +
st652.5 1 + + +
stG7882.2 2 +
stKNB7 1 + + +
Figure 6. 4Distribution of pyrogenic exotoxin superantigen genes among isolates of 
GAS, GBS, GCS and GGS
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6.6.7 Pulse field gel electrophoresis (PFGE) interpretation 
The PFGE of a selection of GAS isolates is in Figure 6.7. PFGE representative band 
patterns analysis of genomic DNA restricted with Smal enzyme. The nine Yemeni 
GAS isolates with the emm%l genotype in lane 5 to lane 13 share an identical pattern of 
chromosomal DNA bands and same size.
The control strain serves as a mean of comparison only. We were looking for the 
relatedness of the isolates (for example if one wanted to establish whether a particular 
set of organisms all belonged to an outbreak). We could establish whether strains 
examined were invasive or not if there was a control strain for either the invasive or the 
non-invasive (or both) strains. In Figure 6.7 the control strains in the PFGE were four 
lanes belonging to GAS isolates identified as emm 12 genotypes from patients with acute 
pharyngotonsillitis at Alder Hey Children’s Hospital, Liverpool.They merely served as 
a comparison with isolates from another site. The main purpose of the PFGE was to 
look for the relatedness of the isolates from the Yemen.
Table 6. 7 Comparison of PFGE genotypes and emm genotypes
Country Serotype emmgenotype
No of 
isolates
PFGE
profile Lanes
Yemen GAS emm 87 9 A 1-9 *
emm 87 1 A1 io**
Yemen GAS emm 12 5 B 7-12**
GAS emm 12 1 B1 6**
Liverpool/UK GAS emm 12 4 B2 A-D*
Yemen GAS emm 28 2 C 3-4
Yemen 1 Cl 2
Yemen GAS
4: Q
emm 5 1 D 5
^Figure 6.7, **Figure 6.8
A— emm 87 indistinguishable strains Al= emm 87 closely related
B = emml2 indistiguishable strains B1 = closely related strains
B2= indistinguishable UK strains C = indinsguishable strains
Cl = closely related D = isolated strain
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Figure 6. 7 PFGE interpretation of GAS isolates with acute pharyngotonsillitis digested 
with restriction enzyme Smal
M lane is a reference molecular size marker.
A, B C and D lanes belong to GAS isolates from patients with acute pharyngotonsillitis 
at Alder Hey Childrens Hospital, Liverpool identified as emm\2 genotypes.
Lanes 1 to 9 belong to GAS isolates from Yemeni patients with pharyngotonsillits 
identified as emm%l genotypes.
Lane S was the standard control for GAS isolate
Figure 6.8 shows the PFGE profile for the GAS isolates emm\2 in lanes 6, 7, 8, 9, 11 
and 12. They showed identical chromosomal patterns with no differences observed in 
the DNA strands and were closely related.
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GAS isolates with emm28 showed identical patterns in lanes 2,3 and 4 of the PFGE 
profile in Figure (6.8). The chromosomal pattern of lane 5 belonged to GAS emm5. 
Lane 10 described a GAS emm%7 that did not differ even in any DNA bands with the 
PFGE shown in figure 6.8
Figure 6. 8 PFGE of GAS isolates with emm5, 12, 28 and 87 genotypes using restriction 
enzyme Smal
Lane 1 molecular weight marker
Lane 3 and 4 belong to emm2S GAS isolates from Yemeni patients with acute 
pharyngotonsillitis. Lane 5 belongs to emm5 GAS isolate with acute pharyngotonsillitis
Lanes 6, 7, 8, 9, 11 and 12 belong to emm\2 GAS pharyngotonsillitis
Lane 10 belongs to emm%l GAS isolate with acute pharyngotonsillitis
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6.6.8 PCR interpretation of the prophage exotoxin superatigen genes
Figure 6. 9 PCR of GAS emm5, 12, 28 and 87 with the prophage pyrogenic exotoxin 
superantigen genes spdl, sdn,spec .silC and silD
PCR with prophage pyrogenic exotoxin superantigen - related virulence factors
Lanes marked M are the molecular weight markers
Lanes 1 to 9 spdl positive for GAS emm5, 12, 28 and 87 genotypes
Lanes 11-13 and lanes 24-28 sdn positive for GAS emm5 and 87
Lane 14and lanes 29 - 35 are speC positive for emml2, 28 and 87
Lanes 15-23 silC positive for emm5,\2, 28 and87
Lanes 36-47 silD positive for emm\2 and 87
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M-vel 2 3 45 6 789 10 11 M 12 1314 1516 17 18 19 20
Figure 6.10PCR of SNA isolates with prophage pyrogenic exotoxin superantigen sof 
genes
Lane M represents the molecular reference weight marker 
Lane 1 and lane 18 are so/12 positive for emm\2 GAS 
Lane 5 and lane 7 are so/87 positive for emmZl GAS 
Lane 15 and lane 17 are sof 2$ for emm2& GAS 
Lane 16 is so/5 positve for emmSGAS
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6.7 Discussion
6.7.1 Emm genotype among GAS isolates with pharyngotonsillitis 
This study describes the characteristics of 34 isolates of GAS and GCS, GGS and GBS 
strains among pharyngotonsillar cultures from patients in Yemen. The isolates included 
known and new emm sequences and were characterized through genotype tests 
detection of the sof and sfbX genes, the streptococcal pyrogenic exotoxin genes, si! and 
PFGE analysis of genomic DNA restriction profiles. The most frequent GAS isolates 
detected among patients with history of ART and RED were 12, 28 and 5
More than 200 GAS genotypes have been documented at the CDC emm database 
laboratories (Shulman, et al 2004). It is known that some GAS serotypes are more 
‘rheumatogenic’ than others (WHO 2004) The GAS emmM protein serotypes emm\, 3, 
5, 6, 14, 18, 19, 24, 27 and 29 have been linked to ART/RHD (Kaplan, et al 2001, 
Stollerman 1991). The rheumatogenic types 3, 5, 6, 14, 18, 19, and 29 made up 49.7% 
of pharyngeal isolates during the 1960s but only 10.6% of isolates 40 years later 
(Shulman, et al 2009, Steer, et al 2009d).
The most common ARP associated emm GAS strains were emm5 and emm 18 in the 
United States, emm5 and emml in Chile (Cresti, et al 2002) and emml 1 and emm4l in 
Trinidad. emm/Ml& in Utah was associated with ARF (Veasy, et al 2004), while the 
GAS emm types isolated from patients with ARF in Hawaii were 65, 69, 71, 92, 93, 98, 
103, 122 (Erdem, et al 2009) and emm25 in Thailand (Pruksakorn, et al 2000).
In the Aboriginal territory in Australia emm 14 and emmst3765 were the frequent 
rheumatogenic strains (Bessen, et al 2000) while in Auckland, New Zealand emm6, 53, 
55 and 66 were associated with ARP (Marlin, et al 1994). The predominant strains 
reported in Kuwait were emml, 9, 12 and 33 (Majeed, et al 1992b) and in Tunisia 
emml, 9, 11,33, and 49 (Mzoughi R2004) while emm5 and 6 were found in Iran (Jasir 
2000) (Table 6.8).
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Table 6. 8Distribution of emm GAS rheumatogenic strains on throat swabs in different
countries
Country Emm GAS rheumatogenic strains Reference
Kuwait 1,9,12,33 Mageed et al 1992
New Zealand 6, 53, 55,66 Martin et al 1994
Iran 5, 6 Jasir et al 2000
Australia 14 and st3765 Bessen et al 2000
Thailand 25 Proksakron et al 2000
Chile 1,5 Cresti et al 2002
Tunisia 2, 9,11,33,49 Mzoughi et al 2004
Utah 18 Veasy et al 2004
Trinidad 11,41 Veasy et al 2004
United States 3,5,6, 14,18,19, 29 Shulman et al 2009
Hawaii 65,69,71,92, 93,98,103,122 Erdem et al 2009
Yemen 5,12,28,87 Current study
The most frequent GAS types among Yemeni patients with acute pharyngotonsillitis 
having a history of ARF and RHD in this study were emm%l, 12,28 and 5 in order of 
frequency. GAS emm 87 was the most frequent genotype detected in more than half 
ARF and RHD patients 11/24 (52.4%) with acute pharyngotonsillitis. This is the first 
report of GAS emm%l to be detected among patients with ARF/RHD in the literature 
and it may be potentially rheumatogeinc.
Emm 12 and 28 detected among patients with ARF and RHD may also have a 
possibility of being rheumatogenic. Even though emml2 and 28 are among the 
relatively common causes of acute pharyngotonsillitis they have not yet been attributed 
to cause ARF (Abdissa, et al 2006, Kaplan 1996) with the exception of two reports. 
One report from Kuwait where emm\2 was isolated in 7% of rheumatic children and
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their families and the other from Pennsylvania where 9 isolates were recovered from 
patients with ARP (Majeed, et al 1992b, Martin and Green 2006). GAS emm5 genotype 
is a global rhenmatogenic strain reported in different countries. Very different spectra of 
GAS genotypes have been associated with ARP in some developing countries, with 
some being M-nontypable or representing newly identified types (Majeed, et al 1992b, 
Martin, et al 2004, Shulman, et al 2009). Me Donald described one emm 87 in throat 
and skin in populations with high rated of ARP and many GAS skin infections but it is 
rather difficult to comment on comparisons to Yemen since we have no studies on skin 
infections and neither skin isolates
Uncommon emm GAS serotypes could have a role in the epidemiology of ARP/RHD in 
Yemen. However we cannot be certain as we do not know the emm strains that are not 
associated with ARP/RHD in the same geographical area for comparison. On the other 
hand, it might be explained on the basis of the small sample size of isolates evaluated 
for emm type.
6.7.2 Serum opacity factor (jsof) gene
Rheumatogenic GAS have distinct biologic characteristics. They belong to Class I 
strains, do not bind fibronectin and are predominantly SOF-negative. Although 
rheumatogenic strains are less likely to produce SOP, there are no studies to indicate 
that they cannot produce SOP (Martin, et al 1994).
All the GAS isolates which were Group A (3 haemolyitc Streptococci representing 
genotypes of emm 87, emm 28, emm 12 and emm 5 were both positive for the sof 
geneand sfbX genes. The sof and sfbX genes were located on the same DNA bands of 
the same chromosome in all the 21 isolates of GAS Group A genotypes by PCR 
analysis. These findings may further support the fact that sof geneis likely to be linked 
invariably to a second gene {sfbX) encoding a new streptococcal fibronectin-binding 
protein (Johnson, et al 2006). The presence of the two genes, sof gene and sfbX gene 
encoding fibronectin-binding functions may have an effect on the spectrum of tissue 
colonization and disease manifestations in specific GAS strains (Jeng, et al 2003, 
Peacock, et al 2000, Peacock, et al 1999).
142
The presence of these two genes together could influence the spectrum of tissue 
colonized by GAS strains (Jeng et al, 2003) .The 11 GAS isolates with the same emm%l 
type were positive for the so/and sfbX geneand contained the so/87 gene sequence. This 
is in contrast to the literature describing emm 87 to be sof negative. This may indicate 
that there is a possibility that emm%l may possess a sof gene that is only detectable by 
PCR and is not expressed. Isolates shared a common toxin gene profile with the 
presence of the five toxin genes spec, spdl, sdn, silC and silD. There were no striking 
differences between the PFGE types of emm 87 GAS strains. This is the first report 
describing the profile of these five exotoxin genes among GAS emm$7.
The emm 12 isolates of GAS were all sqfmd sfbX gene positive and contained the sof 12 
gene sequence among the pharyngeal cultures in this study. This is in contrast to the 
Italian, Iranian and German studies where the emml2 isolates were invariably sof gene 
negative (Brandt et al 2001). Although some studies indicate that emml2 isolates are 
phenotypically SOF negative but the sof gene is detecTable by PCR (Lintges, et al 
2007). To date, emml2 represents the only laiown emm/emmAike gene patterns 
associated with the presence of a sof gene (Dicuonzo, et al 2001, MA, et al 2009).
The emm28GAS strains were positive for sof and sfbX gene which is comparable to a 
study conducted in Germany (Brandt ^ 2001). These sof types and their
corresponding emm sequence types in several combinations of GAS isolates may appeal* 
to be highly predictive of some genetically related strain sets (Maripuu, et al 2008). The 
ability to detect the combinations of the sof gene and emm sequence type in different 
GAS isolates may lead to a revision of the previous association of sof and emm type.
6.7.3 Prophage exotoxin superantigen genes
Pyrogenic exotoxin C {sped) is bacteriophage-mediated and its expression is likewise 
highly variable. Recently, mild cases of scarlet fever in England and the United States 
have been associated with ^peC-positive strains (Vitali, et al 2009). In this study, the 
streptococcus pyrogenic exotoxin C {speC) was identified in 11/11 of the emm%l, 6/6 of 
emm\2 and 3/3 of emm2% GAS strains. Rivera et al in Spain found positive sped in only 
1/7 isolates with emm 12, 7/9 isolates with emm28 and 3/3 isolates with emm$l (Rivera, 
et al 2006). Bingen et al in France reported sped in 2 isolates of emm 12, 5 strains of
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emm2$ and one strain of einmS7. This is the highest proportion of the speC toxin gene 
reported among emm 87 isolates (Bingen, et al 2004).
GAS emm2% strains are highly diverse in prophage-encoded virulence gene content and 
integration site and are contributors to GAS genetic diversity and population biology 
(Green, et al 2005). Three GAS emm 28 strains were positive for speC and spdl genes 
encoding streptococcal pyrogenic exotoxin C and a DNase, respectively. This is similar 
to a study by Green et al who observed that GAS emm28 genotype had the speC and 
spdl genes in 84% of the isolates and was reported to be the major profile for this type.
In this study the presence of streptodornase (DNase) sdn was not identified among the 
e/7^28GAS strains in contrast to the presence in 34% of isolates in Israel (Green, et al 
2005, Moses, et al 2003).
6.7.4 Streptococcus invasive locus among GAS strains
PCR was positive for silC in 21 (100%) and silD in 17 (81%) GAS pharyngotonsillitis 
isolates compared to a study in French children with invasive GAS infections but not 
ART, where both silC and silD were positive in 12 GAS isolates (16%). The silC and 
silD loci were positive in all the emm%l and emm\2 GAS pharyngotonsillitis isolates 
among Yemeni children with ARP and RHD. In this study, the emmS and emm2S GAS 
strains were only positive for silC but not for the silD loci. This is in contrast to a study 
among French children where only one isolate of emm&7 was positive for both silC and 
silD while the emm\2 and emm2% were neither positive for silC nor silD among their 
invasive GAS isolates (Bidet, et al 2007). The silC was found in the three isolates of the 
emm2% and emm5 GAS genotype which has not been previously reported in literature.
6.7.5 Emm genotype among SNA isolates with pharyngotonsillitis 
The reported prevalence of GCS/GGS carriage and disease incidence varies globally. 
Most studies originate from temperate regions of the northern hemisphere and limited 
data are available from tropical regions (McDonald, et al 2007b, Teixeira, et al 2001).
In this study the emmlDl virulence genotypes of GGS in 6 patients with ARF/RHD and 
pharyngotonsillitis were genetically heterogeneous having 5 different genotypes each of 
emm st2917, emm st7406, emm stG652.5, stKNB7 and two isolates of emm st7882.2.
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The emm/M virulence genotypes of 6 GCS patients with acute pharyngotonsillitis were 
of st2917 in 4 isolates and emm stCK249 in two strains.
These GGS and GCS emm sequence strains are different from those reported in India, 
Jerusalem, Portugal, Hungary and Argentina (Cohen 2004, Hashikawa, et al 2004, 
Lopardo, et al 2005, McMillan, et al 2004, Pinho, et al 2006). One emm sequence type 
detected among GGS strain, stKNB 7 was originally recovered among GGS pharyngeal 
isolates in Chennai, India (Menon, et al 2008). These variations might be attributed to 
geographic differences. The new seven emm sequences among GCS, GGS and GBS 
pharyngeal isolates in this study are the first reports in the literature.
6.7.6 Prophage exotoxin superanitgen and (sof) genes among SNA 
strains
SNA particularly GCS/GGS are known to possess class IM proteins similar to 
rheumatogenic GAS strains. A high proportion of these strains appear to be sof 
negative, albeit few sof positive emm types have been reported including stG166b and 
stG 480.0 (McDonald, et al 2007a). The prophage toxin genes spell was positive in all 
the SNA, GBS, GCS and GGS pharyngotonsillitis isolates, sof and speC genes were 
negative in all the SNA, GBS, GCS and GGS different genotypic strains were consistent 
with the sq/-negative phenotype described by Bisno & Collins in 2003. There was only 
one report of GCS strain st 4974 positive for speC in the US (Kalia) Interestingly, 
strain st 4974 was recovered from the throat of a patient with ART but the evidence was 
not conclusive (Kalai et al 2003).The exotoxin superantigen sdn was positive in GCS 
strains but the GBS and GGS were all negative for this sdn superantigen that has not yet 
been identified elsewhere.
It is noteworthy that all the emm genotypes of GCS strains were positive for spdf sdn, 
silC and silD prophage exotoxin superantigens. The GCS strains shared the presence of 
these virulence genes with GAS isolates. These GCS strains with particular' genotypes 
in susceptible hosts and their association with the presence of these virulence genes 
traits may have a greater likelihood to be associated with ARF. This is the first report to 
highlight the prophage gene toxin sequence of specific GCS strains.
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Moreover, the emmA genotype among four GCS and one GGS Yemeni 
pharyngotonsillitis strains were positive for both silC and silD toxin gene. Bidet et al 
reported 50% of GAS isolates harbouring the silC and silD loci which belonged to 
emmA genotype (Bidet, et al 2007).
6.7.7 PFGE interpretation
Tenover’s guidelines were used to determine the relatedness of GAS isolates.The ten 
throat isolates of GAS emm&l were from different schools from different districts of 
Aden city. PFGE profiles within the ten isolates of individual GAS emm&l did not show 
differences within the chromosomal DNA bands. This suggests that these PFGE profiles 
were closely related and each individual emm type of 87 shared a high degree of genetic 
relatedness indicating a possible outbreak pattern.
GAS strains belonging to emml2 exhibited similar and highly related PFGE profiles. 
GAS emm2% also shared similar DNA patterns within the same emm PFGE profiles. 
Other characteristics varied from isolate to isolate, although some associations were 
consistently found within some emm types. Most strains belonging to a given emm type 
had similar or highly related PFGE profiles that were distinct from profiles of strains of 
another type. This information may provide baseline data on the epidemiological 
aspects of GAS pharyngotonsillitis infection.
In some instances, PFGE profiles within a given GCS and GGS emm type were not 
related, but were distinct from the strain profiles of another GCS and GGS emm types. 
These data indicate that the majority of isolates within each individual emm type shared 
a high degree of genetic relatedness among the SNA GCS and GGS genotypes. This 
high degree of relatedness within certain emm types might hold true only within this 
particular geographical area. However we did not compare PFGE with profiles from 
other countries.
6.8 Conclusions
The most frequent emm GAS isolates among patients with acute pharyngotonsillitis 
with a history of ARP and RHD were emmSl, 12, 28 and 5. GAS genotype emm5 and
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emm 12 were previously reported to be rheumatogenic. The two other emm genotypes 
87 and 28 have not been previously reported among rheumatogenic GAS strains.
The 11 isolates of GAS strain were positive for the sof and sfbX gene and
contained the unique so/87 sequence. Isolates shared a common toxin gene profile with 
the presence of the five toxin genes speC, spdl, sdn, silC and silD. There were no 
striking differences of sequence types in the PFGE of emm 87 GAS strains.
The emmll isolates of GAS were all 50/and sft>Xgene positive and contained the so/12 
gene sequence. The emm28 GAS were all 50/and sfbX gene positive for the sof 28 gene 
sequence among the pharyngeal cultures. emm5 GAS was 50/and sfbX gene positive
There is a continuing worldwide problem of disease mediated by GAS isolates. 
Monitoring of GAS isolates and the study of their emm genetic variability, should 
eventually lead to a better understanding of the epidemiology of specific GAS strains. 
The variations in the serotypes and emm genotyping may reflect differences in the 
circulating strains due to geographical separation or different proportions of 
submissions by site of isolation and the different period examined.
GAS infections can be appropriately treated with antibiotics. It is essential to assess the 
burden of the disease with an epidemiologic data on the isolates causing disease through 
active and continuous surveillance. This will guide public health action policy in for 
preventive and therapeutic strategies. The understanding of the genetic regulation of 
GAS, its structure and function will form the basis to the development of effective and 
safe vaccines.
The high and alarming prevalence of ARF/RHD in underdeveloped and developing 
countries and the advancement of techniques in molecular biology will facilitate the 
development of a vaccine that is safe, economical and efficacious to combat GAS 
infection and its serious life-threatening complications. Knowledge of the genetic 
diversity among bacterial strains provides an insight into pathogen evolution and 
facilitates the study of the relationships between strain genotypes and pathogeneicity.
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6.9 General implication
This study demonstrates variations in the emm genotype sequence among GAS and the 
SNA GGS and GCS isolates. The pyrogenic exotoxin superantigen genes spdl was 
detected in all the GAS, GCS and GGS strains and the silC and silD was positive in 
more than half of the GAS and SNA GCS and GGS isolates. These different strains 
possessed similar pyrogenic exotoxin superantigen virulence genes that may support the 
speculation of them sharing distinct structural features with GAS genotypes. Further 
comparison of the structures of these different genotypes of GAS with GCS and GGS 
may cast light on the configuration of the virulence protein molecules which could be 
critical for the expression of rheumatogenicity.
This study presents the phenotypic and genotypic characteristics of GCS and GGS and 
GBS isolates belonging to seven new emm sequence types with a variety of 
characteristics which are tire first to be detected among Yemeni children with acute 
pharyngotonsillitis and a history of ARF and RED. The data suggests that strains 
circulating in Yemen, an area not previously surveyed, may be different from those 
known to circulate in other geographical areas. Such information can contribute to a 
better understanding of the local and global dynamics and epidemiologic aspects of 
GAS and GGS, GCS and GBS infections occurring in various regions.
This study possibly represents the first genotypic and exotoxin virulence gene survey of 
GAS isolates recovered among children in the Middle-East. Although the study sample 
was small and from a convenience sample.(A convenience sample describes a sample 
in which patients were selected at the convenience of the researcher and which related 
to the inability to assess other isolates due principally to cost constraints),rather than 
from community-based studies, GAS isolates from patients with pharyngotonsillitis 
having history of ARF and RHD appeared to be associated with emm types not 
commonly observed in ARF and RHD patients. Although emm types are good 
predictors of clonal types within a given geographic location, there is considerable 
genetic diversity within certain emm types, especially when comparing strains from 
different countries.
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In this part of the study there were no controls that makes it somewhat difficult to 
determine if the genotype and phenotype of strains associated with GAS and SNA 
pharyngotonsillitis and a history of RED reflect the general bacterial population 
circulating in the Yemen or a specific subset of this and further studies should include a 
control group.
149
Chapter 7
7 Antimicrobial Patterns among GAS and SNA
pharyngotonsillitis with a history of ARF and RHD
7.1 Introduction
Antimicrobial resistance is a major global problem that challenges physicians with the 
management of infections (Hawkey and Jones 2009, Jensen, et al 2009, Bronzwaer, et 
a/2002). Antimicrobial drugs are used in GAS infections to control and to minimize the 
occurrence of suppurative complications, prevent ARP and reduce person to person 
transmission (Leung and Kellner 2004, Reynolds 2009). There are many studies 
documenting the inappropriate use of antibiotics in acute pharyngtonsillitis in children 
(Deasy 2009, Nash, et al 2002, Weber 2005).
GAS remains universally susceptible to penicillin and this continues to be the first-line 
therapy for GAS pharyngotonsillitis (Bisno 2001, Weber 2005). There are no reports 
documenting clinical isolates of GAS pharyngotonsillitis resistant to penicillin or 
cephalosporins in vzYro(Sauermann, et al 2003). Erythromycin is the macrolide 
antibiotic of choice in patients allergic to penicillin (Betrru, et al 1993, Bingen, et al 
2000, Krause 2002). There are however many countries reporting increasing rates of 
erythromycin resistance due to excessive usage of macrolides (Bingen, et al 2004)
Patients with GAS pharyngotonsillitis can be treated with antibiotics with the use of a 
clinical scoring system, RADT or positive culture tests (Leung and Kellner 2004). 
Rapid treatment of GAS infections is important as inappropriate treatment leads to 
changes in the characteristics of the bacteria enhancing the process of bacterial 
resistance to antibiotics (Kim and Lee 2004b, Linder, et al 2005, Liu, et al 2009, 
Szczypa, et al 2004).
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Information on bacterial susceptibility to commonly used drugs has not been reported 
from Yemen, where the use of antibiotics is less regulated and is available over the 
counter. The aim of this study thus was to analyse antimicrobial susceptibility patterns 
and genetic diversity among patients with GAS and SNA pharyngotonsillitis.
7.2 Objective
To analyze the susceptibility pattern of antibiotics of GAS and SNA isolates from 
patients with pharyngotonsillitis
7.3 Literature review
Antibiotic resistance is the ability of bacteria to oppose the inhibitory (bacteriostatic) or 
killing (bactericidal) effect of antibiotics (Deasy 2009, Szczypa, et al 2004). Antibiotic 
resistance has increased during the past 15 years creating problems in treating bacterial 
infections (Alos, et al 2003, Barker 1999, Woodford, et al 2009). Antimicrobial 
resistance increases morbidity, mortality, and length of hospital stay and health care 
costs due to delay in therapy (Hawkey and Jones 2009). These adverse outcomes may 
be the result of the unsuccessful use of antibiotics or a delay in therapy (Borg, et al 
2008).
Antimicrobial resistance is a growing problem worldwide, requiring international 
approaches to continuously focus on the importance of the emergence and determinants 
of resistance and the need for control strategies (Dryden, et al 2009, Green, et al 2004, 
Reynolds 2009). The major factors leading to the emergence and transmission of drug- 
resistant bacterial strains are directly related to the antimicrobial consumption of drugs 
(Al-Najjar and Uduman 2008, Dryden, et al 2009, Jensen, et al 2009).
Despite the extensive use of penicillin for more than 50 year's, GAS has not acquired 
resistance to penicillin and still remains the recommended drug of choice for the 
treatment of GAS pharyngotonsillitis (Bandak, et al 2000, Brook and Dohar 2006, 
Descheemaeker, et al 2000, Martin, et al 2004). Penicillin exhibits proven efficacy with 
a narrow spectrum and is cheap (Holm 2000, Linder, et al 2005, Palavecino, et al 2001). 
However, reports of failure of penicillin in eradication GAS from the oropharynx of 
healthy carriers are now causing some concern possibly due to penicillin tolerance
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(Adam, et al 2000, Beckmann, et al 2005, Gerber, et al 2009). Amoxicillin is another 
medication in common use, particularly among children, because of its greater 
compliance and increased palatability (Barzilai, et al 2001, Leelarasamee, et al 2000, 
Shulman, et al 2006).
Erythromycin is recommended only for GAS patients allergic to penicillin (Alos, et al 
2003, Bae, et al 2007, Green, et al 2004). In contrast to penicillin, erythromycin was 
introduced in the late 1950s and was immediately followed by the emergence of drug 
resistance. Lowry & Hurst (1952) in Birmingham reported the first eiythiomycin 
resistant GAS (Lowbury and Hurst 1959). Then in the 1970s the first widespread 
erythromycin resistance was reported in Japan (Miyamoto, et al 1978) followed by an 
increase in erythromycin resistance from Finland (Canton, et al 2002, Seppala,e/ 
a/1995). Macrolide resistance is increasing in many countries possibly due to the use 
and overuse of macrolides (Alos, et al 2003, Borg et al 2008, Descheemaeker, et al
2000) . Studies indicate a nationwide macrolide resistance from as low as 1.3% - 5% to 
> 45% in several countries (Alos, et al 2003, Gagliotti, et al 2006, Green, et al 2004, 
Jensen, et al 2009).
First-generation cephalosporins are also used for patients allergic to penicillin, but they 
have a broader spectrum and are more expensive (Adam, et al 2000, Palavecino, et al
2001) . Clindamycin can be used if other antibiotics are not an option (Beekmann, et al 
2005, Choby 2009). Tetracyclines and sulfonamides are ineffective in eradicating GAS 
and tetracycline is contraindicated in young children (Beekmann, et al 2005, Weber 
2005).
Clinical treatment failure of GAS pharyngotonsillitis has rarely been reported 
(Brahmadathan and Gladstone 2006, Manyemba and Mayosi 2003). A patient with 
recurrent symptoms of GAS pharyngotonsillitis with positive throat culture following a 
few weeks of treatment should be considered as having a chronic pharyngeal carriage 
state with superimposed viral infection, non compliance with antibiotics, or an infection 
with a different new GAS strain (Oran, et al 2000). Recurrent pharyngitis caused by the 
same GAS strain in a patient who has received proper antibiotic treatment is uncommon 
(Shulman, et al 2009)
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7.4 Patients and methods
Antibiotic sensitivity patterns were determined in 24 representative culture isolates fiom 
patients with acute pharyngotonsillitis of whom 11 were GAS isolates from patients 
described in chapter 4 and 13 SNA isolates were patients described in chapter 5.A small 
proportion of isolates were tested for antimicrobial susceptibility patterns due to the 
lack of funding and this amount of money was generously donated by the Department 
of Medical Microbiology at the University of Liverpool.
Antibiogram tests were conducted using penicillin G, amoxicillin, erythromycin,, 
tetracycline and chloramphenicol on the 24 isolates on 5% defrbrinated horse blood 
using the disc diffusion method (Andrews 2001b). The diameter of the zone of 
inhibition was measured to the nearest millimetre and bacteria were classified as 
susceptible or resistant according to the standard Table by the BSAC system.
The minimum inhibitory concentration (MIC) was defined as the lowest concentration 
of the drug that inhibited visible growth after overnight incubation (Andrews 2001a). 
The breakpoint refers to the point at which GAS is considered to be resistant to a 
particular antibiotic. MIC > breakpoint concentration defines an organism as resistant 
and the MIC < breakpoint concentration defines the organism as susceptible (Scavizzf 
et al 2002). The zone diameter breakpoints for each antibiotic are derived from the 
respective MIC breakpoint (MacGowan and Wise 2001). The interpretation of zone 
diameters was done according to the BSAC standard for penicillin G, amoxicillin, 
erythromycin, tetracycline and chloramphenicol (Andrews 2007) . The data were 
analyzed by SPSS17.0 software and the level of significance was determined as p<0.05.
7.4 Results
7.4.1 General antimicrobial susceptibility patterns among GAS 
and SNA strains
The 24 patients recruited in this analysis had a mean (SD) age of 13(1.4) years, with a 
range of 10-15 years. There were 15 males and 9 females. Eleven patients had GAS 
isolates and thirteen SNA isolates.
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All GAS strains were sensitive to penicillin and amoxicillin. All SNA strains were 
sensitive to penicillin and amoxicillin. Erythromycin resistance was encounteied among 
four (36%) GAS strains and seven (54%) SNA isolates. GAS and SNA isolates were 
resistant to chloramphenicol in 10 (91%) and 12 (92%) patients, respectively. 
Resistance to tetracycline among GAS isolates was observed in six (54.5%) cases and 
four (30.8%) SNA isolates. The difference of sensitivity and resistance patterns varied 
between GAS and SNA isolates but was not statistically significant (Table 7.1).
Table 7. lAntibiotic sensitivity and resistance pattern among GAS and SNA 
pharyngotonsillitis
GAS n=11(%) SNA n=13(%)
PAntibiotic
Sensitive Resistant Sensitive Resistant
Penicillin 11 (100%) 13 (100%)
Amoxicillin 11 (100%) 13 (100%)
Erythromycin 7 (64%) 4 (36%) 6 (46%) 7 (54%) 0.4
Chloramphenicol 1 (9%) 10(91%) 1 (7.7%) 12 (92.3%) 1.0
Tetracycline 5 (45.4%) 6 (54.5%) 9 (69.2%) 4 (30.8%) 0.4
7.4.2 Anibiotic susceptibility patterns among GBS, GCS and GGS 
isolates
Erythromycin resistance was observed with equal proportions among the three (50%) 
GCS and three (50%) GGS isolates. Chloramphenicol and tetracycline were both 
resistant in all (100%) GCS and GBS isolates. Among the GGS isolates 
chloramphenicol and tetracycline were both resistant in five (83%) of the patients 
respectively. The antimicrobial resistance patterns of the five antibiotics are shown in 
Table 7.2. The patterns differed among GBS, GCS and GGS isolates.
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Table 7. 2Antibiotic sensitivity and resistance in GBS, GCS and GGS
pharyngotonsillitis
Antibiotics
GBS n=l(%) GCS n=6(%) GGS n=6 (%)
Sensitive Resistant Sensitive Resistant Sensitive Resistant
Penicillin 1(100%) 6 (100%) 6 (100%)
Amoxicillin 1(100%) 6 (100%) 6(100%)
Erythromycin 1 3 (50%) 3 (50%) 3 (50%) 3 (50%)
Chloramphenicol 1 (100%) 6 (100%) 1 (17%) 5 (83%)
Tetracycline 1 (100%) 6(100%) 1 (17%) 5(83%)
7.4.3 Antibiotic susceptibility patterns among GAS emm 
genotypes
The antimicrobial patterns of GAS varied within the six strains of emml2 genotype, of 
which three (50%) were erythromycin resistant, five (83%) chloramphenicol resistant 
and one(17%) tetracycline resistant. The three GAS emm 28 genotype expressed no 
sensitivity to either chloramphenicol or tetracycline and only one was erythromycin 
resistant. One GAS emm 5 and one emm87 were neither sensitive to chloramphenicol 
nor tetracycline. A statistically significant pattern of antimicrobial sensitivity and 
resistance pattern was observed with tetracycline within the different GAS emm 
genotypes (Table 7.3 p<0.05).
7.4.4 Antibiotic susceptibility patterns among SNA emm 
genotypes
One strain of GBS emm stG4974 genotype was resistant to both erythromycin and 
chloramphenicol (Table7.4).
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Table 7. 3Antibiogram tests in patients with GAS emm genotype and sof gene based on 
disc antibiotic sensitivity and resistance pattern _____ ______
Antibiotic
Emm
genotype sof
Sensitive
n (%)
Resistant
n(%)
Penicillin 5 1 (100%)
12 + 6 (100%)
28 + 3 (100%)
87 + 1 (100%)
Amoxicillin 5 + 1 (100%)
12 + 6(100%)
28 + 3 (100%)
87 1 (100%)
Erythromycin 5 + 1 (100%)
12 + 3 (50%) 3 (50%)
28 -H 2 (67%) 1 (33%)
87 + 1 (100%)
Chloramphenicol 5 + 1 (100%)
12 + 1 (17%) 5 (83%)
28 + 3 (100%)
87 + 1 (100%)
Tetracycline* 5 + 1 (100%)
12 "1" 5 (83%) 1 (17%)
28 -f. 3 (100%)
*p=<0.05
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Table 7. 4Antibiogram tests in patients with GBS emm genotype and sof gene based on 
disc antibiotic sensitivity and resistance pattern
„ . . Bacteria
Antibiotic Q^p Emm genotype
Sensitive Resistant
S0f n (%) n(%)
GBS stG4974 Negative
Penicillin 1 (100%)
Amoxicillin 1 (100%)
Erythromycin 1 (100%)
Chloramphenicol 1 (100%)
Tetracycline 1 (100%)
All the four strains of GCS emm genotype st2917 were chloramphenicol resistant, three 
(75%) tetracycline resistant and two (50%) were erythromycin resistant. Two strains
GCS emm stCIC249 were chloramphenicol resistant while one strain was erythromycin
resistant (Table 7.5).
Table 7, 5 Antibiogram tests in patients with GCS emm genotype and so/based on disc
antibiotic sensitivity and resistance patterns
. . Bacteria Emm Sensitivesof
n (%)
Resistance
Group genotype n(%)
Penicillin GCS st2917 4 (100%)
stCK249 2 (100%)
Amoxicillin st2917 4(100%)
stCK249 2 (100%)
Erythromycin st2917 2 (50%) 2 (50%)
stCK249 1(50%) 1(50%)
Chloramphenicol st2917 - 4(100%)
stCK249 - 2 (100%)
Tetracycline st2917 1 (25%) 3 (75%)
stCK249 2 (100%)
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Two emm GGS stGl$&2.2 were sensitive to erythromycin. GGS emm st2917 and emm 
stG652.5 were resistant to erythromycin and chloramphenicol. One strain of GGS 
emmstl406 was resistant to both chloramphenciol and tetracycline (Table 7.6).
Table 7. 6 Antibiogram tests in patients with GGS emm genotype and so/based on disc 
antibiotic sensitivity and resistance pattern
Antibiotic
Bacteria
Group
Emm
genotype sof
Sensitive
n(%)
Resistance
n (%)
Penicillin GGS st29ll 1 (100%)
stonm - 2 (100%)
sf]4()6 - 1 (100%)
stG652.5 - 1 (100%)
Amoxicillin st29ll - 1 (100%)
stGnS22 - 2 (100%)
stl406 - 1 (100%)
Erythromycin st29\7 - 1 (100%)
stKNB7 - 1 (100%)
smoe - 1 (100%)
stGlM22 - 2(100%)
stG652.5 - 1 (100%)
Chloramphenico 1 5t2917 - 1(100%)
stKNB7 - 1 (100%)
st7406 - 1 (100%)
5/G7882.2 - 1 (50%) 1 (50%)
stG652.5 - 1 (100%)
Tetracycline st29\7 - 1 (100%)
st74Q6 - 1 (100%)
stG7M22 - 2 (100%)
stG652.5 — 1 (100%)
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7.5 Discussion
7.5.1 Antibiotic sensitivity and resistance patterns among GAS 
isolates
All GAS strains were sensitive to the (3-lactam antimicrobials, penicillin and amoxicillin 
and which is consistent with the report in different developing and developed countries 
(Adam, et al 2000, Brook and Dollar 2006, Danchin, et al 2007, Jain, et al 2008, Leung 
and Kellner 2004, Lloyd, et al 2007, Palavecino, et al 2001, Rimoin, et al 2005).
Table 7. 7GAS resistance pattern to erythromycin in different countries
Country Erythromycin resistance to GAS Reference
Germany 18.9% (11/59) Arvand,e/ al 2000
Spain 19% (19/100) Granizo,e/ al 2000
Belgium 6.5% (131/2014) Descheemaeker,c/ al 2000
Italy 43.5% (40/92) Savoia,<?/ al 2000
Iran 0.2% (3/1335) Jasir,e/ al 2000
France 9.6% (29/303) Weber,et al 2001
Chile 5.4% (32/594) Palvecino,eZ al 2001
Brazil 0.5% (1/211) De al 2003
Canada 14.4% (72/500) Low,e/ al 2003
Hungary 3.7% (7/191) Gattringer,e/ al 2004
Poland 12% (98/816) Szczypa,e? al 2004
Hawaii 2.9% (16/546) Erdem,<?£ al 2005
India 10.2 (5/49) Lloyd,e/ al 2007
India 15.6 (5/32) Jain,e/ al 2008
China 96.8% (182/188) Liu,e/ al 2009
Yemen 36% (4/11) Current study
Increased resistance to macrolides by GAS is directly related to the use of antibiotics in 
pharyngeal infections which is reported in several countries (Gerber 1996, Jensen, et
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a/2009, Seppala, et al 1997, Tarlow 1997, Weber, et al 2001, Yan, et al 2000). In this 
study, GAS was resistant to erythromycin in 36% (4/11) comparably higher to studies in 
India 10.2% (5/49) and 15.6% (5/32) (Jain, et al 2008, Lloyd, et al 2007), Iran 0.2% 
(3/1335) (Jasir, et al 2000), France 9.6% (29/303) (Weber, et al 2001), Germany 18.9% 
(11/59) (Arvand, et al 2000), Spain 19% (19/100) (Granizo, et al 2000), Austria 4.7% ( 
7/150) and 3.7% (7/191), Hungary and Hawaii 2.9% (16/546) (Erdem, et al 2005). 
(Gattringer, et al 2004) but lower than that in Italy 43.5% (40/92) (Savoia, et al 2000).
Tetracycline resistance among Yemeni GAS isolates was observed in 54.5% (5/11) 
which was similar to the GAS pattern in Brazil with 50% tetracycline resistance (De 
Melo, et al 2003). On the contrary it was higher than reports of tetracycline resistance in 
Iran 42.8% (214/500) and India 25% (8/32) (Jasir, et al 2000, Lloyd, et al 2007) but 
lower than that in China 96.6% (140/145) (Liang, et al 2008). A higher proportion of 
the GAS isolates 91% (10/11) were resistant to chloramphenicol in this study higher 
than the reports from Japan (22%) and India (4.3%) 2/32 (Lloyd, et al 2007, Nakae, et
al 1977).
7.5.2 Antibiotic sensitivity and resistance patterns among SNA 
isolates
The antimicrobial agent of choice for Group C and Group G streptococci, is penicillin G 
with reports indicating no resistance to the |3 lactams (Zaoutis, et ctl 1999). All the 
thirteen SNA GBS, GCS and GGS strains were sensitive to penicillin and amoxicillin 
comparable to similar reports in different countries (Palavecino, et al 2001, Zaoutis, et
a/2001).
GCS and GGS strains were each 50% (3/6) resistant to erythromycin which was 
comparably higher than a report from India ((37.5% (3/8) GCS and 46% (6/13) GGS)), 
Turkey ((1.5% (1/68) GCS and 16.2% (6/37) GGS)), China ((41.7% ( 5/12) GCS and 
23.5% (23/34) GGS)) and Spain ((5.3% (1/19) GCS and 33.3% (6/18) GGS)) were 
erythromycin resistant (Di'az, et al 2008, Ergin, et al 2003, Lloyd, et al 2007, Wu, et al 
1997). This high resistance pattern among GAS, GCS and GGS strains may be 
explained by the selection of antibiotics used frequently for throat infections and the
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free availability of drugs and antibiotics over the counter in Yemen and other countries. 
All the (6/6) GCS throat isolates in this study did not demonstrate any sensitivity to both 
tetracycline and chloramphenicol whereas in India, GCS isolates were 62.5% (5/8) 
tetracycline resistant and 75% (6/8) chloramphenicol resistant (Lloyd et al 2007) 
wheras in China GCS were all sensitive to tetracycline (12/12) and chloramphenicol 
sensitivity was detected in 58.3% (7/12) of isolates (Wu, el al 1997).
In this study GGS strains were 83% (5/6) resistant to tetracycline which is higher than 
GGS strains reported in India 23% (3/13), China 73.5% (25/34) and Italy (26.7/o). GGS 
was chloramphenicol resistant in 83% (5/6) which is different from a report in India 
with all (13/13) GGS isolates chloramphenicol sensitive and in China 2.9% (1/34) 
chloramphenicol resistant (Lloyd, et al 2007, Rondini, et al 2001, Wu, et al 1997) .
7.5.3 Antibiotic susceptibility patterns among GAS strains 
positive for the sof gene
In this study macrolide resistance was widespread among sof gene positive GAS strains 
including the erythromycin resistant emm\2 sof positive (50%) and emm28 sof positive 
(33%) genotypes (Beelonann, et al 2005, Sauermann, et al 2003, Yan, et al 2000). GAS 
emmS, emm&l were sof positive strains and did not show any erythromycin resistance 
pattern which is contrary to other reports (Creti, et al 2007, Gagliotti, et al 2006, Green, 
et al 2004). GAS emm5, 28 and 87 were all chloramphenicol and tetracycline resistant, 
while GAS emmll was chloramphenicol resistant in 5/6 strains (87%) with one strain 
tetracycline resistant. There are no reports to compare these results in the literature.
GBS emm stGA91A genotype was resistant to chloramphenicol and tetracycline. The six 
GCS genotypes were chloramphenicol resistant and 50% of each genotype was 
erythromycin resistant. GGS were all chloramphenicol resistant except one emm 
stG7&%2.2 strain. Erythromycin resistance was detected in one GGS stKNBl&nd. one 
stG6S2.S strains (Table7.6). The antimicrobial patterns of the GBS, GCS and GGS emm 
genotypes described in this study have not been studied elsewhere and are reported for
the first time.
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Antibiotics are still seen as miracle drugs and patients expect a rapid cure. There is an 
increasing trend for antibiotic resistance in clinical practice which creates challenges for 
the general healthcare provider (Reynolds 2009, Schito 2003). The emergence of . . 
antibiotic resistance must be taken into consideration cautiously by clinicians to limit its 
spread though effective treatments of infections by narrow spectrum antibiotics with 
appropriate duration (Hawkey and Jones 2009, Jensen, et al 2009, Nash, et al 2002). It 
is important to use accurate diagnostic methods for the identification of the causative 
agent and to educate patients and doctors on use and misuse of antibiotics (Dicuonzo, et 
al 2002, Dryden, et al 2009). It is also necessary to continue research to detect any 
change in the susceptibility pattern of GAS isolates to antimicrobials and to assess the 
best-practice for antimicrobial regimens (Shet and Kaplan 2004).
7.6 Conclusions
GAS and SNA isolates from Yemen still remain susceptible to the p-lactam 
antimicrobials used for treating pharyngotonsillits. The level of resistance to 
erythromycin was moderately high. In GAS infections, a specific genetic background, 
the phenotype, and host-parasite interaction could favour acquisition of a particular 
antibiotic resistance. GAS infections may be treated with several therapeutic options but 
penicillin still remains the drug of choice and continued momtonng of susceptibility of 
this pathogen are critical for the future.
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Chapter 8
8 Cytokines and chemokines in acute rheumatic fever 
and recurrent rheumatic fever
8.1 Introduction
ARF is a multisystem inflammatory disease of childhood which occurs as a delayed 
sequelae to GAS (Ralph, et al 2006, Wang and Yang 2009). ARF is mediated by an 
autoimmune response in 3—4% of susceptible and untreated children and adolescents 
(aged 5-18 years) with GAS infections (Guilherme, et al 2006). Arthritis is the earliest 
presentation of the disease in 60-80% of the patients . Carditis affects 30-45% of ARF 
patients and is the most serious manifestation of the disease, leading to valvular’ lesions 
mainly in the mitral and aortic valves (Fae, et al 2006).
The pathogenic mechanisms involved in the development of ARF and progression to 
RHD are still not fully understood (Karthikeyan and Mayosi 2009, Schaffanski, et al 
2008). The pathogenesis involves the triad of a genetically susceptible individual with 
a rheumatogenic GAS infection developing an abnormal host immune iesponse(Biyant, 
et al 2009). It is believed that the molecular mimicry mechanism is responsible for the 
cross-reactions between GAS antigens, mainly M protein epitopes, and human heart 
tissue proteins leading to autoimmunity in patients with genetic susceptibility(Fae, et al 
2006) . It is now clear that the disease is mediated by both humoral and cellular- immune 
responses and that the cellular- branch of the immune response is more involved in the 
development of RHD (Guilherme and Kalil 2007).
Cytokine analysis in various body fluids has become a major emerging field of research 
interest that has enhanced the knowledge of many immunologic and inflammatory 
disorders (Martins, et al 2004). Recently, some cytokines have been implicated as being 
key coordinators in the development or progression of ARF (Corwin 2000).
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The purpose of this study was to analyze the concentrations of a wider range of 
cytokines and chemoldnes as potential makers in the immune activation of patients 
with ARP and RRF. Some of these cytokines and chemoldnes have not been previously 
studied in ARP. The results may help further understanding of the mechanism of 
autoimmunity in ARP and new modalities for treatment to reduce the development and 
progression of cardiac involvement.
8.2 Objective
To compare the concentrations of selected cytokines and chemokmes m Yemem 
children with ARF and RRF.
8.3 Literature review
8.3.1 Molecular pathogenesis of ARF and RFID
Molecular mimicry is proposed as a potential autoimmune mechanism that mediates the 
cross-reactions between GAS antigens and human proteins leading to ARP and RHD 
(Kaplan 2005, Ramasawmy, et al 2007, Veasy and Hill 1997). The presence of 
molecular mimicry between GAS antigens and human tissue proteins is mediated by the 
B and T cell responses of peripheral blood cells and cells infiltrating heart lesions 
(Gufflrerme and Kalil 2007). Cytokines are produced from these peripheral and heart- 
infiltrating mononuclear- cells. It is suggested that T helper 1 (Thl)-type cytokines are 
the mediators of RHD heart lesions (Guilherme, et al 2005b).
8.3.2 Molecular rnimcry and autoimmune reaction following GAS 
infections
Molecular mimicry is the sharing of epitopes between human and GAS antigens. 
Molecular- mimicry for T cells is mediated by antigen presenting cells such as 
macrophages, dendritic cells and B lymphocytes. The HLA class II molcelues are 
expressed on the surface of these antigen presenting cells. Epitope spreading is the 
mechanism that mediates the recognition of self proteins by other cells where an inintial 
immune response produces autoantigen recognition that tends to become more diverse 
as the response persists (Guilherme et al 2009). The molecular basis of T-cell 
recognition is assessed through heart-cross-reactive antigens expressing some homology 
with GAS antigens, ie, the GAS antigen epitopes share structural similarity to self
epitopes. This activates the autoreactive T lymphocytes that were not exposed to the 
immune tolerance by the molecular mimicry which in turn can also activate B cell to 
produce antigen specific antibodies. The M protein which is the most virulent structure 
of GAS shares similar structure with a-helical coiled human proteins mainly cardiac 
myosin, laminin and vimentin. The crossreactive streptococcal epitope involves N- 
acetyl [3-Dglucosamine, a polysaccharide present in both GAS cell wall and heart 
valvular’ tissue.
Human antibodies against the A-acetylp-D-glucosamine show crossreactivity against 
the protein laminin that surrounds the heart and its valves . An epitope of the N~ 
terminal M5 and M6 proteins with a five amino acid residue was demonstrated as cross­
reactive with cardiac myosin by Cunningham (Cunningham 2000). These GAS and 
human protein cross-reactive antibodies also bind to the endothelial surface and 
upregulate the adhesion molecule VCAM-1 leading to inflammation, cellular infiltration 
and valve scarring (Roberts, et al 2001).This cross-reactive immune attack occurs as a 
result of the immune response polarisation towards either B cells/T cells and causes 
rheumatic carditis and Syndenham chorea. Since molecular mimicry between GAS and 
host antigens is present in almost all individuals, the question is why only 3% of 
patients with GAS infection develop ART (Carapetis, et al 2005a, Guilherme, et al
2005b).
8.3.2.1 Humoral immune response
The humoral phase predominates during ART whereas the cellular’ response is initated 
during the acute phase and leaves traces in the chronic phase (Guilherme, et al 2007, 
Olivier 2000). Cardiac myosin and vimentin are the major cross-reactive antigens 
among the human proteins (Ellis, et al 2005). Cunningham discovered that cioss- 
reactive antibodies interact with N-acetyl glucosamine, a polysaccharide present in both 
GAS and heart valve tissues which results in cytotoxic activity against heart cells that 
bind to the endothelial surface and lead to inflammation, cellular infiltration and 
scarring of valves in RHD (Guilherme and Kalil 2007). An exaggerated antibody 
response to GAS carbohydrate was noted in ART patients with increased titres in 
residual MV disease (Carapetis et al 2005). This supports the hypothesis that these 
antibodies cause valve damage.
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8,3.2.2 Cellular immune response
A cellular immune response based on T cell reactivity has been described m ARF 
patients (Carrion, et al 2003, Hilario and Terreri 2002). CD4+ cells were found to be 
increased in tonsils and peripheral blood of ARF and RHD patients (Cunningham 2003, 
El-Demellawy, et al 1997). Carditis is initially mediated by a humoral immune 
response, but evidence suggests it is the T-cell-mediated response which leads to RHD 
(Figueroa, et al 2002). Studies on acute ARF/RHD patients demonstrated the presence 
of CD4+ T cells and macrophages in mitral valve heart lesions (Cunningham 2003, 
Guilherme, et al 2004, Guilherme and Kalil 2004), Zabriskie et al reported the presence 
of CD4+ and CD8+ T cells in RHD valves (Guilherme, et al 2004, Zabriskie 1995).
The Aschoff body, a granulomatous lesion contains T and B cells, mononuclear and 
multinucleated cells, macrophages and PML is the pathognomonic sign of acute RHD 
(Fraser, et al 1997). It is found in the myocardium and endocardium due to cellular 
infiltration that occurs through the endothelium (Necil Kuttikculer 2008). The protein 
M5 (81-103) region was described as one of the GAS trigger of autoimmune reactions 
in RHD (Cohen 2001). It is not clear whether the initial valvular- insult is due to 
antibody or cell-mediated immunological damage, but subsequent damage seems to be 
caused by T-cell and macrophage infiltration (Campetis, et al 2005a). This valvular 
disease is then responsible for cardiac morbidity and mortality of ARF (Lee, et al 2009,
Roberts, era/2001).
8.3.3 Epitope spreading
Epitope spreading is the recognition process of several self-antigens after an initial 
response against a pathogen antigen which then become the target of immune response 
(Cohen 2001, Kivity, et al 2009). GAS recognition leads to antibody formation and T- 
cell epitopes that are crossreactive with human proteins (Cunningham 2004). This 
crossreactivity might occur first through mimicry that leads to other human valvlular 
proteins recognition and eventually through an epitope spread (Hilario and Terreri 
2002). The structural and immunological similarities between GAS M protein and 
human myosin, both a-helical coiled molecules seem essential to rheumatic carditis and 
probably contribute to the progression of tissue damage in ARF/RHD (Cunningham 
2001, Ellis, et al 2005).
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8.3.4 General review of cytokines and chemokines 
Cytokines are soluble hormone-like proteins or glycoproteins that act m a network m 
combination with specific cytokine inhibitors and receptors to regulate the human 
immune response. They have functions in inflammation and hematopoiesis. Stanley 
Cohen first introduced the temi t£cytokine” (Cohen et al., 1974, 2004) and the term 
encompasses interleukins, chemokines, monokines, lymphokines, interferons, Colony 
Stimulating Factors and Tumour Necrosis Factor (Leonard, 1999). Cytokines aie 
secreted by WBCs, fibroblasts and endothelial cells in response to inducing stimuli; but 
the predominant producers are Th-cells and macrophages (Vandana et al 2008(Tayal 
and Kalra 2008).
Basal and cell-stimulated cytokine levels vary between individuals due to both genetic 
and environmental influences (Smith and Flumphries 2009) .The therapeutic use of 
cytokines is a rapidly progressing area of research. Purified recombinant cytokines and 
their antagonists are increasingly used in various inflammatory disorders (Dayer 2004, 
Feldmann 2008, Strom and Koulmanda 2008).
8.3.4.1 8.4.3.1 Classification of Cytokines, Chemokines and Growth 
Factors
8.3.4.2 Cytokine Families
8.3.4.2.1 Type I Cytokine Family
Type I cytokines and receptors share a similar structure of an extracellular region 
containing four a helices, a characteristic motif of type I receptors. Members include 
interleukin IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-12, G-CSF and GM-CSF 
(Kourilsky and Truffa-Bachi 2001). T cell growth factors include IL-2, IL-3, IL-4 and 
IL-7 (Rook 2001). Proinflammatory cytokines include IL-1, IL-2 and IL-6. 
Haematopoietic cytokines are G-CSF and GM-CSF. IL-2 is a Thl cytokine but IL-4 and 
IL-5 are Th2 cytokines (Jankovic, et al 2001).
8.4.3.1.1.1 Interleukin -1 (IL-1) Family
IL-1 family is called the immunoglobulin superfamily that encodes three peptides, IL- 
la, IL-1 (3, and IL-1 receptor antagonist (IL-lra). IL-1R family includes four' primary 
members: IL-la, IL-1(3, IL-18, and IL-IRa (Dinarello 1994). IL-IRa is the specific
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receptor antagonist for IL-la and IL-lp but not for IL-18. IL-1 ligands (IL-la and IL- 
1 p, referred as IL-1) induce genes associated with infections, autoimmune disease, solid 
tumors, asthma, leukemia, Alzheimer's disease and trauma (Smith and Humphnes 
2009). IL-1 is strongly implicated in rheumatoid arthritis causing cartilage degradation 
(Szekanecz, et al 2003). 11-1 p may also be activated in patients with CCF. A 
biologically active product of IL-lra, Anakinra I is used in rheumatoid arthritis that 
blocks IL-1 activity by competitively inhibiting IL-1 binding IL-1RI (Genovese, et al
2004)
8.4.3.1.1.2 Interleukin - 6 (IL-6)
IL 6 is a pleiotropic cytokine produced by macrophages and endothelial cells and is 
involved in B cell stimulation and antibody production (Dayer 2004). IL 6 is likely to be 
elevated in infective endocarditis because bacteria display surface molecules which 
stimulate the release of IL 6 from monocytes and endothelial cells (Watkin et al 2007). 
Increased levels of IL-6 were found in dilated cardiomyopathy, compared to controls 
(Tentolouris, et al 2004). IL-6 was identified in patients with congestive cardiac failure 
as the most powerful independent predictor of new heart failure episodes, death, or need 
for heart transplantation (Mocelin, et al 2005, Oms, et al 2000, Sharma, et al 2000).
8.4.3.1.1.3 Interleukin 12p70
Interleukin-12p70 (IL-12p70), the bioactive form of IL-12, is the principal 
immunoregulatory cytokine that govern Thl immune response polarization. It is 
produced rapidly by the activated antigen-presenting cells in response to bacterial 
antigens and intracellular pathogens. Interleukin-12 p70 (IL-12p70) is a key cytokine 
produced by dendritic cells which is able to drive the development of Thl lymphocytes 
(Dobreva, et al 2008). It induces the release of IFN-y. IL-12p70 is reported to be highly 
correlated with IL-2 (Gu, et al 1997).
8.3.4.2.2 Type II Cytokine Family
Type II cytokines include IL-10, IL-19, IL-20, IL-22 and IFN (IFN-ot,-(3,-s, k, to, 8,
t and -y) (Spellberg, et al 2001). They induce cellular antiviral states, inhibit/stimulate 
cell growth and affect many immune mechanisms (Dmnoutier, et al 2003, Hu 1998).
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IL-10 is an anti-inflammatory cytokine. The IFN system is a major contributor to innate 
immunity with IFN-y serving as a potent pro-inflammatory cytokine. The type II 
cytokine family is comprised of both Thl and Th2 cytokines; IFN-y is a Thl cytokine 
while IL-10 is a Th2 cytokine (Jankovic, et al 2001, Pestka, el al 2004).
8.4.3.1.2.X Interleukin -10 (IL-10)
IL-10 is an important immunoregulatory cytokine which controls Thl and Th2 balance 
and is secreted by macrophages, Th2 cells and mast cells. It inhibits some cytokine 
synthesis such as IL-1, IL-2, IL-3, IL-6, IL-12, IL-18, GM-CSF, TNF-a and IFN-y 
(Moore 2001). It stimulates NK cells and augments the ability of IL-18 to stimulate NK 
cells (Yadav and Sarvetnick 2003). Increased levels of IL-10 are associated with SLE, 
asthma and influence the inflammatory activation of monocytes and limits thrombotic 
complications (Patel, et al 2009). Patients treated with IL-10 showed some 
improvement in chronic hepatitis C, Crohn’s disease and rheumatoid arthritis (Li, et al
2009, Zhou, et al 2009).
8.4.3.1.2.2 Interferon-gamma (IFN-y)
Interferons (IFN) are natural glycoproteins induced in response to viral infections and 
involved in innate and adaptive immune responses (Baron, et al 1991). Type I IFN 
includes over 25 subtypes of interferon-a, (3, omega and tau. Only one type II interferon 
exists, IFN-y, distinct from IFN-a and IFN-p (Loza, et al 2002). Type I IFNs induce 
anti-proliferative and anti-viral activity whereas type II (IFN-y) has weaker anti-viral 
activity but more potent immunomodulatory properties, and binds to different receptor 
than type I IFNs (Jonasch and Haluska 2001). IFN-y is a pleiotropic cytokine, produced 
by effector T and NK cells and is vital for host defence. IFN-y is the major 
proatherogenic Thl cytokine which promotes macrophage and endothelial cell 
activation (Pestka 2007). It leads to expression of specific chemokines such as 
Mig/CXCL9 and IP-10/CXCL10 and their receptor CXCR3 in atheroma (Oliveiia, et al 
2009). IFNs approved for clinical use include: IFN-ct-2a, 2b, pegylated IFN-ct-2a, 2b, 
IFN-a-n3, IFN-a con-1, IFN-p-la, IFN-p-lb and IFN-y-lb (Plozumi, et al 2008, Tayal
and Kalra 2008).
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8.3.4.2.3 Tumor necrosis factor (TNF) Family
The TNF family is primarily involved in the regulation of cell proliferation and 
apoptosis with pro-inflammatroy properties (Yadav and Sarvetnick 2003). Members 
include TNF-a, TNF-p, Fas ligand (FasL), CD40 ligand (CD40L), and TNF-related 
apoptosis-inducing ligand (TRAIL) (Wong et al 2008). TOF-a is an inflammatory Thl 
cytokine released during infection which activates platelets, and lias a role in the genesis 
of fever, anaemia and cachexia (O'Dell, 1999). Elevated TNF- a levels were first 
documented in congestive cardiac failure and hypertrophic cardiomyopathy (Oral, et al 
2003, Torre, et al 1996). TNF-a has a central role in rheumatoid arthritis and this has 
led to the emergence of TNF blocking strategies. The first neutralizing monoclonal anti- 
TNF antibody, infliximab, now has an established role in treating rheumatoid disease 
(Heiko, et al 2009, Szekanecz, et al 2003, Wong, et al 2008).
8.3.4.2.4 Growth Factor Families
Growth factors have unique functions that include vascular- endothelial growth factor 
(VEGF) and Platelet-derived growth factor (PDGF), potent mitogenic and angiogenic 
factors (Ferrara and Davis-Smyth 1997). Insulin-like growth factor (IGF)-I and IGF-II 
belong to the family of IGF that are structurally homologous to proinsulin. The 
Fibroblast growth factors (FGF)family is another group of cytokines involved in cell 
growth and differentiation (Jiang, et al 2000).
8.3.5 Structure and Classification of Chemokines and their 
Receptors
Chemokines include a group of secreted proteins within the cytokine family. They are 
chemoattractants for neutrophils, leukocytes and monocytes that direct white blood cell 
migration to site of injury/infection (Baggiolini, et al 1997, Gouwy, et al 2005). 
Chemokines are important regulators of the immune system through their actions on T 
and B cell development (Min, et al 2002) and are involved in angiogenesis and 
oncogenesis (Horuk 2009). Chemokine activity is mediated by binding to a family of 
seven transmembrane G-protein coupled receptors (GPCR) (Sallusto, et al 2000). 
Numerous disease states manifest particular patterns of chemokine expression 
(Deshmane, et al 2009, Luster 1998, Szekanecz, et al 2003). The coordinated release of
170
chemokines into tissues is the most likely mechanism for white cell infiltration seen m 
these diseases (Gouwy, at qI 2005, Shin, et ctl 2002).
Chemokine receptors are classified into four families based on number and position of 
N-terminal-conserved cysteine residues within the receptor binding domain (Esche, et al 
2005, Sallusto, et al 2000). Receptors with two cysteine residues separated by one 
amino acid are categorized as a-chemokine receptors (CXCR2 and CXCR4); wheieas 
those with two cysteines next to each other are [3-chemokine receptors (CCR5, CCR4, 
CCR3 and CCR2) (Campbell, et al 2001, Luster 1998, Moser and Wilhmann 2004).
8.3.5.1 CC Chemokines
CC chemokines are the largest group of chemokines named beta/ CC, that target 
primarlily mononuclear cells and serve in homeostasis and inflammation (Zlotnik and 
Yoshie 2000). They are divided into allergenic, pro-inflammatory, developmental and 
homeostatic groups. Inflammatory chemokine are inducible and can amplify 
inflammation through the recruitment of effector cells (Szekanecz, et al 2003).
8.3.5.1.1 CCL2 ((Monocyte chemoattractant protein-1 (MCP-1))
MCP-1, a CC chemokine is potent for monocytes in inflammation sites with an effect 
on neutrophils similar to IL-8 (Shin, et al 2002), It is an important component of a 
hierarchical, differential pattern of chemokine expression that results in monocyte 
extravasations through vascular endothelium (Mukaida, et al 1998). It has been 
documented in atherosclerotic lesions. MCP-1 release is stimulated by IL-1, IL-6 and 
IL-8(Deshmane, et al 2009).
8.3.5.1.2 CCL3 (Macrophage inflammatory protein -1 a (M1P-1 a))
MIP-1 a and MIP-1 (3 are highly related members of the CC chemokine subfamily. Only 
low levels of MIP-1 mRNA were detected in resting monocytes and macrophages. 
Significant secretion was observed on stimulation of human blood monocytes with IL- 
lp and IFN-y (Rot and Von-Andrian 2004). MIP-1 a was detected during inflammation, 
malaria, tuberculosis and IL py/un-associated gastritis (Djoba Siawaya, et al 2009, 
Kutscher, et al 2008). HIV-linfected macrophages and T cells have been shown to 
secrete MIP-1 a (Carrol, et al 2007, Paximadis, et al 2009). A weak inhibition of MIP- 
la secretion by T lymphocytes was detected after addition of IL-4, IL-10, IL-18 or IFN-
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y (Menten, et al 2002) . IL-10 suppressed the release of MIP-la. Eosinophils secrete 
MIP-la in RSV infections. Pulmonary vascular smooth muscle cells, stimulated with 
IL-4, IFN-y, IL-10, IL-ip or TNF-a were also shown to release MIP-la. Furthermore, 
bone marrow CD34+ cells and epithelial cells were reported to secrete MIP-la. (Van 
Damme 2002).
8.3.5.1.3 CCL4 ((Macrophage inflammatory protein -1 p (MIP-lp))
MIP-lp was effective in augmenting adhesion of T lymphocytes to VCAM-1. High 
amounts of MIP-ip are produced by monocytes when stimulated with LPS or IL-7. 
MIP-ip production is counteracted by addition of IL-4 (Menten, et al 2002). IFN-y up 
regulates MIP-lp induction, whereas IL-10 down regulates it. Pulmonary vascular 
smooth muscle cells secreted MIP-lp after addition of IL-lp, TNF, IL-4, IFN-y and IL- 
10. It participates in recruitment of monocytes and T cells into the synovium in 
rheumatoid arthritis (Mclnnes and Schett 2007, Menten, et al 2002). MIP-la and MIP- 
lp have been implicated in the pathology of rheumatoid arthritis, glomerulonephritis, 
pnemnococcal meningitis, human sepsis and atherosclerotic lesions (Carrol 2005,
Carrol, et al 2007, De Jager, et al 2007, Mclnnes and Schett 2007).
8.3.5.1.4 CCL5 ((Regulated upon activation, normal T cell expressed and 
secreted (RANTES))
RANTES is a chemotactic factor with selective chemoattractant properties on 
monocytes, macrophages and eosinophils. RANTES causes selective migration of blood 
monocytes and T lymphocytes expressing the cell surface antigens CD4 involved in 
memory T cell function (Schall, et al 1990, Song, et al 2003). Thl cells preferentially 
secrete CC-chemoldnes with selective properties as MIP-laand RANTES as well as 
MIP-lpand lymphotactin, but Th2 cells express high levels of MCP-1. INF-y m 
synergy with TNF-a produces RANTES from endothelial cells or airway smooth 
muscle cells, inhibited by Th2 cell (Rossi and Zlotnik 2000). RANTES was also found 
in higher levels in survivors with HIV infection than in non-survivors suggesting an 
impaired immune respone (Carrol, et al 2007). In rheumatoid arthritis, synovial 
fibroblasts produce RANTES/CCL5 mRNA upon stimulation with TNF-a or IL-ip. It 
was shown to serve as a useful marker for monitoring disease activity in rheumatoid 
arthritis (Yang, et al 2009).
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8.3.5.2 CXC Chemokines
The second largest group of chemokines named alpha or CXC group with a variable 
amino acid that lays between two N-termtaal cysteines, hence CXC. CXC chemokines 
are divided into two subgroups based upon the presence/absence of a specific 3 ammo 
acid sequence, the Glu-Leu-Arg residues found adjacent to CXC and constitute the ELR 
motif. ELR(+) chemokines induces chemotaxis and promote angiogenesis. Chemokines 
in this group include CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8, 
and CXCL15 and interact with neutrophils via CXCR1 and CXCR2 receptors (Strieter, 
et al 2007). ELR(-) chemokines attract lymphocytes and monocyte with little affinity 
for neutrophils and include CXCL4, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, 
CXCL14 and CXCL16. They have angiostatic properties and induce chemotaxis.
8.3.5.2.1 CXCL8 ((Interleukin-8 (IL-8))
IL-8 is an ELR protypic CXC chemokine secreted by human endothelial cells in 
hypox(ia and infection (Ley, et al 2007). It acts as a potent neutrophil chemoattractant, 
and is secreted by infected airway epithelial cells. CXCL8 mKNA was detected m 
human atherosclerotic lesions (Charo and Taubman 2004). TNF-a and IL-lp are potent 
stimuli of endothelial IL-8 secretion. Histamine triggers production of IL-8 enhanced by 
stimulation with TNF- a (Smith and Humphries 2009).
8.3.5.2.2 CXCL10 ((Interferon-inducible protein-10 (IP-10))
IP-10 is a highly inducible, primary response protein which belongs to the CXC 
chemokine superfamily (Gouwy, et al 2005, Neville, et al 1997). IFN-y in human cells 
on stimulation was able to induce a transcript encoding a protein named gIP-10 with 
sequence homology to platelet factor 4 (PF4). IP-10 is capable of stimulating 
monocytes, NK and T-cell migration, regulation of T-cells, bone marrow progenitor 
maturation and inhibition of angiogenesis (Campbell, et al 2001). More interest is now 
likely to be focused on IP-10 due to recent cloning of an IP-10 receptor (White, et al
2005).
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5.3.5.3 XCL1
This is the gamma or XC chemokine group with a single cysteine molecule present at 
the N-terminus. XCL1 (lymphotactin) is the only representative of the C family and 
targets CD4 + and CDS + lymphocytes, but does not act on monocytes, and binds a 
unique receptor, XCR1 (David and Mortari 2000). It has some homology to ligands 
CCL3 and CCL8, XCL1 but lacks the first and third cysteines characteristic of CC and 
CXC chemokines (Greaves, et al 2001).
8.3.5.4 CX3CL1
This is the delta or CX3 C group with 3 intervening residues between the first two 
cysteines. CX3CL1 (Fractalkine, FKN) is the lone member of the CX3C subfamily 
(Cotter, et al 2002). FKN, the ligand for CX3CR1, is found in liver, intestine, kidney, 
and brain. FKN targets monocytes and T cells (Cook, et al 2001)
8.3.6 Chemokine receptors
Chemokine receptor is based on the chemokine group (CC, CXC, C or CX3C) to which 
its ligand(s) belong and are mainly found on WBCs (Koenen and Von-Hundelshausen 
2008). Chemokine and their receptors function in haematopoiesis, cell differentiation, 
viral pathogenesis and immunity (Esche, et al 2005).
8.3.7 Anticytokines as therapeutic agents
Anticytokine therapy has and will be successful when disease causing mechanisms are 
relatively “simple” and cytokine driven. Future direction in complex disorders may be 
the simultaneous inactivation/activation of multiple cytokines. Cytokine gene therapy 
for cancer treatment is the latest development in the field of cytokines (Podhajcer et ah, 
2007). Cytokine-based drugs and anti-cytokines play a crucial role in the understanding 
of pathogenesis and the management of several diseases. Research is continuing to 
develop new therapies, refine those already in use and establish the safest and most 
effective dosage levels.
8.3.8 Cytokines and Chemokines in ARF/RHD
Cytokines can be strong stimuli for influencing cytokine patterns, as quantitative 
differences in their expression leads to ARF (Dayer 2004, Necil Kutuk9uler 2008). In a 
susceptible host the pathogenic response in ARF includes the production of
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crossreactive antibodies and microbial epitopes recognized by MHC proteins that 
present these epitopes to inflammatory (Thl, CD4+) and cytotoxic (CD8+) T cell 
subsets (Cunningham 2004). CD4+ T cells (Thl) produce tissue inflammation and 
scarring while cytotoxic CD 8+ T cell subsets cause destruction of target tissues 
(Shevach 2000). CD4+ Thl lymphocytes produce IFN-y that may influence the CD8+ X 
cells to become more effective cytotoxic lymphocytes (Cunningham 2003, Pestka 
2007). Cross-reactive antibodies and influential cytokines also affect the endothelium 
and VCAM-1 expression, a sign of inflammation and cellular infiltration 
(Springerl 994).
Thus lesions within ARP valves contain both CD4p and CD8p lymphocytes (Roberts, et 
al 2001) .CD41d lymphocytes have the subsets Thl and Th2 which secrete a known 
lymphokine profile. Thl cells secrete IL-2, IFN-y, TNF-a and IL12. Tli2 cells secrete 
IL-4, IL-5, IL-6, IL-10 and IL-13. CD8£ T cells have subsets which exhibit Thl-like 
(Tel) and Th2-like (Tc2) profile (Mclnnes and Schett 2007, Rochman, et al 2009). 
Arthritis, chorea and RED are partly due to a reaction probably mediated by Th2-type 
cytokines, leading to an exaggerated humoral response (Guilhenne, et al 2007). 
Increased levels of CD4+ and CD25+ cells are due to activated T cells in peripheral 
blood during ARF (Cunningham 2003).
8.3.8.1 Cytokines in the peripheral blood
The kinetics of cytokines shows an imbalance in the production of cytokines due to 
abnormality in the T-cell response in ARF. Antigen-activated CD4 T cells polarize to 
T-helper (Thl or Th2) based on the pattern of cytokines they secrete .Thl cells are 
involved in the cellular’ immune response and produce TNF-a, IFN-y, IL-2, IL-12. Th2 
cells mediate humoral immune responses and produce IL-4, IL-5,IL-10 and IL-13 
(Guilhenne, et al 2011). The evidence for an increased cellular immune response in 
ARF is the increased percentages and absolute counts of CD4+ and CD25 cells, the 
CD4/CD8 ratio, and the increased plasma concentration of cytokines and chemokines .
TNF-a is the initiator of inflammatory response in ARF and usually produced earlier 
than all other cytokines during the acute phase of inflammation. TNF-a is produced 
prior to IL-p that is produced earlier than IL-10, whereas IL-6 is produced later and 
followed by IL-12 (Murthy, et al 2000). TNF-a is also associated with the severity of
ARP and leads to IL-6 and IL-8 production (Kutuk^ler, et al 2008). Moreover, IL-6 
and TNF-a are considered to be inducers of acute phase of ARP and are stiongly 
con-elated with ESR and C-reactive protein (Yegin, et al 1997).IL-8 is increased m the 
active phase of ARP and RHD patients with CCF; it is involved in the activation of 
chemotaxis and accumulation of WBC at the inflammation site (Kutukculer and Nairn 
1995). IL-1 and IL-2 production may persist in ARP patients for 48 weeks. Production 
ofiL-l, IL-2, TNF-a, IFN-y by monocytes /macrophages and T cells correlates with the 
Aschoff nodule progression in the heart lesions and this is a major mechanism in 
mounting an immune response in ARF/ARHD (Guilherme and Kalil 2010).
Thus GAS antigens are able to stimulate peripheral mononuclear- cells to produce 
increased amounts of proinflammatory cytokines and inflammatory cytokines in 
patients with ARP or RRF(Guilherme and Kalil 2010). The release of cytokines 
depends on the function of monocytes/macrophages and T cells which are usually 
functional in a highly active state during the acute period of the disease . Further studies 
are needed to clarify the kinetics of cytokines in ARP mainly during the early days of 
the active period and data is required on the the differences in cytokine levels between 
the time of onset of symptoms and hospital admission.
Increased levels of TNF-a, IL-1, IL-2, IL-6 and IL-8 in peripheral blood/plasma were 
reported in ARP and active CRHD patients (Morris, et al 1993, Narin, et al 1995). IL- 
la and IL-1 (3 were increased in ARP but with no statistical significance. TNF-a was 
reported to be the major cytokine in ARP leading to IL-6 and IL-8 production (Miller, et 
al 1989, Yegin, et al 1997). Oral reported patients with chronic MR to have high 
production of TNF-a in the plasma (Oral, et al 2003). Increased IL-8 plasma levels by
cellular- infiltrates were reported in ARP and decreased levels during remission 
(Kutukculer and Narin 1995). Miller reported that blood mononuclear cell cultures horn 
ARP produced more TNF-a and IL-2 than controls (Miller, et al 1989). IL-7 
concentrations remained unchanged during the acute and chronic stages of ARP 
(Kutukculer and Narin 1995). In ARP/ RHD patients, increase in TNF-a, IL-6 and IL-8 
concentrations were correlated with GRP and ESR levels (Miller, et al 1989, Samsonov, 
et al 1995, Yegin, et al 1997). Increased plasma concentrations of IL-1, IL-2 and TNF-a
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With alterations in lymphocyte subsets have been reported as evidence of increased 
cellular immune response in ARF(Guilherme and Kalil 2010).
8*3.8.2 Cytokines in the heart valve lesions and myocardium
In ARP and CRHD patients, mononuclear cells from heart lesions predominantly 
secrete IFN-y and TNF-a (Guilherme and Kalil 2010). Cytokine profile studies 
demonstrated TNF-a, IL-1 and IL-2 secretion by macrophages in Aschoffs bodies 
(Fraser, et al 1995). IFN-y secreted by Thl cells also mediate the granuloma formation 
in Aschoff nodules in ARF valves (Guilherme, et al 2006). Cells derived from 
myocardium produced IL-4 and IL-10 that play a protective role during regression of 
inflammation (Fraser, et al 1997). Cells derived from the valves produced small 
amounts of IL-10 and did not secrete IL-4 which may contribute to permanent valve 
damage . Oral et al showed increased expression of TNF-a in the myocardium m 
CRHD (Oral, et al 2003). IL-1 and TNF-a stimulate the production of IL-8 by tissue 
macrophages and synovial cells (Narin, et al 1995). The predominance of inflammatory 
cytokines in the heart lesions confirms that RED is mediated by inflammatory immune
responses .
Mononuclear cell in the tonsils secreted small amounts TNF-a, IL-1 and IL-2(Miller, et 
al 1989). Increased IL-8 levels by cellular infiltrates were reported in ARF joints and 
decreased levels during remission (Kutukculer and Narin 1995). Antigen-specific 
crossreactive infiltrating T cell clones displayed the same cytokine pattern, as observed 
in situ, thus reinforcing the proinflammatory cytokines’ role in the progression of RHD 
(Guilherme, et al 2006).
8.3.9 Genetic influence of Cytokines and Chemokines 
Recently cytokine and chemokine genes have been studied to try and understand the 
ARF/RHD pathogenesis. IL-1 is one of these gene cluster located on chromosome 2 
(Smith and Humphries 2009). It includes the genes expressing IL-1 a and IL-lp and 
their inhibitor IL-1RA. A study from Taiwan reported variations in IL-1 (3 and IL-1RA 
not associated with RHD but future studies are required before excluding IL-1 as a 
susceptible or protective factor (Chou, et al 2005). A molecular study of TNF-a 
documented its association with a gene having inflammatory function located in the
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MHC class II regions (Ramasawmy, el al 2007). TNF increases the production of 
proinflammatory cytokines which activates the transcription of proinflammatory genes 
(Hemandez-Pacheco, et al 2003).
a Periphery
Streptococcal
antigen Anti-streptococcal
antibodiesMacrophage Been
TCR CD4- Streptococci-primed 
CD4* T cellT cell
class II
b Myocardium
T TNF-ct. IFN-y. IL-10, 1L-4CrossreactlveCrossreactive 
anti-heart tissue 
antibodies
Mononuclear cells
c Valvular tissue
Crossreactive
t IFN-y. TNF-«. IL-10
Crossreactive 
anti-heart tissue 
antibodies
VLA-4
Major events triggering rheumatic heart disease lesions
Figure 8. 1 Cytokine and chemokine expression in RHD lesions(Guilherme, et al 2005a)
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A key role for TNF- a in the imimmopathogenesis of ARF/RHD has been proposed 
(Guilherme, et al 2007). In a Brazilian study either one of two TNF-a alleles 308A or 
238A was associated with ARF/RHD (Ramasawmy, et al 2007). In Mexico and Turkey 
the TNF-a allele 308 was associated with ARF/RHD (Flernandez-Pacheco, et al 2003, 
Sallakci, et al 2005). Another Turkish study did not confirm the presence of any of the 
TNF-a allele in ARF/RHD(Berdeli, et al 2006). It is probable that one TNF-a allele 
variant is capable of acting in synergy with other genetic and environmental factors m 
ARF/RHD (Guilherme and Kalil 2007). Cytokine gene mutations can lead to a degree 
of difference in their expression and cause further damage (Sallusto and Baggiolini
2008).
8.3.10 Role of Genetics in ARF and RHD
The determination of a genetic pattern of susceptibility to ARF and RHD has been
sought for more than a century and has often been debated (Wilson and Morton 1937).
A familial incidence and a single recessive gene suggested that genetic factors play a 
role in ARF susceptibility (Wilson, et al 1943). Some have assumed an autosomal 
recessive model and a Mendelian inheritance (Davis 1970, Winter 1972).
Recent studies have uncovered specific markers such as B-cell alloantigen D8/17 (Kaur, 
et al 1998, Rodriguez, et al 1990). Subsequent studies of HLA class II antigens have 
disclosed an association with different HLA-DR alleles according to the population 
analyzed (Ayoub, et al 1986, Guilherme, et al 2005a).
Anastasiou et al (1986) in Utah reported a negative association between RHD and DR6 
(Anastasiou-Nana, et al 1986). Maharaj et al (1987) found a high frequency of DR6 in 
South Africans (60%) with MVD (Maharaj, et al 1987). Kayanagi et al (1996) reported 
a high frequency of DRB1*1405 -DQA1*0104 - DQB1*0503 in Japanese RHD 
patients with MV lesions. Kaur et al (1998) suggested ethnic differences in 
susceptibility marker(s) in ARF/RHD patients using different monoclonal antibodies 
(Kaur, et al 1998). Guedez et al (1999) found the HLA class II associations with RHD 
were more evident and consistent among patients with similar- clinical findings (Guedez, 
et al 1999). HLA A10, DRwl lhaplotypes and DRBU0701 allele in RHD patients have 
been detected (Olmez, et al 1993). Carreno et al (2000) documented an increased 
frequency of HLA-DR4 and HLA-DR2 with RHD white and black patients,
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respectively (Can-eno-Manjan-ez, efa/2000). Others have implicated DR1 andDRwh. 
DR7 and Dw53and DR4 in different populations (Bhat, et al 1997, Gmlherme and Kahl 
2004, Guilherme, et al 1991, Rajapakse, et al 1987, Visentainer, et al 2000). Certain 
class IIMHC molecules and/or the D8/17 alloantigens were reported with an increased 
risk of ARF (Cunningham 2004, Guilherme, et al 2004, Hernandez-Pacheco, etal
2003).
These conflicting results have raised speculations between different haplotypes of class 
IIHLA among ARF and RHD and that the observed associations might be because 
there me class II genes close to an ARF-susceptibility gene (Carreno-Manjarrez, et al 
2000) (Table 8.1).
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Table 8.1HLA markers of ARF and RHD in different countiies
Author (year of study) Country HLA markers
Cheadle and Goodhart (1889) UK First familial predispostion of ARF
Wilson (1943) New York Autosomal recessive trait
Taranta (1959) Australia Low concordance in monozygotic twins
Patarryo (1979) New York Novel B'-cell alloantigen marker 883
Zabriskie (1985) South Africa Monoclonal antibodies
Ayoub (1986) Florida HLA-DR2 and HLA-DR4
Monplaisir (1986) Martinique HLA-DR1
Maharaj (1987) South Africa DR1 and DRW6 markers of RHD
Rajapakse (1987) Saudi Arabia HLA-DR4
Khanna et al (1989) West Indies Third monoclonal antibody D8/17
Arnold (1989) Australia HLA-DR4 and HLA-DR2
Guilherme (1991) Brazil HLA DR7 and DW 53
Ozkan (1993) Turkey HLA-DR3 and HLA-DR5
Koyanagi (1996) Japan DRB1*1405-DQA1*0104-DQB1',,0503
Goldberg (1997) India HLA-Dr4 and HLA-DR7
Gue'dez (1999) Egypt DRB1*0701} DR6 and DQB 1*0201
Donadi (2000) Brazil HLA-B49 and HLA-DR1
Carreno (2000) Unites States HLA-DR4 and HLA-DR2
Hard (2002) Israel B-cell alloantigen D8/17
Stanvechia (2003) Latvia DRBl*07-DQBl:!50401-2 and DRB1*07- 
DQB1*0302
Hernandez-Pacheco (2003) Mexico HLA-DR16 (DRB1*1602) allele and DR16- 
DQA1*0501-DQB1*0301
Sadia (2007) Pakistan HLA-DRB1*07
Chou (2008) China DR11-05-DQ7
Factor H (FH) and factor H-like protein 1 (FHL-1) regulate complement activation via 
the alternative pathway (AP). AP attacks any surface not specifically protected against
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it. Host cells need down regulation on their surfaces by plasma protein complement 
factor H (CFH) that provides a first line defence against invading GAS. GAS protect 
themselves from AP attack by obtaining host CFH on their surfaces via domains 6-7 
and this permits domains 1-4 to regulate C activation on GAS (Kotarsky, et al 2001). M 
protein binds to FH and FHL-1 that potentially minimize complement C3 derived 
opsonin deposition on their surface contributing to GAS phagocytosis resistance.
Several GAS strains bind host CFH via its domain 7 and avoid complement attack and 
C3b~mediated opsonophagocytosis (Haapasalo, et al 2008).
It has been documented that CFH binding by GAS is essential for bacterial survival m 
human blood. A recombinant fragment of CFH lacking regulatory functions can be used 
to inhibit CFH binding on the GAS surface and impair its blood survival. One CFH 
variant 402H was found to impair CFH binding to.GAS and was associated with 
decreased susceptibility to recurrent tonsillitis (Haapasalo, et al 2012). CFH binding 
was shown to be important for GAS survival in vivo by studying the association 
between the polymorphism Y402H of the CFH domain 7 and clinical GAS infections. It 
was reported that host CFH was important for immune evasion of GAS in blood. It 
could also be blocked by using CFH5-7 that causes impaired GAS survival. It was 
reported that impaired GAS-CFH interaction mediating allele 402H (1277C) may be 
associated with protection from human recurrent tonsillitis (Haapasalo, et al 2012).
Mamran-binding lectin (MBL) is a collectin, an acute phase inflammatory protein that 
binds to A-acetylglucosamine, a target molecule present on the GAS cell wall and 
human heart valves. MBL functions as a soluble pathogen recognition receptor m innate 
immunity due to its ability to opsonize pathogens. MBL then activates the complement 
system through the lectin pathway leading to production of C3 convertase (C4b2b) and 
the membrane-attack complex releasing many opsonic and inflammatory fragments 
causing phagocytosis and several immune-mediated reactions.
MBL is encoded by the gene MBL2 located on the chromosome lOql 1 .l-q21 region. 
Mutations in exon 1 of the MBL2 gene correlate with deficient MBL in the plasma and 
have been shown to be associated with recurrent infections in children (Schafranski, et
al 2008).
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It has been reported that high levels of MBL and MBL2 associated genotypes were 
detected in patients with CRHD. The association between MBL2 polymorphisms,
YA/YA and YA/XA genotypes in ARF was reported with acute carditis associated with 
the high production of MBL (Messias Reason, et al 2006).Although MBL2 genotypes 
related to low production of MBL were commonly seen in patients with rheumatic 
arthritis.
Increased serum levels of immune complexes and complement activation products 
(C3d) were seen in patients with ARF and CRHD, suggesting that the complement 
system might be involved in their pathogenesis (Schafranski, et al 2008) (Gibofsky and 
Zabriskie, 2001). (Ramasawmy, et al 2008). Future studies on immune regulation will 
contribute to the understanding of new genetic markers and how these genes act in the 
complex network of autoimmune reactions that occur in ARF/RFID(Guilherme, et al
2011).
In summary ARF appeal’s to be a post-infectious autoimmune disease triggered by 
specific GAS characteristics and some undefined genetic human predisposition. RFID is 
considered to be an organ-specific Tl-type autoimmune disease . Molecular mimiciy 
between GAS antigens and heart proteins is considered as the mechanism leading to 
ARF/RHD (Cunningham 2004, Stollerman 1991). Intralesional CD4qT cells may cross 
react with GAS M proteins and heart proteins and play a direct role in the development 
of ARF (Guilherme and Kalil 2004). A greater understanding of the pattern of cytokines 
and chemokines in acute and recurrent rheumatic fever may help to shed some more 
light on the pathogenic process.
8.4 Objective: 6
Compare the concentrations of selected cytokines and chemokines m Yemeni children 
with ARF and RRF.
8.5 Patients and methods
Fourteen serum cytokine and chemokine concentrations determined in Yemeni children 
with ARF and RRF are described in this chapter. These include IL-1[3, IL-6, -7, IL-8, 
IL-9, IL-10, IL-12p70, TNF-a, IFN-y, MCP-1, MIP-la, MIP-lp, IP-10 and RANTES.
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These were analyzed by the BD FACS Array Bioanalyzer and using FCAP Array 
Software.
Review of the literature on different studies which investigated the levels of cytokines 
and cheraokines in healthy controls was done. The values for the detection levels of the 
studied cytokines and chemoldnes in healthy controls are summarized m Table 8.2. The 
interpretation of the results in this study was based on these detection levels.
8.5.1 Data analysis
Data analysis was conducted using SPSS version 17 with descriptive statistics using 
median and inter-quartile ranges. The Mann-Whitney test was used to compare medians 
between ART and RRF groups. Medians and interquartile ranges were used to compare 
the levels of cytokines and chemoldnes between the two groups. Spearman conelation 
coefficient was conducted on the study of correlations between the different cytokines 
and chemoldnes and the level of significance was p — <0.05.
The multiple comparisons were not corrected for in the statistical analysis using the 
Bonferroni correction since statistical advice cautioned on its relevance for this type of 
analysis. The Bonferroni correction is a conservative correction leading to P values that 
may be too high and confidence intervals that are too wide (Thomas 1998). The 
correction thus may lead to insufficient power to detect significant differences and may 
miss the real differences. It is currently not recommended to apply the correction, even 
if a large number of tests are performed, since few, if any tests, will be significant after 
the correction has been applied (McHugh 2011)
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Table 8. 2Lowest detection levels of cytokines and chemokines in healthy controls
Cytokine/chemokine
Lowest detection level in healthy 
controls pg/ml
Reference
IL-ip 1,2-15 Gu et al 2009
Orus et al 2000
IL-6 3-6 Orus et al 2000
IL-7 8.6-29,3 Darcissa et al 2001
Kutukculer 1995
IL-8 1.9-21.7 Arican et al 2005
Yegin et al 1997
IL-9 7.8- 8.9 Gu et al 2009
IL-10 0.3-5 Shimada et al 2001
IL-12p70 2.9 Arican et al 2005
TNF-a 7.5-20 Gu et al 2009
Yegin et al 1997
IFN-y 15 Fuji! et al 2004
MCP-1 20 Gu et al 2009
MIP-la 9-25 Breemen et al 2007
MBP-ip 17 Breemen 2007
IP-10 0-41.5 Shimada et al 2001
Fujii et al 2004
RANTES 6.3-26 Bai et al 2005. Gu et al 
2009
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8.6 Results
8.6.1 Cytokine and chemokine concentrations
Although, hypothetically 96 well plates could test 40 in duplicate and we had 2 plates 
equal to 80, we could only test 49 samples due to the need to retest some specimens and 
technical problems with the machine. Forty nine patients, 24 with ARF and 25 with 
RRF were included in this analysis. One serum sample of an ARF patient was discarded 
due to an interpretation error. Patients with ARF had a mean (SD) age of 12.3 (2.3) 
years and 11 were male while patients with RRF had a mean (SD) age of 14.8 (1.5) 
years and 9 were male.
All patients fulfilled the Duckett Jones’ criteria with one major manifestation or arthritis 
or carditis and two minor manifestations (Ferrieri 2002). The major manifestations 
included carditis in 29 (59%) and polyarthritis in 21 (41%) patients. None of the 
patients had congestive cardiac failure. There were no patients with chorea, erythema 
marginatum or subcutaneous nodules. Patients with RRF were echo-proven to have 
RHD and had established valvulopathies. The mitral valve lesions were MR diagnosed 
in 18, MR with AR in four* and MR with MVP in six patients. ASO titres were > 200 
Todd units, CRP was positive and ESR was raised in all patients. A positive family 
history was obtained in 19 patients and 18% reported a family history of ARF with 
echo-proven RHD in 10 (20%) family members.
8.6.2 Cytokines and chemokines in children with ARF and RRF 
The cytokine and chemokine levels are in Table 8.3 and Figure 8.2. All the cytokines 
and chemokines concentrations were elevated above healthy control levels as 
determined by the levels in different studies shown in Table 8.2.
Overall, children with RRF had higher median concentrations of cytokines and 
chemokines than children with ARF. Chemokines, IL~1(3, IL-8 and RANTES were only 
significantly higher among RRF when compared to ARF patients.
IL-8 had higher median concentrations in patients with RRF (383.6pg/ml) than patiens 
with ARF (224.5pg/ml) (p = 0.04). IP-10 concentrations were high in both RRF and
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ARF patients with medians of 167.8pg/ml and 162.4pg/ml, respectively (p 0.4).
Patients with RRF had higher concentrations of IL-12p70 and IFN-y (65pg/ml versus 
67.1pg/ml) than children with ARP (55pg/ml versus 56.5pg/ml) respectively (p=0.001) 
(Table 8.2),
Similarlily median IL-6 and IL-10 concentrations were highei in RRP than ARF 
patients (106.5 versus 90.2pg/ml and 89pg/ml versus 73pg/ml) respectively, (p=0.001). 
IL-1(3, IFN-y and TNF-a values were also significantly higher in patients with RRF than
patients with ARF (p= 0.001).
MlP-la levels did not vary between ARF and RRF patients (p-0.9). MIP-lp had higher 
median values in patients with RRF (123pg/ml) than patients with ARF (95.7pg/ml) (p 
= 0.02). MCP-1 had a higher median value in RRF (85pg/ml) than ARF (77pg/ml) 
patients (p=0.1). The median concentration of RANTES was statistically liigher in 
patients with RRF (91pg/ml) than in patients with ARF (73pg/ml) (p=0.004).
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Table 8. 3Median cytokine and chemokine concentrations in patients with ARF/RRF
Cytokines
And
chemokines
ARF
n=24
Median pg/ml
IQR
n=25
Median
Pg/ml
IQR P
IL-ip 66.3 62.8-71.1 76 72.4-91.3 0.001
IL-6 90.2 83.7-92.6 106.5 101.2-115.1 0.001
IL-7 91.7 81.2-107.5 100.7 90.8-140.8 0.001
IL-8 224.5 166.6-373.8 383.6 196.6-831.6 0.04
IL-9 81.2 65.9-94.3 89.2 77.4-123.6 0.001
IL-10 73 66.8-79.3 89.2 82.1 -100.7 0.001
IL-12p70 54.9 50.9-60.2 64.6 57.1-71.9 0.001
TNF-a 71.9 67.5-76.3 80.4 74.5-93.4 0.001
IFN-7 56.5 51.4-63.6 67.1 60.4-77.1 0.001
MCP-1 76,9 62.8-93.0 85.1 76-115.3 0.1
MIP-la 92.6 85.5 -112.6 111.6 101.2-134,1 0.9
MIP-lp 95.7 80.4-113.3 123.1 101.2-155.1 0.02
IP-10 162.4 121.8-209,5 167.8 131.3 -209.3 0.4
RANTES 72.8 67.1 -84.4 90.8 79.3-117.5 0.004
IQR = interquartile range
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a. IFN-Y tt , IL12p70 ft , IP-10 and IL-10 ft
ARF RRF
b. MIP-la, MIP-1B t * MCP-1 and RANTES ft
ARF RRF
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Figure 8. 2 (a-b) Cytokine and chemokine concentrations in patients with ARF andRRF 
Boxplots describe medians, interquartile values and range. Asterix depict outliers, and 
t denotes a p value <0.01 and ++ a p value <0.001
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c. IL-1B ft , IL-6 tt , IL-8 t and TNF-a ft
(HDc.
ARF RRF
TNF-a
2000*
1500-
1000-
d IL-7 ft and IL-9 tt
ARF RRF
ARF RRF
Figure 8. 3 (c-d) Cytokine and chemokine concentrations in patients with ARF and RRF
Boxplots describe medians, interquartile values and range. Asterix depict outliers, and + 
denotes a p value <0.01 and ++ a p value <0.001
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8.6,3 Correlations between cytokines and chemokines 
concentrations in patients with ARF
The correlations of the cytokines and chemokines tested in patients with ARF are shown 
in Table 8.3. A large number of correlations were observed. IL-ip was positively 
associated with IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, TNF-a and IFN-y (p^O.Ol).
TNF-a and IFN-y had significant positive correlations (correlation coefficient 0.9, 
p=0.001). TNF-a and IFN-y had strong positive correlations with IL-lf3, IL-6, IL-7, IL- 
9, IL-10, IL-12p70 and MIP-ip (p-0.001). TNF-a and IFN-y were not correlated with 
IL-8, MCP-1 and RANTES (p >0.1).
In addition to IL-lp, TNF-a and IFN-y, IL-6 was correlated with IL-7, IL-9, IL-10 and 
IL-12p70. IL-8 was significantly coirelated withILip, and MIPl-p (p=0.01). IL-7 and 
IL-9 were significantly correlated with ILip, IL-6, IL-9, IL-10, IL-12p70, MIPl-p, IP- 
10 TNF-a and IFN-y. IL-10 was positively correlated with ILip, IL-6, IL-7, IL-10, IL- 
12p70, MIPl-p, TNF-a and IFN-y (p=0.01).
IL-12p70 was associated with ILip, IL-6, IL-7, IL-9, IL-10, MIPl-p, TNF-a and IFN-y.
MIP1-P was correlated with IL-7, IL-8, IL-9, IL-10, IL-12p70, IP-10, TNF-a and IFN-y 
(p=0.01). IP-10 was significantly correlated with IL-7,IL-8 and MIP-1 P (p=0.05).
IP-10 was associated with IL-7 and MIP-1 p. RANTES was only positively correlated 
with its subgroup MCP-1 (p=0.01). MIP-l-a was not correlated with other cytokines nor 
chemokines.
191
Ta
bl
e 8
. 4
 C
or
re
la
tio
ns
 o
f C
yt
ok
in
es
 an
d C
he
m
ok
in
es
 in
 p
at
ie
nt
s w
ith
 A
RF
<N
O
<0
.0
1 *p = <
0.
05
8.6.4 Correlations of cytokines and chemokines in patients with 
RRF
Similarly to patients with ARF, patients with RRF had a large number of correlations as 
shown in Table 8.4. Proinflammatory cytokines TNF-a and IFN-y were correlated with 
each other (Spearman rho coefficient of 0.9, p^O.Ol) and these in turn had strong 
conelations with IL-lp, IL-6, IL-7, IL-9, IL-10, IL-12p70 andMCP-1 (p=0.01). TNF-a 
and IFN-y were not correlated with IL-8, MIP-1 a, MIP-lp, IP-10 and RANTES.
IL-ip was conelated with IL-6, IL-7, IL-9, IL-10, IL-12p70, MCP-1, TNF-a and IFN-y 
(p=0.01), IL-6 was conelated with IL-ip, IL-7, IL-9, IL-10, IL-12p70, TNF-a, IFN-y 
(p=0.01) and MCP-1 (p-0.05). IL-8 was negatively conelated with IL-9 and IL-12p70 
(p=0.05) but had no significant correlations with MCP-1, MIP-1 a, MIP-1 P and 
RANTES.
IL-10 was positively correlated with IL-ip, IL-6, IL-7, IL-9, IL12p70, MCP-1, TNF-a 
and IFN-y (p=0.01).IL12p70 was positively conelated with IL-ip, IL-6, IL-7, IL-9, IL- 
10, MCP-1, TNF-a and IFN-y, and was negatively correlated with IL-8.
MCP-1 was positively correlated with IL-Ip, IL-6, IL-7, IL-9, IL-10, IL-12p70, TNF-a, 
IFN-y and RANTES (p=0.01).IP-10 was conelated with MIP-1 a (p=0.01) and MIP-1 p 
(p^O.05). RANTES was positively correlated with MCP-1 (p=O.01).
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8.6.5 Difference in the correlation of cytokines and chemokines in 
ARF compared with RRF
IL-1J3 was significantly correlated with IL-8 in patients with ARF but not in patients 
with RRF. IL-1(3 was significantly correlated with MCP-1 in patients with RRF patients 
but not in patients with ARF.
IL-6 was significantly correlated with MCP-1 in patiens with RRF but not in patients 
with ARF. IL-7 was associated with MIP-1J3 and IP-10 in patients with ARF but was 
not present in RRF, IL-7 was associated with MCP-1 in patients with RRF but was 
absent in patients with ARF.
IL-8 was significantly correlated with IL-lj3 and MIP-lp in patients with ARF but was 
not evident in patients with RRF. In patients with RRF, IL-8 was significantly 
negatively correlated with IL-9 and IL12p70 but was not present in ARF.
IL-9 was correlated with MIp-ip in patients with ARF but not in RRF while it was 
positively correlated with MCP-1 and negatively correlated with IL-8 in patients with 
RRF. IL-10 was signifcantly correlated with MIP-lj3 in patients with ARF but not in 
RRF. IL-10 was correlated with MCP-1 in patients with RRF but not in ARF.
MCP-1 was significantly correlated with IL-lp, IL-6, IL-7, IL-9, IL-10,1 L-12p70, 
TNF-a and IFN-y in patients with RRF but this correlation was not present in patients 
with ARF. MIP-la was associated with MIP-ip and IP-10 in patients with RRF but this 
correlation was not evident in patients with ARF. MIP-ip was significantly correlated 
with IL-7, IL-8, IL-9, IL-10, IL-12p70, TNF-a and IFN-y in patients with ARF. In 
patients with RRF, MIP-ip was only correlated with MIP-la but not in patients with 
ARF. IP-10 was correlated with IL-7 in ARF but not in patients with RRF while it was 
correlated with MIP-la in patients with RRF but not in patients with ARF.
TNF-a and IFN-y were both significantly associated with MIP-ip in patients with ARF 
but not in patients with RRF. TNF-a and IFN-y were both significantly associated with 
MCP-1 in patients with RRF but not in patients with ARF.
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a. Correlation of MCP-1 with the different chemokines and cytokines
b.Correlation of MIP-1B with the different chemokines and cytokines
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Figure 8. 4(a-b) Scatterplots of cytokine and chemokine concentrations
IL-ip, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p20, TNF-a, IFN-y, MCP-1, MIP-la, MIP- 
lp, IP-10 and RANTES in patients with ARE and RRF (See Appendex c-i) for the 
correlations of the other chemokines and cytokines)
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8.7 Discussion
8.7.1 General characteristics of cytokines and chemokines 
ARF and RHD pathogenesis is a complex autoimmune process involving genetic and 
environmental factors (Guilherme and Kalil 2010). The differential cytokine 
polarization in RHD is probably related to immigrant autoreactive T cells, local 
chemokines and adhesion molecules.
In tins study the concentrations of all the cytokines were observed to be significantly 
higher in patients with RRF than ARF. Selected chemokines IL-8, MIP-lp and 
RANTES were only significantly higher in patients with RRF than ARF patients.The 
proinflammatory cytokines TNF-a and IFN-y was significantly correlated with IL-lf3, 
IL-6, IL-10, IL-12p70 in ARF and RRF patients. The variation observed in 
chemoattractant chemokines correlation profile was interesting in ARF and RRF 
patients. MIP-lp was significantly correlated with IL-7, IL-8, IL-9, IL-10, IL-lp270, IP- 
10, TNF-a and IFN-y only in ARF patients. MCP-1 was significantly correlated with 
IL-lp, IL-6, IL-7, IL-9, IL-10, IL-12p270, TNF-a and IFN-y only in RRF patients. MIP- 
1 (3 may play a significant role in the induction of acute inflammatory reactions and may 
possibly activate macrophages to facilitate the autoimmune process in patients with 
rheumatic fever. MIP-1[3 may probably serve as an inflammatory biomarker in patients 
with ARF. MCP-1 does not appear to have a role in acute inflammatory reaction. MCP- 
1 may probably serve as an inflammatory biomarker in patients with RRF.
Chemokines direct the migration of leukocytes throughout the body and play an 
important role in the coordination of the inflammatory response. Serum chemokines 
levels may be clinically useful as an objective indicator of activity, and may have the 
potential to improve disease management. Patients with high serum chemokine levels 
may be more likely to develop early recurrence of ARF with possible cardiac valve 
involvement and end up with RHD. Recurrences of ARF may have a greater likelihood 
to occur in patients with marked elevation of some serum chemokines. Monitoring 
frequent chemokine levels in rheumatic patients may provide a tool to evaluate disease 
activity and identify patient’s likelihood of future recurrences and RHD development. 
Further prospective studies with a larger number of patients and matched control group 
are needed to evaluate this.
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Guilhereme (2006) reported that heart lesions secrete IFN-y and TNF-a in ARF and 
CRHD patients (Guilherme, et al 2006). Recently, Oral documented that patients with 
MR had a high production of TNF-a in the serum and the myocardium (Oral, et al 
2003). These results are in line with this study where patients with ARF and RRF 
showed elevations of both TNF-a (72pg/ml versus 80.4pg/ml) and IFN-y (56.5pg/ml 
versus 67.1pg/ml) compared to normal healthy controls (TNF-a <20pg/ml and IFN-y 
<15pg/ml) as reported in different studies (Fujii, et al 2004, Gu, et al 2009, Yegin, et al 
1997). These values of TNF-a and IFN-y were significantly higher in patients with
RRF than ARF (p=0.001). The significant elevations of TNF-a and IFN-y in ARF and 
RRF patients in this study may favour' the suggestion that they act by augmenting the 
inflammatory response triggered by an autoimmune reaction indicating that Thl-type 
cytokines (TNF-a and IFN-y) could mediate RHD (Guilherme and Kalil 2004).
Increased proinflammatory cytokines such as IL-1, IL-6, and TNF-a have been 
described in patients with congestive cardiac failure and rheumatoid arthritis 
(Armstrong, et al 2006, Necil Ktitukctiler 2008). Macrophages secrete the IL-1 and 
TNF-a required for B and T cell activation and aggregation, suggesting that 
macrophages arrive at rheumatic injury before the lymphocytes to produce an early 
inflammatory response (De Jager, et al 2007, Fraser, et al 1997). Monocyte- 
macrophages can produce TNF-a while a number of endogenous mediators such as IL-1 
are active inducers of TNF-a (Dayer 2004). In this study the median concentrations of 
cytokines IL-1 (3 and TNF-a were similar but significantly higher in RRF (IL-1 (3 = 
76pg/ml versus TNF-a = 80.4pg/ml) than ARF (IL-1 (3 = 66.3pg/ml versus TNF-a = 
80.4pg/ml) patients. These changes are consistent with reports from different countries 
(Moms, et al 1993,Narin, et al 1995, Samsonov, et al 1995).
Infiltrating mononuclear cells produce cytokines which correlate with activity of 
Aschoff nodules during the acute active phase of ARF and RHD and may serve as 
indicators of disease progression and severity (Guilherme and Kalil 2007). The high 
concentration of T cells which infiltrate the heart in RHD may be related to the 
differential secretion of specific chemokines (Cunningham 2004). These cells may have 
been activated by IL-5, a Th2-type cytokine, which contributes to local inflammation
200
through several proinflaimnatory cytokines e.g. IL-6, IL-8, TNF- a, IL-1 and 
chemokines (Spellberg, et al 2001). In this study IL-6 cytokine was elevated with higher 
values in patients with RRF than ARF who all clinically had high ESR and positive 
CRP levels. IL-6 has been reported to have a direct effect on the regulation of the 
release of the acute-phase proteins from hepatocytes and Kuppffer cells (Nishimoto and 
Kishimoto 2006)
IL-8 (normal value < 21.7pg/ml) had the highest magnitude among all the cytokines in 
both ARE and RRF (224.5pg/ml versus 383.6pg/ml) and was twice as high in children 
with RRF as ARF. Yegin (1997) found a significant increase in TNF-a, IL-6 and IL-8 
in ARF and significant IL-6 and TNF-a correlation with CRP and ESR levels in ARF 
/RHD patients. In this study a significant correlation was demonstrated between IL-6 
and TNF- a in ARF and RRF groups and all the patients had increased levels of ESR 
and CRP. Kutukculer & Narin (1995) reported that IL-8 concentrations were 
significantly elevated in the acute stage and decreased in remission. It is possible that 
the excessive production of IL-8 could be caused by the cellular infiltration in the joints 
during the ARF period.
IL-10 is a cytokine with both an anti-inflammatory and immune- regulatory activities. It 
is mainly produced by Th2 subset of CD 4 and some activated B cells(BeebeJ et al 
2002). It inhibits the synthesis of pro-inflammatory cytokines and chemokine by 
monocyte, macrophages, neutrophils and eosinophils (Bryant, et al 2009). It is also an 
important immunoregulatory cytokine that inhibits T-cell function, inhibits antigen- 
presenting cells and promotes B-cell-mediated functions (Sonderegger, et al 2012).
IL-10 is a cytokine with both an anti-inflammatory and immune- regulatory activities. It 
is mainly produced by Th2 subset of CD 4 cells and some activated B cells(Beebe, et al 
2002),(Armstrong, et al 2006, Diveu, et al 2008). It inhibits the synthesis of pro- 
inflammatory cytokines and chemokines by monocytes, macrophages, neutrophils and 
eosinophils (Bryant, et al 2009). It is also an important immune regulatory cytokine that 
inhibits T-cell function, inhibits antigen-presenting cells and promotes B-cell-mediated 
functions (Sonderegger, et al 2012). Increased levels of IL-10 and IFN-y were reported 
in patients with acute malaria (Angulo and Fresno 2002). In this study IL-10 and IFN-y
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were observed to be significantly higher among RRF than ARP patients. This is 
different to a report from India where higher levels of IL-10 were observed in patients 
with CRHD with no active disease process than active ARP (Bhatnagar, et al 1999).
It relates to the clinical presentation of the disease either with arthralgia, arthritis or 
carditis with or without CCF and ESR and CRP to determine the activity of the disease 
(Col-Araz, et al 2012). IL-10 was reported to be synthesized later than other immuno 
regulatory cytokines by activated T cells or monocytes, demonstrating its regulatory 
role in later phases of the immune response (Settin, et al 2007). It is a prominent 
regulatory cytokine secreted by large numbers of cells in both valve and myocardial 
tissues (Col-Araz, et al 2012). Its production in the valvular- lesions of ARP patients 
was correlated with Aschoff nodule progression (Guilherme, et al 2011). Tins could be 
explained by the time and site variation when the sample was taken during the disease 
process. Children with active process of RHD are more likely to have extensive 
inflammatory disease response.
The profile of chemokines RANTES, MCP-1, MIP-la and MIP-ip have not been 
described in ARP and this is the first report to assess these chemokines among these 
patients. MCP-1 was reported to be elevated inpatients with congestive cardiac failure 
(Bidzhekov, et al 2006). TNF-a induces the production of RANTES(Deslnnane, et al 
2009) and the latter RANTES is reported to be upregulated in the heart (Guilherme, et 
al 2004, Schober 2008). In this study RANTES was detected with significantly higher 
values in RRF than ARP group (p=0,004). MCP-1 and MIP-la values did not 
significantly vary between either group. MIP~1|3 concentration was significantly 
elevated in RRF than ARP patients. MIP-1 and RANTES have been studied in an 
animal model of destructive autoimmune myocarditis(Cunningham 2001). The 
significant elevations of the above chemokines RANTES, MCP-1, MIP-la and MIP-1 [3 
in RRF and ARP may be explained by their possible recruitment from macrophages and 
activated T cells which could contribute to the inflammatory response and damage to 
the tissues (Guilherme and Kalil 2010). They may provide to act as useful markers of 
immune activation and may help to provide information on prognosis of this utoimmune 
disease.
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IP-10 is produced by inflammatory cells such as macrophages and monocyte which 
attract activated T lymphocytes (Cassatella, et al 1993). IP-10 is reported to be manily 
induced by IFN-y (Chuang, et al 2005), It could particate in the activation of some cells 
dining the autoimmune response in some infectious diseases but not in ARF (Nicolettf 
et al 2002, Salomon, et al 2002, Shimada, et al 2001). In this study patients with ARF 
and RRF had elevated IP-10 values. This is the first report to describe IP-10 levels in 
patients with ARF/RRF which may suggest its role in T cell-mediated autoimmunity. It 
may also indicate that disease reccurence, the target autoanitgens become more activated during 
the immunoinflammatory processes. Thus IP-10 may act as a new inflammatory biomarker 
to assess the susceptible patients to the disease severity.
IL-12p70 was expressed with a low concentration similar to IFN-y in both groups. 
However, IL-12p70 had significantly higher values within RRF than ARF patients. This 
is the first study to describe the cytokine IL-12p70 in patients with ARP and supports 
the suggestion that IL-12p70 regulates Thl response by inducing IFN-y.
Significantly higher concentration of the profiles of 14 cytokines and chemokines 
investigated in this study was demonstrated among RRF than ARF patients. The report 
by Guilherme (2001) found that mitral valve T cells in ARF displayed lower 
inflammatory levels of IL-10, IFN-y and TNF-a than in RHD patients (Guilherme, et al 
2001). It could be explained by the different sites ie.heart tissue as opposed to serum 
from where the samples were taken and to different activity of the disease
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8.7.2 Correlations of Cytokines and Chemokines in ARF and RRF 
patients
Recently cytokines have been implicated as key coordinators in several inflammatory 
and autoimmune diseases including ARF. The results in this study support the role of 
cytokines and chemokines in the initiation of the inflammatory response during the 
active phase of ARF and RHD. Proinflammatory cytokines TNF-a and IFN-y were 
significantly correlated with IL-ip, IL-6, IL-10, IL-12p70 in both ARF and RRF 
patients. Previous reports have demonstrated the role of TNF-a, IFN- y, IL-lf3 and IL-6 
in the production of acute phase reactants (Armstrong, et al 2006). Yegin (1997) 
reported TNF-a to be a major cytokine in ARF leading to production of IL-6 and IL-8 
while Kapadia (1996) described these cytokines in congestive cardiac failure. Angulo et 
al (2002) reported the levels of IL-6, IL-10, TNF-a and IFN-y were found in higher 
values among patients who died of malaria that those who survived (Angulo and Fresno 
2002).TNF-a was reported to have additive effects with IL-1 in ARF (Necil Kutukftiler 
2008). This is the first report to describe the correlation of IL-12p70 in ARF and RRF 
with TNF-a and IFN-y. In previous reports IFN-y was found in valves of patients with 
carditis involved in Th-1 granuloma forming Aschoff nodules (Pestka 2007). In this 
study the strong colocalization of TNF-a and IFN-y in both ARF and RRF patients may 
be due to active inflammatory response associated with carditis, a major feature in both 
groups.
IFN- y has immunoregulatory properties and preferentially inhibits Th2 proliferation 
responsible for IL-10 production (Pestka 2007). In experimental studies IL-10 exhibited 
a proinflammatory action but in patients with acute coronary syndrome it had a 
protective effect against proinflammatory mediators (Armstrong, et al 2006). These 
findings are different to this study where IFN-y was significantly correlated with IL-10 
in both ARF and RRF patients. This difference in the pattern of cytokines may reflect 
the variation in the response to the pattern of inflammatory cells in different tissues and 
needs to be clarified in future studies.
IL-8 an inflammatory cytokine produced by TNF-a, plays a role in the increased 
neutrophil chemotaxis during ARF (Kutukculer and Narin 1995). In this study, IL-8 in
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patients with ARE was significantly correlated with MIP-la and IP-10 while in patients 
with RRF, IL-8 was negatively correlated with IL-12p70. RANTES was only positively 
correlated with its subgroup MCP-1 in both patients with ARE and RRE. Further studies 
with larger sample size are required to explain these significant correlations.
The significant correlations of IL-lp and IL-6 with cytokines IL-10 and IL-12p70 was 
higher in patients with RRE than ARE. IP-10 was significantly correlated with MIP-la 
only in patients with RRF but with MIP-lp in both ARE and RRF patients. IL-10 shared 
similar significant correlations with IL-1(3, IL-6 and IL12p70 in patients with ARE and 
RRE but the difference was with MIP-ip in patients with ARE and MCP-1 in patients 
with RRF. These differences express the variations in response of inflammatory cells by 
different tissues during acute and recurrent disease activity
The variation observed in chemoattractant chemokines profile was interesting in 
patients with ARE and RRF. MIP-lp was significantly correlated with IL-8, IL-10, IL- 
12p70, IP-10, TNF-a and IFN-y only in patients with ARE. MCP-1 was significantly 
correlated with IL-ip, IL-6, IL-10, IL-12p70, TNF-a andIFN-y in RRE patients which 
was not evident in patients with ARE . The chemoattractant chemokine MIP-lp 
probably serves as an immunological biomarker in patients with ARE and 
chemoattractant cytokine MCP-1 probably serves as an immunological biomarker in 
patients with RRE. These differences in overall pattern of chemokines and cytokines 
may result from a variation of balance in the inflammatory cells in the lesions and the 
severity of the damage in patients with ARE and RRE.
The non correlation of IL-lp with IL-8 and IP-10 with IL-7 in patients with RRF could 
possibly serve as potential markers to differentiate ARE from RRF. The significant 
negative correlation of IL-8 with IL-12p70 and IL-9 in patients with RRE not evident in 
ARE could be a potential marker to differentiate between the two groups.MIP-la was 
not associated with MIP-lp and IP-10 in patients with ARE but this correlation was 
evident in patients with RRF making it a possible point of differentiation between them. 
The association of IP-10 with IL-7 in patients with ARE but not in RRF was also 
significant. TNF-a and IFN-y were not correlated with MIP-ip in patients with RRE and
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also not associated with MCP-1 in patients with ARF and this serves a potential point to 
differentiate between the two groups.
The studied chemokines and cytokines could play an important role in the development 
of the inflammatory response in patients with ARF and RRF. These results will provide 
new clues for the potential roles of these chemokines and cytokines in the exacerbation 
of this disease and shed light on the development of ARF and RRF disease markers.The 
identification of specific chemokines involved in T-cell polarization and/or differential 
migration contribute toward a better understanding of immunopathogenesis and 
treatment of ARF and RHD patients (Guilherme, et al 2004). This information may 
open new possibilities for immunotherapy such as T-cell vaccination for patients with 
severe RHD. Molecular knowledge of the autoimmune reactions will aid in the choice 
of GAS protective epitopes for an effective and safe vaccine (Guilherme, et al 2005a).
Future direction in complex disorders may be the simultaneous inactivation/activation 
of multiple cytokines (Kourilsky and Truffa-Bachi 2001). Cytokine gene therapy for 
cancer treatment is the latest development in the field of cytokines (Feldmann 2008) 
Podhajcer et al., 2007). Cytokine-based drugs and anti-cytokines play a crucial role in 
understanding pathogenesis and management of several diseases (Feldmann 2008). 
Research is continuing to develop new therapies, refine those already in use and 
establish the safest and most effective dosage levels (Mellado and Carrasco 2008).
It is essential for clinicians to stay abreast with the latest information on the ongoing 
studies for the benefit of their patients. Since GAS vaccine development is progressing 
and hopefully will eventually lead to prevention of ARF and RHD in the near future 
(Guzman-Cottrill, et al 2004).
8.8 Conclusions
In this study, in addition to the role of IL-lp, IL-6, IL-8, IL-10, TNF-a and IFN-y 
involved in the inflammatory response of ARF, a further six new cytokines and 
chemokines RANTES, MCP-1, MIP-la, MIP-lp, IP-10 and IL12-p70 were for the first 
time analyzed in patients with ARF.
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MCP-1 was significantly correlated with cytokines, IL-lp, IL-6, IL-10, IL-lp270, TNF- 
a, IFN-y and RANTES in patients with RRF. This suggests tliat MCP-1 could serve as a 
potential inflammatory biomarker for patients with RRF with underlying RHD. MIP-1J3 
had significant correlations with IL-8, IL-10, IL-lp270, IP-10, TNF-a and IFN-y in 
patients with ARF not apparent in patients with RRF and this MIP-lp may serve as a 
potential inflammatory biomarker in patients with ARF.
8.9 Recommendations
These interesting results require further comprehensive studies on cytokine and 
chemokine profile among patients with ARF and RRF in developing countries to lead to 
a better understanding on the immunopathogenesis of the disease. This will facilitate in 
the development of a vaccine for the prevention of ARF and RHD.
S.lOClinical implications
Knowledge of the humoral and cellular cross-reactive epitopes is important for the 
production of a safe vaccine to prevent GASinfections. Some cytokines and chemokines 
such as TNF-aalleles and other immimoregualted genes which are located in the same 
chromosomal region as HLA genes are currently under investigation. It will contribute 
to the understanding of new genetic markers and how these genes act in the complex 
autoimmune network in ARF/RHD.
S.llLimitations
Although hypothetically 96 well plates could test 40 in duplicate and we had 2 plates 
equal to 80, we could only test 49 samples due to the need to retest some specimens and 
logistic problems with the machine.The small sample size of patients investigated for 
cytokines and chemokines in this study (Sadiq, et al 2008) requires a future study with a 
larger sample size to confirm their role as immunological biomarkers for ARF. It might 
be interesting to correlate the type of inflammatory cells ie. macrophages, monocytes 
and endothelial cells present with the pattern of chemokine and cytokine expression.The 
association of ARF with a genetic susceptibility in the causation of RHD has not been 
studied in Yemen. One of the original aims of this study was to determine the 
distribution of HLA class II system genes among Yemeni patients with RHD. However,
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due to the sad death of Professor Tony Hart, my principal supervisor and limitations in 
the funding this objective has been postponed.
9 General Discussion
9.1 General overview discussion
In this chapter the work contribution to the knowledge on immmiopathogenesis of ART 
and RHD due to GAS and SNA pathogens is reviewed according to the objectives 
outlined in this study.
9.2 RHD among Yemeni school children at Aden city
9.2.1 9.2.1 Prevalence of RHD among Yemeni school children 
This study has demonstrated that RHD is a major contributor to cardiovascular- disease 
in both children and adults in Yemen. This will lead to recurrent hospital admissions 
and premature disability. The school echocardiography survey for RHD in this study 
found a prevalence of 36.5/1000 which is alarmingly high.This is the highest figure for 
the prevalence of echo-proven RHD amongst school children in any country. The 
highest prevalence of RHD was between 11-16 years. However, this high prevalence 
could still be an underestimate of the true prevalence as students with poor health may 
experience frequent school absenteeism. This high RHD prevalence requires urgent 
regular school screening surveys and RHD prophylactic programs to try to control the 
problem ARP/RHD in Yemen.
9.2.2 9.2.2 Socio economic factors
Overcrowding, poverty and poor housing conditions in children was associated with 
RHD but this observation did not differ from reports in other countries (Lennon 2004; 
Kurahara, Grandinetti et al. 2006).
9.2.3 9.2.3 Echocardiogaphic findings
Of 219 children with RHD, 51% had isolated MR involvement, 26.6% had MR with 
MYP and 17.8% combined MR and AR. There was with no sex predilection which is 
consistent with previous reports (Carapetis 2008b, McDonald,er al. 2005). Mitral 
stenosis was detected in one female and four- males even though it is more commonly
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reported among females (Andy & Soomro 2001). More than one third of the children 
had complex lesions of MR and MVP involving the anterior leaflet. Further 
consideration should be given to include MVP as a common cardiac valve lesion in 
ARF/RHD and specifically correlate its primary or secondary origin. Normal values 
may vary from one laboratory to another from CRP 0-1.0 milligrams per deciliter 
(mg/dL) or less than 10 mg/L (SI units). The values for CRP in the tables are <5mg/dL 
and >5mg/dL. The highest values for CRP were up to lOmg/dL equivalent to lOOmg/L.
It is essential to monitor CRP during the follow up of RHD patients since a higher- 
proportion of children with multiple valve involvement presented with increased CRP. 
Continually raised CRP levels may be a marker of on-going inflammation of severely 
affected valves in RHD (Golbasi, U9ar et al. 2002).
9.2.4 9,2.4 Familial pattern of ARF/RHD
RHD was diagnosed in more than one family member in 53 children with ARF/RHD 
including 20 affected siblings. Further studies are required to document the familial 
patterns of ARF/ RHD and undertake research on possible specific genetic modes of 
inheritance. However, studies so far- have found a wide range of gentic markers 
associated with ARF/RHD with no particular marker demonstrating a strong correlation.
9.2.5 9.2.5 Penicillin prophylaxis
Health professionals should provide continuous education and reassurance to families 
on RHD prevention since only 16.4% of parents were aware of a RHD problem in their 
children prior to the survey. It is important to identify children with ARF/RHD early 
and to start penicillin prophylaxis to prevent ARF recurrences and progression of RHD. 
Only 18 students were on secondary prophylaxis and in many it was irregular. 24 
parents refused prophylaxis due to fear of penicillin hypersensitivity.
9.3 GAS among patients with acute pharyngotonsillitis
9.3.1 Prevalence of GAS among patients with acute 
pharyngotonsillitis
This is the first Yemeni report of GAS prevalence in children with acute 
pharyngotonsillitis and the 41.5% prevalence is higher than other neighbouring 
countries (Menon, et al 2004, Rimoin, et al 2008) The prevalence was 68.3% in the 11-
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15 years age group. A low GAS frequency was found in children <5 year's of age which 
may be due to absence of classical symptoms at this age. A high occurrence of GAS 
pharyngotonsillitis 85% during the winter months was consistent with other countries 
(Rimion et al 2008). GAS pharyngotonsillitis requires early diagnosis with prompt 
appropriate antibiotic therapy to reduce the risk of ARF and RHD.
9.3.2 9.3.2 Diagnostic clinical criteria
The clinical characteristics of fever, sore throat, tonsillar erythema and exudates with 
enlarged anterior tender lymph nodes were noticed in a higher frequency in Yemeni 
children with GAS pharyngotonsillitis than in other reports (Lazar R. 2004, Mzoughi 
R2004) Cough, hoarseness and rhinorrhea favoured a viral infection as reported by 
others (Lindbaek, Hoiby et al. 2005). In this study many patients with GAS 
pharyngotonsillitis presented with petechial lesions on the soft palate and a red 
erythematous uvula which was three times higher than other reports(Bisno, et al 2002) 
Kaplan et al 2006). Including these two particular signs into the Maclssac score will 
improve the specificity of GAS diagnosis. In poor countries with limited laboratory 
resources, the clinical diagnosis of GAS pharyngotonsillitis is an essential part in the 
effort to control ARF.
9.3.3 9.3.3 Rapid Antigen Detection Test for GAS
In this study a Mclssac score with a cut off point of 4 had a higher sensitivity (93%) and 
specificity (82%) which could remove the need of a backup culture to confirm GAS 
diagnosis. However, throat cultures are still the gold standard for the diagnosis of GAS 
pharyngotonsillitis. Although RADT can overcome the time delay in diagnosis 
associated with GAS throat cultures, they are expensive. Current RADT are expensive. 
However when used on a large scale such as with malaria and HIV testing these become 
more accessible. Some RADT for the latter diseases cost about £ leach. These reduced 
costs may still be considered high for a disease that is less common and not widely 
perceived to be a serious problem by some authorities.Further studies on cost benefit are 
required before routine application of RADT in poor countries. A school education 
program is essential to increase awareness of ARF and its sequelae among parents 
having children with recurrent GAS sore throats.
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9.4 Non-group A beta-haemolytic streptococci, Lancefield 
groups C, G and B
9.4.1 Prevalence of SNA pharyngotonsillitis
This is the first study to document SNA pathogens, GCS, GGS and GBS in children 
with acute pharyngotonsillitis in Yemen. The prevalence of 4.3% was similar to other 
reports (Wong and Chung 2002, Zaoutis 2004) Also similar gender distribution was 
observed within 11 — 15 years age group.
9.4.2 Diagnostic criteria of patients with SNA pharyngotonsillitis 
All patients with SNA pharyngotonsillitis presented with five positive criteria of 
Mclssac scoring system. RADT was negative in all SNA patients. Six patients had 
GCS, six GGS and one had GBS. Their clinical manifestations were consistent with 
GAS pharnygotonsillitis as in other studies (WHO 2004; Gerber et al 2004). An 
interesting finding was that all SNA patients presented with pain on swallowing which 
was not identified in other reports (Lindbaek, et al 2005).
9.4.3 History of ARF and RHD in patients with SNA 
pharyngotonsillitis
There are no reports to confirm that SNA are implicated in the pathogenesis of 
ARF/RHD. However, all patients with GCS, GGS and GBS pharyngotonsillitis in this 
study had a positive ARF history and were echocardiography-proven cases of RHD. 
Also all had a positive family history of ARF and RHD which suggests a possible 
clinical association of SNA with ARF and RHD. Stronger evidence for rheumatogenic 
potential of SNA could be obtained if these patients had regular follow up for any 
reccurrence of ARF and throat swabs taken. Further studies on the possible association 
between SNA and ARF are required,
9.5 Emm serotypes, exotoxin genes and serum opacity factor 
of GAS
9,5.1 emm genotypes among GAS pharyngotonsillitis
Thrity four GAS and SNA strains obtained from pharyngealtonsillar isolates in patients
with ARF/RHD included some known and new emm sequences characterized by using
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genotypic tests, streptococcal pyrogenic exotoxin genes and genomic DNA restriction 
profiles by PFGE, emmS?, 12, 28 and 5 were the most frequent GAS isolates. emmSl 
was detected in 11 (52.4%) of throat swabs of GAS. This is the first report of GAS 
emm%l to be potentially associated with ARF/RHD patients and suggests that it is likely 
to be rheumatogenic. Also GAS emm2% detected in 3 (14.3%) has not been identified as 
being rheumatogenic. These results suggest that uncommon emm GAS genotypes may 
have a significant role in the epidemiology of ARF/RHD in Yemen. Further studies 
with larger sample size are required.
9.5.2 Pyrogenic exotoxin superantigen and sof gene among GAS 
isolates
GAS emm%l strains were all sof gene positive for the unique sof%l sequence which 
suggests that the sof gene is detecTable by PCR only. This is the first report to describe 
the profile of the five prophage gene exotoxin sequences among GAS emm%l with the 
presence of speC^ spdf sdn, silC and silD and no striking sequence differences in their 
PFGE. emml2 GAS isolates were all sof positive for sof\2 gene sequence. Pyrogenic 
exotoxin C (sped) was identified in all emmftl, 12 and 28 GAS pharyngotonsillitis 
strains. This is the first report of speC toxin gene among emm 87 GAS throat isolates. 
GAS emm2S strains revealed positive results for exotoxin genes for spec and spell genes 
but not for sdn.
9.5.3 Streptococcal invasive locus (sil) among GAS 
pharyngotonsillitis isolates
The silC and silD loci were PCR positive in all emm'&l and emm 12 GAS 
pharyngotonsillitis isolates. SilC was positive in emm2H and emmS isolates which has 
not been described among these strains before. This is the first report to describe the sil 
exotoxin gene pattern of emm87, 12, 28 and 5 isolates on throat swabs from GAS 
patients with a history of ARF/RHD.
9.5.4 Emm serotypes, exotoxin genes and serum opacity factor 
gene of SNA
The emm virulence genotypes of GGS pharyngotonsillitis in patients with a history of 
ARF/RHD were genetically heterogeneous. They comprise 5 different genotypes, two 
isolates of emm st7882.2, and one isolate each of emm st2917, emm st7406, emm
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stG652.5 and stKNB?. The emm virulence genotypes of GCS pharyngotonsillitis were 
emm st2917 in four’ isolates and two isolates of S/CK249. One GBS genotype was 
stG4974. These GGS,GCS and GBS emm genotypes sequence strains from pharyngeal 
isolates are totally different from that found in the literature (Horii et al., 2006). stKNB 
7 in the GGS strain was the only gene sequence previously reported in India (Menon, et 
al 2008). These new emm sequences among GCS, GGS and GBS pharyngeal isolates 
were detected for the first time and possibly related to study in a different geographical 
site, Yemen, sof gene was negative in all SNA GBS, GCS and GGS different genotypic 
strains with no available reports to compare.
9.5.5 Pyrogenic exotoxin superantigen in patients with SNA 
pharyngotonsillitis
The prophage toxin gene spdl was positive and speC was negative in all SNA, GBS, 
GCS and GGS isolates. The superantigen gene sdnN was positive in GCS strains but 
negative in the GBS and GGS isolates. It is noteworthy that all emm genotypes of GCS 
strains were positive for spdl, sdn, silC and silD prophage exotoxin superantigens. The 
GCS strains shared the presence of these virulence genes with the GAS isolates. The 
presence of these GCS strains with particular genotypes in a susceptible host and their 
association with these virulence genes traits supports the likelihood of an association 
with ARF. This is the first report to highlight the prophage gene toxin sequence of 
specific GCS strains. There are no current reports of these pyrogenic exotoxin 
superantigens in patients with SNA pharyngotonsillitis available for comparison in the 
literature.
9.5.6 Streptococcal invasive locus among SNA pharyngotonsillitis 
The presenc of the emmA genotype among four GCS and one GGS pharyngotonsillitis 
demonstrated positive results for both silC and silD toxin genes which have been 
similarly reported in invasive streptococcal isolates in France (Bingen et al 2007). 
Streptococcus invasive locus including silC and silD in some of these genotypes of 
GGS and GCS has not been described in the literature.
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9,5.7 PFGE pattern interpretation
PFGE profiles of emm%l GAS isolates were similar and highly related. GAS emml2 
and emm2S did not differ among their related genotypes in their DNA PFGE profiles 
fragments. PFGE profiles within a given GCS and GGS emm type were not related, but 
were distinct from other emm GCS and GGS profile strains. These results may indicate 
that each individual emm type shared a high degree of genetic relatedness among SNA 
GCS and GGS genotypes.
9.6 Antimicrobial patterns among GAS and SNA 
pharyngotonsillitis
9.6.1 Overall antimicrobial patterns among GAS and SNA 
pharyngotonsillitis
GAS strains were all sensitive to the (3- lacatm antimicrobials penicillin and amoxicillin 
consistent with findings in different countries (Adam, et al 2000, Brook and Dollar 
2006, Lloyd, et al 2007, Palavecino, et al 2001). GAS isolates among Yemeni patients 
exhibited tetracycline and chloramphenicol resistance with rates comparably higher than 
in studies from Iran and India (Jasir, et al 2000, Lloyd, et al 2007). All the SNA GBS, 
GCS and GGS strains were sensitive to penicillin and amoxicillin similar- to other 
reports (Di’az, et al 2008, Ergin, et al 2003, Zaoutis, et al 2001).
GAS developed with increasing resistance to erythromycin to GAS in several countries 
directly related to antibiotics use in throat infections (Weber 2005). GAS was 
erythromycin resistant in 36% of the strains and GCS and GGS strains were each 50% 
resistant to erythromycin which is comparably higher than some reports (Di'az, et al 
2008). Macrolide resistance is also reported to be widespread among sof positive GAS 
strains consistent with emm\2 sof positive (50%) and emm2S sof positive (33%) 
genotypes in this study. GAS emmSl and emm5 were so/positive and erythromycin 
resistant but it differed from other reports (Bernard Beall et al 2002). The antimicrobial 
patterns of GBS, GCS and GGS emm genotypes varied among their sensitivity and 
resistance patterns which is reported for the first time. This high macrolide resistance
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pattern among GAS, GCS and GGS strains may be explained by the free availability of 
drugs over the counter in Yemen.
It is necessary to continue further careful research to detect any change in the 
susceptibility pattern of GAS isolates to antimicrobials and to assess the best-practice 
for antimicrobial regimens (JoAmr Deasy et al 2009). It is difficult to create and follow 
a strict single prediction rule for all countries with the changing epidemiology of GAS 
infections but it is essential to minimize the inappropriate use of antibiotics and avoid 
antimicrobial resistance.
9.7 Cytokines in acute rheumatic fever and recurrent 
rheumatic fever
9.7.1 General aspects of Cytokines in ARF and RRF 
There were significantly higher concentrations of all the 14 profiles of cytokines and 
chemokines in patients with RRF than in ARF patients. The significantly higher 
elevation of TNF-a and IFN-y in RRF than ARF supports the possibility of their 
secretion by heart mononuclear cells associated with an autoimmune reaction and 
suggests that Thl-type cytokines could mediate RED (Guilherem et al 2004). 
Inflammatory cytokines IL-1(3 and TNF-a which were significantly elevated in RRF 
than in ARF patients correlates with the progression of Aschoff nodule activity during 
the acute active phase of ARF and RHD and may serve as useful indicators of disease 
activity. IL-8 was twice as high in children with RRF compared to ARF probably 
caused by cellular infiltrates in the joints during the ARF period. IL-10 secreted by 
CD41) T cells was higher among RRF than ARF patients in contrast to a study in India 
where higher IL-10 levels were observed in CRHD than ARF patients.
The profile of RANTES, MCP-1, MIP-la, MIP-ip, IL-9, IP-10 and IL12p70 has not 
been previously studied in patients with ARF and this is the first study to assess these 
cheomokines and cytokinesly among patients with ARF and RRF. IL-12p70 was 
comparable to IFN-y levels with significantly lower values in patients with ARF than 
RRF supporting the fact that IL-12p70 regulates Thl response by inducing IFN-y. This
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was the first study to describe elevated concentrations of IP-10 and IL12p70 in patients 
with ARF.
9.7.2 Correlations of cytokines and chemokines in patiens ARF 
and RRF patients
The results in this study support the role of cytokines in the initiation of inflammatory 
response dining the active phase of ARF and RHD. Pro inflammatory cytokines TNF-a 
and IFN-y showed strong positive correlations with cytokines IL-1[3, IL-6, IL-10 and 
IL-12p70 in both patients with ARF and RRF. Previous reports demonstrated TNF-a, 
IFG- y, IL-lp and IL-6 in the production of acute phase reactants. However, this is the 
first report to describe the correlations of TNF-a and IFN-y with IL-10 and IL-12p70 
among patients with ARF.
The results suggest that the strong colocalization of TNF-a and IFG-y in patients with 
ARF and RRF may be associated with carditis, a major feature in both groups. It is well 
established that the lymphokine IFN- y preferentially inhibits Tli2 proliferation 
responsible for anti-inflammatory cytokine IL-10 production. This fact does not 
coincide with this study where IFN-y was strongly correlated with IL-10 (Th-1 
response) among patients with ARF and RRF and needs to be clarified in future studies.
In patients with ARF IL-8 was positively correlated with MIP-la and IP-10 while 
among patients with RRF. IL-8 was negatively correlated with IL-12p70. RANTES 
was only positively correlated with its subgroup MCP-1 in patients with ARF and RRF. 
The expression of positive correlations between IL-1J3 and IL-6 with cytokines IL-10 
and IL-12p70 was stronger in patients with RRF than ARF. IP-10 was associated with 
MIP-lp in both patients with ARF and RRF. IP-10 was correlated with MIP-la in 
patients with RRF. IL-10 shared strong positive correlations with IL-1 [3, IL-6, and 
IL12p70 in patients with ARF and RRF. IL-10 was only positively correlated with MIP- 
lp in patients with ARF but with MCP-1 in patients with RRF.
Patients with ARF expressed chemokine MIP-ip with strong positive significant 
correlations with cytokines IL-8, IL-10, IL-lp270, IP-10, TNF-a and IFG-y that was not 
apparent in patients with RRF. RRF patients expressed chemoattractant chemokine
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MCP-lwith strong positive significant correlations with cytokines, IL-1 p, IL-6, IL-10, 
IL-lp270, TNF-a and IFG-y and RANTES which was not evident in patients with ARF.
TNF-a and IFN-y were not correlated with MIP-lp in patients with RRF and also were 
not associated with MCP-1 in patients with ARF which serves a potential point to 
differentiate between the two groups. The chemoattractant chemokine MIP-lp may 
probably serve as a biological marker in patients with ARF and the chemoattractant 
cytokine MCP-1 may probably serve as a biological marker in patients with RRF. These 
differences in the overall pattern of chemokines and cytokines may result from a 
variation of balance in the inflammatory cells in the lesions and the severity of their 
damage in patients with ARF and RRF. Further future analysis with a large sample size 
are required to study these correlations with different cytokines and chemokines that 
have not been reported in patients with ARF to explain their pathogenic importance.
The identification of these specific chemokines and cytokines and their significant 
correlations may contribute towards a better understanding on immunopathogenesis of 
ARF and RHD. This information will introduce novel possibilities for immunotherapy 
such as T-cell vaccination for patients with severe RHD. The molecular' knowledge of 
the autoimmune reactions mediated by intralesional T cells will aid in the choice of 
GAS protective epitopes for an effective and safe vaccine (Guilherme et al 2005)
9.8 Conclusions
The prevalence of RHD among Yemeni school children was 36.5/1000. This is higher 
than in other Middle Eastern countries and demonstrates that RHD continues to be a 
major and serious health problem in Yemen.
In the primary health care and school survey a high prevalence of GAS 
pharyngotonsillitis was detected particularly in the 11 - 15 years age groups. The most 
frequent genotypes of GAS isolated from children with a history of ARF and RHD were 
12, 28 and 5. The genotypes emm 87 and emm28 were possible new 
rheumatogenic GAS strains not previously reported. The existence of a significant 
proportion of newly recognized emm types with a variety of characteristics, suggests
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that strains circulating in Yemen, an area not previously surveyed, may be different 
from those known to circulate in other geographic areas. Such information can 
contribute to a better understanding of the local and global dynamics and epidemiologic 
aspects of GAS and GGS, GCS and GBS infections occurring in different regions.
SNA strains, GCS, GGS and GSB were infrequent causes of pharyngotonsillitis 
compared with GAS. This study presents the genotypic characteristics of GCS, GGS 
and GBS isolates belonging to seven new emm sequence types first detected among 
Yemeni children with acute pharyngotonsillitis having a history of ART and RHD.
This is the first report to describe the pattern of the exotoxin prophage superantigen 
genes spec, spdl, sdn, silC} silD and sof of emm 87,12, 28 and 5 GAS and GCS, GGS 
and GBS isolates in patients with pharyngotonsillits and a history of ARF and RHD.
The PFGE profiles of emm'&l, 12 and 28 GAS isolates did not differ within their related 
genotypes. GAS and SNA isolates still remain susceptible to the majority of 
antimicrobials tested including the (3-lactams antibiotics penicillin and amoxicillin.
There were some erythromycin resistant strains.
Seven new cytokines and chemokines RANTES, MCP-1, MIP-la, MIP-1(3, IP-10 and 
IL12-p70 were investigated for the first time in patients with ARF. They were elevated 
in patients with ARF and RRF. The chemokine MIP-1J3 may be a potential 
immunological biomarker in patients with ARF due to its strong positive correlation 
with cytokines IL-8, IL-10, IL-12p70, IP-10,TNF-a and IFG-y. MCP-1 may probably be 
a potential immunological biomarker in patients with RRF with RHD due to its strong 
positive con-elation with cytokines IL-1(3, IL-6, IL-10, IL-lp270, TNF-a and IFG-y and 
RANTES.Chemokines direct the migration of leukocytes throughout the body and play 
an important role in the inflammatory response. Serum chemokines levels may be 
clinically useful as an objective indicator of activity and may have the potential to 
improve disease management. Patients with high serum chemokine levels may be more 
likely to develop early recurrence with possible cardiac valve involvement and end up 
with RHD. Monitoring frequent chemokine levels in rheumatic patients could provide a 
tool to possibly evaluate the disease activity and identify patients with a likelihood of
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future recurrences and RHD development. Further prospective studies with larger 
number of patients are needed to make firm conclusions.
9.9 Recommendations
It is important to use schools as a means to educate and motivate teachers, parents and 
children about the importance of treatment of sore throats. Primary prevention of a first 
attack of ARF in children with oral penicillin for GAS pharyngotonsillitis requires 
strong evidence (Lennon, et al 2009). Penicillin may fail to prevent an acute attack of 
ARF. Guidelines for diagnosis and management of GAS pharyngotonsilitis with cheap 
and available rapid tests will aid prevention of ARF(Lennon and Craig 2009). Primary 
health care delivery will be more effective when focused on a wider community of 
individuals including siblings and schools to reduce GAS load on the population
It is time for the public health authorities to understand the burden of this hazardous 
preventable heart disease ARF/RHD and provide necessary financial and manpower 
resources to promote a successful program of control with support of policy makers.
Future studies are required to assess the diagnosis of pharyngotonsillitis in children and 
should include the two clinical signs of petechie in the soft palate and red erythematous 
uvulawhich in this study were predictive clinical criteria of GAS pharyngotonsillitis. 
Further research is required to investigate the role of SNA in the causation of 
ARF/RHD.
It is important to monitor GAS isolates and their emm genetic variability through active 
and continuous surveillance to lead to a better understanding of the epidemiology of 
specific GAS strains in different countries.Further large sample size studies of are 
required to confirm the role of these chemokines as biomarkers for ARF and increase 
our understanding of how they act in the complex network of autoimmune reactions that 
occur in ARF/RHD. A cohort longitudinal study or cross-sectional study of patients with 
ARF, RRF and RHD with a control healthy group adjusted for age sex and race. The 
patients should be followed with frequent visits ( 4 to 5 visits per year) during active 
and inactive stages of the disease. Chemokine levels could then be compared at 
consecutive visits, either before and during active disease or before and during inactive
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stage. The development and use of the advanced techniques in molecular biology will 
enhance understanding of the immunology of ARF/RHD which is required for the 
production of a vaccine.
9.10Limitatioiis of the study
The presence of a portable echocardiography in the field work could have minimized 
the loss of participants who were clinically diagnosed as RHD. Transport problems 
caused a delay in taking some of the throat isolates to the laboratories which might have 
led to some false negative cultures in positive RADT specimens. The absence of 
LancefieldStreptococci Grouping kits during the field work may have caused an 
underestimate of the SNA contribution to pharyngotonsillits. Detailed study of the 
streptococci obtained from throat swabs was only undertaken on a subgroup of the total 
(n=34) due to limited funding. The study of genotype and prophage exotoxin 
superantigen genes on a larger sample size of GAS and SNA isolates would have 
provided more comprehensive results on the epidemiologic aspects of these infections.
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11 Appendices
11.1 Appendix (A): Questionnaire (I)
11.1.1 Questionnaire for children with ARF and RHD
Serial number Code Date
Name
Years M F
Age Gender:
Address
Permanent House number: Street Telephone number
Address
District: Governorate:
Temporary House number: Street Telephone number
Address
District: Governorate:
Name of School: District:
Primary class level No of students in school
Epidemiological background:
Family History
First degree relative Family income:
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Consanguinity Second degree relative
Third degree relative
Family size No of siblings 
Sibling's order
No of bedrooms
Housing
Conditions
Access to 
Health Service 
Family history 
Sore throat 
Scarlet fever 
URTI 
RF 
RHD
Good
Satisfactory
Bad
Occupation:
Father
Mother
Secondary
Primary
Relatives affected Relation to patient
Clinical Background
Riyals per month:
Persons per bedroom
□
Education level 
Father ~
Mother
Tertiary
Relation to patient
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MAC.Weight Height BMI
Nutritional status Grade I Grade II Grade III
Temp P.R. R.R. B.P.
Major Manifestations
Carditis
Apical systolic murmur 1 | Apical mid-diastoiic murmur | j
Change in murmur 1 | Cardiac enlargement | |
Pericarditis Congestive cardiac failure--------- ---------
Arrhythmias
Cardiac lesion
n. n .. □ □ □
mk Mb AK i K AS Combined lesions
Arthritis
Single /Multiple Ankle | | Knee j j Hip Q
Wrist j—| Hand n Elbow |---- 1 Shoulder |—j
Chorea
Subcutaneous nodule Site | | Number | |
Erythema marginatum Site Number j
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Minor Manifestations
Fever | | Arthralgia [ |
Recent sore throat |-----
Previous ARF
Recent scarlet fever
Previous RHD | |
Others: Abdominal symptoms | | Pleural and pulmonary manifestaions| |
Epiataxis □ Anemia Q Vomiting Q Weight loss Q Malaise |---- |
Pam clinical Investigations 
Hb 
ESR
gm% WBC Total
Chest x-Ray 
ECG
Tliroat swab Gram stain Culture
Echocardiography findings
ASO CRP
crcTEra
MPS | Others i
Sensitivity
Drugs Yes No Yes No
Penicillin 1— Aspirin
Steroids Digoxin 1—
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Furosemide 1 1 Vitamins Tonics
Prophylaxis
Primary Drug | | Dose Frequency Duration
Secondary Drug Dose Frequency Duration
Secondary Prophylaxis Regular* Irregular .... Duration
Complications Infect Endocarditis CCF____ Arrhythmias Others
Rheumatic fever Frequency Interval Major criteria Minor criteria
□ □□□□□□ | | | |
Recurrence
Hospital admission |—.. | Duration of stay | | Number | | Interval |—.. |
Surgical Intervention if any □ Dental f~... i Tonsillectomy | [ Others [
Outcome: Full recovery j Recovered but witli valvulopathy |
Others Cause of Death
11.1.2 Questionnaire for children with Sore Throat
Serial number Code Date
Name Age Sex
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Polyclinic
School
Permanent
Address
House number:
District:
Area of Residence 
Name of district
Street Telephone No
Governorate:
Clinical Manifestations of Sore Throat
Group A Beta Hemolytic Streptococcal Infection
Symptoms 
Sudden onset 
Sore throat 
Headache 
Fever 38 -40'C 
Pain on 
Swallowing 
Nausea 
Vomiting 
Abdominal pain
Yes No Signs
Erythema on tonsil
Erythema on pharynx
Exudate on tonsil
Exudate on pharynx
Swollen tender anterior
cervical lymph nodes
Soft, palate petechiae
Red swollen uvula
Skin Rash
Yes No
Mclsaac Scoring System
Criteria Point
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Temperature > 38'C 1
No cough 1
Tender cervical lymphnodes 1
Tonsillar swelling or exudates 1
Age 3-15 years 1
No of attacks per year- CD I I I—II—II—II—II—II II I
No of attacks per 6 months | | |—j |—j \—| \—\ j—|
No of attacks per month [=□ t=Zl □□
Family history
Sore throat
URTI
RF
RFID
No of Relativesaffected Relation to patient Relation to patient
Para clinical Investigations
WBC Total
ASO titer
p □ □ □ cr
CRP 1-------------------- 1
277
Positive Negative
Gram stain 
Culture 
Catalase test 
Bacitracin Sensitivity
Rapid Antigen Detection Test: Positive
Negative
Doubtful
ASOT Positive Value
Negative
CRP Positive Value
Negative
Complications of GABHS1
Suppurative Non-Suppurative
Peritonsillar abscess(quinsy) Rheumatic fever
Para-pharyngeal abscess Acute GNephritis
Retro-pharyngeal abscess Reactive arthritis
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Treatment
Symptomatic: Adequate Fluid intake 
Analgesics: Paracetamol
Others ----------------------------------------
Warm water gargle 
Ibuprofen 
Herbal medicine
Antibiotics
Type Dose Frequency Route Duration
Oral Penicillin
Amoxicillin 
Benzathine Penicillin 
Procaine Penicillin 
Erythromycin 
Clindamycin 
Others
Surgery
Tonsillectomy Age done
What were the Indications for Tonsillectomy? 
Sore throat due to tonsil inflammation 
3 episodes in 6 months r~--~
Date
4 episodes in 12 months
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>4 episodes in 12 months
Peritonsillar abscess Attacks interfere with patients function
Patient at risk for Rheumatic fever orRHD
Relative at risk for Rheumatic fever orRHD
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11.2Appendix (C) Consent Forms 
11.2.1 Minor Child Consent Form No. 1
Primary Investigator: Dr. Iman Ali Ba-Saddik
Title of Project: Rheumatic Fever and Rheumatic Heart Disease: Prevalence 
Among Yemeni School Children and Role of Genetics in Predisposition
I acknowledge that on___________________(date) I was informed by:
Dr.Iman Ali Ba-Saddik, Pediatric Specialist at the department of Pediatrics and Child 
Health, Faculty of Medicine and Health Sciences, Aden University; of a project having 
to do with the following :
Screening for normal school children will be undertaken by simply listening to their 
chest with a stethoscope to find out if any of them may have a heart problem even 
though if they are asymptomatic; If any abnormal heart sound is heard by simple 
auscultation, they will be referred to a pediatric cardiologist to perform an 
echocardiography to diagnose the type of cardiac defect and then given the 
recommended treatment.
I have understood the verbal communication to parents providing the essentials of the 
proposed project AND AM HAPPY FOR MY CHILD TO TAKE PART. I am fully 
aware of the nature and extent of my child's participation in this project and agree with 
hill knowledge to all details to allow my child to participate. I understand that I may
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withdraw my child's participation from the research at any time without any penalty of 
any kind; and that the investigator will take into consideration my child's feeling and 
protect my child's privacy.
Child's name: ______ __________________
Relation to child:______________________ _
Date:_____________________
I do give my consent for my child to participate:
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11.2.2 Minor Child Consent Form No.2
Primary Investigator: Dr. Iman Ali Ba-Saddik
Title of Project: Rheumatic Fever and Rheumatic Heart Disease: Prevalence 
Among Yemeni School Children and Role of Genetics in Predisposition
I acknowledge that on___________________(date) I was informed by:
Dr.Iman Ali Ba-Saddik, Pediatric Specialist at the Department of Pediatrics and Child 
Health, Faculty of Medicine and Health Sciences, Aden University; of a project having 
to do with the following :
The common bacterial causes of throat infections among our children which may lead to 
a heart problem are group A peta hemolytic streptococci. We would like to undergo this 
survey to identify the prevalence of this infection among patients with sore throat. The 
test will be done by talcing two throat swabs from the patients at the pediatric polyclinic. 
One throat swab will be immediately tested on a diagnostic slide to check for the 
presence of these bacteria. If this test turns to be positive within 10 to 15 minutes, then 
the second throat swab will be taken to specialized laboratory. In this diagnostic 
laboratory a medical microbiologist will grow these bacteria on special plates by culture 
methods to detect the specific family strains of these bacteria. The positive culture test 
and the sensitivity of the antibiotic to the specific bacteria will determine the treatment 
to be given to your child to avoid the future heart complications on your child.
I have understood the verbal communication to parents providing the essentials of the 
proposed project AND I AM HAPPY FOR MY CHILD TO TAKE PART. I am folly 
aware of the nature and extent of my child's participation in this project and agree with 
foil knowledge to all details to allow my child to participate. I understand that I may 
withdraw my child's participation from the research at any time without any penalty of 
any kind; and that the investigator will take into consideration my child's feeling and 
protect my child's privacy.
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Child's name:
Relation to child: 
Date:
I do give my consent for my child to participate:
11.2.3 Minor Child Consent Form No.3
Primary Investigator: Dr. Iman Ali Ba-Saddik
Title of Project: Rheumatic Fever and Rheumatic Heart Disease: Prevalence 
Among Yemeni School Children and Role of Genetics in Predisposition
I acknowledge that on___________________(date) I was informed by:
DrJman Ali Ba-Saddik, Pediatric Specialist at the department of Pediatrics and Child 
Health, Faculty of Medicine and Health Sciences, Aden University; of a project having 
to do with the following :
Your child has been diagnosed having Rheumatic Heart Disease by Echocardiography 
at the cardiac clinic. A simple blood test through venipuncture
will be taken to investigate the possible role of immunogenesis in this heart problem. 
This special genetic test will help in the determination of the autoimmune pattern of this 
disease in risky children.
I have understood the verbal communication to parents providing the essentials of the 
proposed project AND AM HAPPY FOR MY CHILD TO TAKE PART. I am fully 
aware of the nature and extent of my child's participation in this project and agree with 
full knowledge to all details to allow my child to participate. I understand that I may 
withdraw my child's participation from the research at any time without any penalty of 
any kind; and that the investigator will take into consideration my child's feeling and 
protect my child's privacy.
285
Child's name:__
Relation to child: 
Date:
I do give my consent for my child to participate:
11.2.4 Appendex D Correlations of the different chemokines 
and cytokines in patients with ARF and RRF
b.Correlation of TNF-a with the diffferent chemokines and cytokines
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h. Correlation of IL-10 with the different chemokines and cytokines
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i. Correlation of IP-10 with the different chemokines and cytokines
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d. Correlation of IL-6 with the different cytokines and chemokines
289
a. Correlation of IL-1 B with the different chemokines and cytokines
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k. Correlation of RANTES with the different chemokines and cytokines
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